WO2024039822A1 - Thiol isomerases inhibitors; preparation thereof; and methods of use thereof - Google Patents
Thiol isomerases inhibitors; preparation thereof; and methods of use thereof Download PDFInfo
- Publication number
- WO2024039822A1 WO2024039822A1 PCT/US2023/030535 US2023030535W WO2024039822A1 WO 2024039822 A1 WO2024039822 A1 WO 2024039822A1 US 2023030535 W US2023030535 W US 2023030535W WO 2024039822 A1 WO2024039822 A1 WO 2024039822A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- cycloalkyl
- hydrogen
- compound
- aromatic
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 34
- 102000004195 Isomerases Human genes 0.000 title abstract description 70
- 108090000769 Isomerases Proteins 0.000 title abstract description 70
- 239000003112 inhibitor Substances 0.000 title description 18
- 238000002360 preparation method Methods 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 174
- 208000007536 Thrombosis Diseases 0.000 claims abstract description 59
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 58
- 201000011510 cancer Diseases 0.000 claims abstract description 54
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 27
- 201000010099 disease Diseases 0.000 claims abstract description 24
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims abstract description 17
- 102000009123 Fibrin Human genes 0.000 claims abstract description 9
- 108010073385 Fibrin Proteins 0.000 claims abstract description 9
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229950003499 fibrin Drugs 0.000 claims abstract description 9
- 208000015181 infectious disease Diseases 0.000 claims abstract description 5
- 208000035473 Communicable disease Diseases 0.000 claims abstract description 4
- 206010061218 Inflammation Diseases 0.000 claims abstract description 3
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 3
- 208000026278 immune system disease Diseases 0.000 claims abstract description 3
- 230000004054 inflammatory process Effects 0.000 claims abstract description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract 2
- 230000003612 virological effect Effects 0.000 claims abstract 2
- 125000003118 aryl group Chemical group 0.000 claims description 262
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 87
- 229910052739 hydrogen Inorganic materials 0.000 claims description 74
- 239000001257 hydrogen Substances 0.000 claims description 74
- 150000003839 salts Chemical class 0.000 claims description 58
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 54
- 125000003282 alkyl amino group Chemical group 0.000 claims description 54
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 45
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 40
- -1 C1-C8 alkyl-OH Chemical group 0.000 claims description 37
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 36
- 125000000217 alkyl group Chemical group 0.000 claims description 34
- 125000003545 alkoxy group Chemical group 0.000 claims description 33
- 229910052736 halogen Inorganic materials 0.000 claims description 30
- 150000002367 halogens Chemical group 0.000 claims description 30
- 125000002252 acyl group Chemical group 0.000 claims description 29
- 229910052760 oxygen Inorganic materials 0.000 claims description 28
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical group [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 27
- 239000013543 active substance Substances 0.000 claims description 26
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 25
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical group O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 23
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 23
- 229910052717 sulfur Inorganic materials 0.000 claims description 23
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 22
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims description 17
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims description 14
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 13
- 206010047249 Venous thrombosis Diseases 0.000 claims description 13
- 125000001072 heteroaryl group Chemical group 0.000 claims description 12
- 206010003178 Arterial thrombosis Diseases 0.000 claims description 11
- 239000003146 anticoagulant agent Substances 0.000 claims description 11
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 11
- 125000003107 substituted aryl group Chemical group 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 230000002785 anti-thrombosis Effects 0.000 claims description 5
- 210000004072 lung Anatomy 0.000 claims description 5
- 210000002307 prostate Anatomy 0.000 claims description 5
- 206010051055 Deep vein thrombosis Diseases 0.000 claims description 4
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 125000006575 electron-withdrawing group Chemical group 0.000 claims description 4
- 230000002611 ovarian Effects 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 3
- 206010002388 Angina unstable Diseases 0.000 claims description 3
- 206010003658 Atrial Fibrillation Diseases 0.000 claims description 3
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 3
- 206010035138 Placental insufficiency Diseases 0.000 claims description 3
- 208000007718 Stable Angina Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 208000032109 Transient ischaemic attack Diseases 0.000 claims description 3
- 208000007814 Unstable Angina Diseases 0.000 claims description 3
- 206010000891 acute myocardial infarction Diseases 0.000 claims description 3
- 210000000481 breast Anatomy 0.000 claims description 3
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 3
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 3
- 238000007887 coronary angioplasty Methods 0.000 claims description 3
- 230000002489 hematologic effect Effects 0.000 claims description 3
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims description 3
- 201000010875 transient cerebral ischemia Diseases 0.000 claims description 3
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 229940127219 anticoagulant drug Drugs 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 36
- 150000003573 thiols Chemical class 0.000 abstract description 28
- 239000003394 isomerase inhibitor Substances 0.000 abstract description 25
- 230000002265 prevention Effects 0.000 abstract description 11
- 238000011161 development Methods 0.000 abstract description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 78
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 78
- 229960004764 zafirlukast Drugs 0.000 description 71
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 58
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 54
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 54
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 51
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 48
- 210000004027 cell Anatomy 0.000 description 45
- 230000000694 effects Effects 0.000 description 43
- 102000006010 Protein Disulfide-Isomerase Human genes 0.000 description 42
- 230000015572 biosynthetic process Effects 0.000 description 42
- 108020003519 protein disulfide isomerase Proteins 0.000 description 42
- 102100037097 Protein disulfide-isomerase A3 Human genes 0.000 description 35
- 101710106224 Protein disulfide-isomerase A3 Proteins 0.000 description 35
- 125000004432 carbon atom Chemical group C* 0.000 description 35
- 239000000203 mixture Substances 0.000 description 35
- 230000005764 inhibitory process Effects 0.000 description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 31
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 30
- 238000005160 1H NMR spectroscopy Methods 0.000 description 30
- 150000002431 hydrogen Chemical group 0.000 description 30
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 30
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 29
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 28
- 239000012267 brine Substances 0.000 description 28
- 229960005127 montelukast Drugs 0.000 description 28
- 239000012044 organic layer Substances 0.000 description 28
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 28
- 239000007787 solid Substances 0.000 description 28
- 229910001868 water Inorganic materials 0.000 description 27
- 101001098769 Homo sapiens Protein disulfide-isomerase A6 Proteins 0.000 description 26
- 102100037061 Protein disulfide-isomerase A6 Human genes 0.000 description 26
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
- 235000019439 ethyl acetate Nutrition 0.000 description 25
- 239000000499 gel Substances 0.000 description 25
- 229910052681 coesite Inorganic materials 0.000 description 24
- 238000004440 column chromatography Methods 0.000 description 24
- 229910052906 cristobalite Inorganic materials 0.000 description 24
- 239000012043 crude product Substances 0.000 description 24
- 239000000377 silicon dioxide Substances 0.000 description 24
- 229910052682 stishovite Inorganic materials 0.000 description 24
- 229910052905 tridymite Inorganic materials 0.000 description 24
- 102100037089 Protein disulfide-isomerase A4 Human genes 0.000 description 23
- 108010063267 endoplasmic reticulum glycoprotein p72 Proteins 0.000 description 23
- 229940126086 compound 21 Drugs 0.000 description 22
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 21
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 20
- 238000003556 assay Methods 0.000 description 20
- 229940118465 Isomerase inhibitor Drugs 0.000 description 19
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 18
- 125000001424 substituent group Chemical group 0.000 description 16
- 102000004877 Insulin Human genes 0.000 description 15
- 108090001061 Insulin Proteins 0.000 description 15
- 229940125396 insulin Drugs 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 15
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000002552 dosage form Substances 0.000 description 12
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 12
- 229910052799 carbon Inorganic materials 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 230000036515 potency Effects 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 235000012239 silicon dioxide Nutrition 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 102000002933 Thioredoxin Human genes 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 235000019341 magnesium sulphate Nutrition 0.000 description 10
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 10
- 108060008226 thioredoxin Proteins 0.000 description 10
- 229940094937 thioredoxin Drugs 0.000 description 10
- 230000004913 activation Effects 0.000 description 9
- 230000028327 secretion Effects 0.000 description 9
- 102000008946 Fibrinogen Human genes 0.000 description 8
- 108010049003 Fibrinogen Proteins 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 8
- 229940012952 fibrinogen Drugs 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 7
- 206010061535 Ovarian neoplasm Diseases 0.000 description 7
- 125000003342 alkenyl group Chemical group 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 125000005842 heteroatom Chemical group 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 206010033128 Ovarian cancer Diseases 0.000 description 6
- 230000010261 cell growth Effects 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 125000006413 ring segment Chemical group 0.000 description 6
- OZFPSOBLQZPIAV-UHFFFAOYSA-N 5-nitro-1h-indole Chemical compound [O-][N+](=O)C1=CC=C2NC=CC2=C1 OZFPSOBLQZPIAV-UHFFFAOYSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 229960004676 antithrombotic agent Drugs 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 208000034158 bleeding Diseases 0.000 description 5
- 230000000740 bleeding effect Effects 0.000 description 5
- 231100000433 cytotoxic Toxicity 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000005284 excitation Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 229910052744 lithium Inorganic materials 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- 239000002480 mineral oil Substances 0.000 description 5
- 235000010446 mineral oil Nutrition 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 206010014522 Embolism venous Diseases 0.000 description 4
- 108010074860 Factor Xa Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 125000004421 aryl sulphonamide group Chemical group 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 4
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 4
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 4
- 125000001041 indolyl group Chemical group 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- CNRMXICSYWVJRD-UHFFFAOYSA-N methyl 5-formyl-2-methoxybenzoate Chemical class COC(=O)C1=CC(C=O)=CC=C1OC CNRMXICSYWVJRD-UHFFFAOYSA-N 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 125000001624 naphthyl group Chemical group 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 125000004430 oxygen atom Chemical group O* 0.000 description 4
- 239000008057 potassium phosphate buffer Substances 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 125000004434 sulfur atom Chemical group 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- 208000004043 venous thromboembolism Diseases 0.000 description 4
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 238000001061 Dunnett's test Methods 0.000 description 3
- 208000005189 Embolism Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 102000004316 Oxidoreductases Human genes 0.000 description 3
- 108090000854 Oxidoreductases Proteins 0.000 description 3
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 3
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 125000003710 aryl alkyl group Chemical group 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 230000009036 growth inhibition Effects 0.000 description 3
- 125000001188 haloalkyl group Chemical group 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 125000004043 oxo group Chemical group O=* 0.000 description 3
- 230000010118 platelet activation Effects 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 3
- 239000003656 tris buffered saline Substances 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 3
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 101710106383 Disulfide bond formation protein B Proteins 0.000 description 2
- 108010053070 Glutathione Disulfide Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 101710116318 Probable disulfide formation protein Proteins 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical group C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000031709 bromination Effects 0.000 description 2
- 238000005893 bromination reaction Methods 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 150000001721 carbon Chemical class 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- JMFVWNKPLURQMI-UHFFFAOYSA-N cyclopentyl carbamate Chemical group NC(=O)OC1CCCC1 JMFVWNKPLURQMI-UHFFFAOYSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 2
- 238000011194 good manufacturing practice Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 238000004896 high resolution mass spectrometry Methods 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 150000002475 indoles Chemical class 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000012771 intravital microscopy Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical group [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 description 2
- 229910001623 magnesium bromide Chemical group 0.000 description 2
- BLQJIBCZHWBKSL-UHFFFAOYSA-L magnesium iodide Chemical group [Mg+2].[I-].[I-] BLQJIBCZHWBKSL-UHFFFAOYSA-L 0.000 description 2
- 229910001641 magnesium iodide Inorganic materials 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229920002113 octoxynol Polymers 0.000 description 2
- 230000006548 oncogenic transformation Effects 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 239000002997 ophthalmic solution Substances 0.000 description 2
- 229940054534 ophthalmic solution Drugs 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000007935 oral tablet Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000010101 prophylactic anticoagulation Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- 238000007817 turbidimetric assay Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- SPYIETQLOVDJCF-XYOKQWHBSA-N (5e)-3-(4-methoxyphenyl)-5-[(5-nitrothiophen-2-yl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1=CC(OC)=CC=C1N(C(=S)S\1)C(=O)C/1=C\C1=CC=C([N+]([O-])=O)S1 SPYIETQLOVDJCF-XYOKQWHBSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- BTUGGGLMQBJCBN-UHFFFAOYSA-N 1-iodo-2-methylpropane Chemical compound CC(C)CI BTUGGGLMQBJCBN-UHFFFAOYSA-N 0.000 description 1
- BLRHMMGNCXNXJL-UHFFFAOYSA-N 1-methylindole Chemical compound C1=CC=C2N(C)C=CC2=C1 BLRHMMGNCXNXJL-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 1
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
- HTMGQIXFZMZZKD-UHFFFAOYSA-N 5,6,7,8-tetrahydroisoquinoline Chemical compound N1=CC=C2CCCCC2=C1 HTMGQIXFZMZZKD-UHFFFAOYSA-N 0.000 description 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
- SZWILUXINLNXHO-UHFFFAOYSA-N COC(=O)C1=C(OC)C=CC(CC2=CN(C)C3=CC=C(C=C23)[N+]([O-])=O)=C1 Chemical compound COC(=O)C1=C(OC)C=CC(CC2=CN(C)C3=CC=C(C=C23)[N+]([O-])=O)=C1 SZWILUXINLNXHO-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical group C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000999373 Homo sapiens Interferon-related developmental regulator 2 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 1
- 102100036480 Interferon-related developmental regulator 2 Human genes 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Substances IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 1
- 108010002998 NADPH Oxidases Proteins 0.000 description 1
- 102000004722 NADPH Oxidases Human genes 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 229910020667 PBr3 Inorganic materials 0.000 description 1
- 101150039088 PDIA3 gene Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 108010022425 Platelet Glycoprotein GPIIb-IIIa Complex Proteins 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 239000012095 PrestoBlue reagent Substances 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 101000639461 Rattus norvegicus Small nuclear ribonucleoprotein-associated protein B Proteins 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 101710167005 Thiol:disulfide interchange protein DsbD Proteins 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000004647 alkyl sulfenyl group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 229940127090 anticoagulant agent Drugs 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 1
- 229940127217 antithrombotic drug Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 230000008321 arterial blood flow Effects 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- KMGBZBJJOKUPIA-UHFFFAOYSA-N butyl iodide Chemical compound CCCCI KMGBZBJJOKUPIA-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 125000005518 carboxamido group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 229910052593 corundum Inorganic materials 0.000 description 1
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- AHOOZADJPNUFOQ-UHFFFAOYSA-N ethyl 2-[[2-(2,4-dimethoxy-n-prop-2-ynoylanilino)-2-thiophen-2-ylacetyl]amino]acetate Chemical compound C=1C=CSC=1C(C(=O)NCC(=O)OCC)N(C(=O)C#C)C1=CC=C(OC)C=C1OC AHOOZADJPNUFOQ-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229940045883 glutathione disulfide Drugs 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- VYFOAVADNIHPTR-UHFFFAOYSA-N isatoic anhydride Chemical compound NC1=CC=CC=C1CO VYFOAVADNIHPTR-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000003600 isomerase activity assay Methods 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- OVSQVDMCBVZWGM-QCKGUQPXSA-N isoquercetin Natural products OC[C@@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@@H]1O OVSQVDMCBVZWGM-QCKGUQPXSA-N 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 238000000608 laser ablation Methods 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 102000003835 leukotriene receptors Human genes 0.000 description 1
- 108090000146 leukotriene receptors Proteins 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 125000003518 norbornenyl group Chemical group C12(C=CC(CC1)C2)* 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 230000006508 oncogene activation Effects 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000009805 platelet accumulation Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000010282 redox signaling Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000009076 regulation of hemostasis Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000009863 secondary prevention Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical compound COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000011521 systemic chemotherapy Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- 229910001845 yogo sapphire Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- Thiol isomerases are members of a large family of disulfide oxidoreductases, which catalyze the posttranslational disulfide exchange necessary for the proper folding of newly synthesized proteins.
- thiol isomerase/disulfide oxidoreductases exist in humans with a domain composition of thiol isomerases is a-b-b’-a’.
- These thiol isomerases are generally capable of oxidation reduction and isomerization reactions and are often found in the endoplasmic reticulum where they catalyze the proper folding of newly translated proteins.
- thiol isomerases such as protein disulfide isomerase (PDI), ERp5, ERp57, ERp72 and thioredoxin (TRX) have recently been discovered to perform extracellular functions.
- PDI protein disulfide isomerase
- TRX thioredoxin
- extracellular thiol isomerases are secreted by cells such as platelets and reattach to the plasma membrane, where they function as extracellular oxidoreductases.
- Extracellular thiol isomerases have also been identified on the surface of endothelial cells and to play a role in the activation of thrombus formation and fibrin formation, as well as in platelet aggregation, granule secretion, fibrinogen binding, and calcium mobilization.
- thrombus formation is the most-well studied and understood, while ERp5, ERp57 and ERp72 are also known to be required.
- PDI family members are upregulated in many distinct cancer types, including ovarian, prostate, lung, melanoma, lymphoma and glioma, while inhibition of PDI is cytotoxic in ovarian cancer cell lines.
- VTE venous thromboembolism
- a method of treating cancer or treating or preventing cancer-induced thrombosis comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I), (II), (III), or a pharmaceutically acceptable salt thereof:
- a pharmaceutical composition comprises a compound of Formula (I), (II), (III), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
- the disclosure may alternately comprise, consist of, or consist essentially of, any appropriate components herein disclosed.
- the disclosure may additionally, or alternatively, be formulated so as to be devoid, or substantially free, of any components, materials, ingredients, adjuvants or species used in the prior art compositions or that are otherwise not necessary to the achievement of the function and/or objectives of the present disclosure.
- FIG. 1A and FIG. 1B The inhibition of thiol isomerase activity with ZAF (FIG. 1A) and MON (FIG. 1B) in an enzymatic thiol isomerase activity assay.
- FIG. 2A and FIG. 2B Evaluation of cytotoxicity for analogues 21, 27, 28, ZAF, and MON against BEAS-2B cell line (FIG. 2A); and HEK-293 cell line (FIG. 2B, legend is the same as found in FIG. 2A).
- FIG. 3A and FIG. 3B The inhibition of mammalian cell growth with ZAF and compound 21. Cells were seeded and treated with drug 24 h later. After an additional 24 h of incubation, cell viability was determined using Prestoblue.
- the figures presents a summary of at least 3 independent experiments per cell line. Cell lines used include HEK-293 non-cancer cells (not shown); OVCAR-8 and HCT116.
- FIG. 4A and FIG. 4B Washed human platelets were incubated with compound 21 five minutes prior to stimulation with collagen and measured by an optical aggregometer.
- FIG. 5 ZAF inhibits cancer cell-induced activation of the coagulation cascade. ZAF has inhibitory effects on Factor Xa generation even at low concentrations on HCT116 cells.
- FIG. 6 Insulin turbidity assay, compound 32 inhibits PDI, ERp5, ERp57, and ERp72 similarly to zafirlukast.
- FIG. 7A-7D Cellular thiol isomerase activity is inhibited by zafirlukast.
- FIG. 8A and FIG. 8B Zafirlukast, montelukast, and compound 32 selectively cause cancer cell cytotoxicity. (FIG.
- FIG. 8B Comparison of the relative potency of each compound in the experiments from FIG. 6, FIG. 7, and FIG. 8A.
- PDI protein disulfide isomerase
- thioredoxin ERp5, ERp57, ERp72, or a combination thereof.
- thrombosis (arterial, venous), a thrombotic disease, or a combination thereof.
- thrombosis arterial, venous
- thrombotic disease or a combination thereof.
- One promising mechanism to combat cancer-induced thrombosis is to utilize compounds that can inhibit thiol isomerases, which include protein disulfide isomerase (PDI) and the closely related enzymes, ERp5, ERp57, and ERp72. These enzymes have extracellular activity with important roles in both arterial and venous thrombosis as well as in a variety of cancers.
- PDI protein disulfide isomerase
- ERp5 protein disulfide isomerase
- ERp72 enzymes have extracellular activity with important roles in both arterial and venous thrombosis as well as in a variety of cancers.
- PDI, ERp5, ERp57, and ERp72 are secreted by platelets; they attach to the plasma membrane, where they function as extracellular oxidoreductases. They are required for thrombus formation and fibrin formation as well as for platelet aggregation, dense granule secretion, fibrinogen binding, and calcium mobilization.
- the ability to inhibit both arterial and venous thrombosis is unprecedented amongst potential and current antithrombotic agents.
- Thiol isomerases are also upregulated in many distinct cancer types, including ovarian, prostate, lung, melanoma, lymphoma, and glioma, and increased levels of thiol isomerases have been positively correlated with increased oncogenic transformation, gene transcription, metastasis, and even promoting resistance to chemotherapy and radiation. Similar to their role in platelets, thiol isomerases can also be secreted from tumor cells and perform functions on the cell surface. Thiol isomerase inhibition is cytotoxic to multiple tumor types. For example, inhibiting thiol isomerases significantly suppresses ovarian tumor growth in xenograft mice without causing toxicity to normal tissues.
- thiol isomerases Because of the potential dual utility of thiol isomerase inhibitors as anticancer and antithrombotic agents, thiol isomerases hold significant promise as targets in the prevention of cancer-associated thrombosis. Interestingly, despite their similarity, thiol isomerases are non-redundant in arterial and venous thrombosis formation in that the inhibition of one thiol isomerase will block thrombosis, and they have distinct roles in cancer growth and progression. An inhibitor of any one of thiol isomerases or a pan-thiol isomerase inhibitor would be valuable.
- zafirlukast ZAF
- MON montelukast
- ZAF zafirlukast
- MON montelukast
- thiol isomerase inhibition-induced cytotoxicity to select cancer cell lines and in a xenograft model of ovarian cancer.
- thiol isomerase inhibitors could significantly improve therapeutic outcomes of cancer-associated thrombosis by targeting both major types of thrombosis without effecting bleeding times, diminishing the risks of current prophylactic treatment and at the same time they could constitute a part of the chemotherapeutic regimen as antineoplastic agents.
- the compounds excluded from Formula (III) according to proviso b) are also excluded within the scope of Formula (I) and (II).
- the compound of Formula (I), (II), or (III), or a pharmaceutically acceptable salt thereof, wherein wherein R 1 and R 2 are as previously defined.
- the compound of Formula (I), (II), or (III), or a pharmaceutically acceptable salt thereof wherein R 4 is C1-C8 alkoxy, including branched alkoxy; more specifically wherein R 4 is C1-C4 alkoxy.
- the compound of Formula (I), (II), or (III), or a pharmaceutically acceptable salt thereof wherein wherein R 1 and R 2 are as previously defined and R 4 is C 1 -C 8 alkoxy, including branched alkoxy.
- R 8 is halogen, specifically F.
- R 4 is C 1 -C 8 alkoxy, including branched alkoxy.
- Forma (I) encompasses all compounds that satisfy Formula (I), (II), and (III) including any enantiomers, racemates and stereoisomers as well as all pharmaceutically acceptable salts, solvates, and hydrates of such compounds.
- the compounds of Formula (I), (II), and (III) may contain one or more asymmetric elements such as stereogenic centers, stereogenic axes and the like, e.g. asymmetric carbon atoms, so that the compounds can exist in different stereoisomeric forms. These compounds can be, for example, racemates or optically active forms.
- these compounds can additionally be mixtures of diastereomers.
- these compounds can additionally be mixtures of diastereomers.
- all of the optical isomers and mixtures thereof are encompassed.
- single enantiomers i.e., optically active forms
- isotopes of atoms occurring in the present compounds are contemplated. Isotopes include those atoms having the same atomic number but different mass numbers.
- isotopes of hydrogen include tritium and deuterium and isotopes of carbon include 11 C, 13 C, and 14 C.
- Certain compounds are described herein using a general formula that includes variables, e.g. R 1 -R 9 , Y, Z, etc. Unless otherwise specified, each variable within such a formula is defined independently of other variables.
- active agent means a compound (including a compound of Formula (I), (II), and (III)), element, or mixture that when administered to a patient, alone or in combination with another compound, element, or mixture, confers, directly or indirectly, a physiological effect on the patient.
- the indirect physiological effect may occur via a metabolite or other indirect mechanism.
- the active agent is a compound
- salts, solvates (including hydrates) of the free compound, crystalline forms, non-crystalline forms, and any polymorphs of the compound are included. All forms are contemplated herein regardless of the methods used to obtain them.
- a dash (“-") that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, -(CH 2 )C 3 -C 8 cycloalkyl is attached through carbon of the methylene (CH2) group.
- Alkanoyl groups have the indicated number of carbon atoms, with the carbon of the keto group being included in the numbered carbon atoms.
- a C 4 alkanoyl group or greater can include a cycloalkyl group (e.g. cyclopropane group) as well as linear or branched groups.
- alkyl as used herein, means a branched or straight chain saturated aliphatic hydrocarbon group having the specified number of carbon atoms, generally from 1 to about 12 carbon atoms.
- C 1 -C 6 alkyl indicates an alkyl group having from 1, 2, 3, 4, 5, or 6 carbon atoms.
- Other embodiments include alkyl groups having from 1 to 8 carbon atoms, 1 to 4 carbon atoms or 1 or 2 carbon atoms, e.g. C1-C6 alkyl, C1-C4 alkyl, and C 1 -C 2 alkyl.
- C 0 -C n alkyl When C 0 -C n alkyl is used herein in conjunction with another group, for example, (cycloalkyl)C0-C4 alkyl, the indicated group, in this case cycloalkyl, is either directly bound by a single covalent bond (C0), or attached by an alkyl chain having the specified number of carbon atoms, in this case 1, 2, 3, or 4 carbon atoms.
- alkyl include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, 3-methylbutyl, t- butyl, n-pentyl, and sec-pentyl.
- cycloalkyl indicates a saturated hydrocarbon ring group, having only carbon ring atoms and having the specified number of carbon atoms, usually from 3 to about 8 ring carbon atoms, or from 3 to about 7 carbon atoms.
- cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl as well as bridged or caged saturated ring groups such as norborane or adamantane.
- heterocycloalkyl indicates a saturated cyclic group containing from 1 to about 3 heteroatoms chosen from N, O, and S, with remaining ring atoms being carbon. Heterocycloalkyl groups have from 3 to about 8 ring atoms, and more typically have from 5 to 7 ring atoms. Examples of heterocycloalkyl groups include morpholinyl, piperazinyl, piperidinyl, and pyrrolidinyl groups. A nitrogen in a heterocycloalkyl group may optionally be quaternized.
- alkenyl means straight and branched hydrocarbon chains comprising one or more unsaturated carbon-carbon bonds, which may occur in any stable point along the chain.
- Alkenyl groups described herein typically have from 2 to about 12 carbon atoms.
- Exemplary alkenyl groups are lower alkenyl groups, those alkenyl groups having from 2 to about 8 carbon atoms, e.g. C 2 -C 8 , C 2 -C 6 , and C 2 -C 4 alkenyl groups.
- alkenyl groups include ethenyl, propenyl, and butenyl groups.
- cycloalkenyl means a saturated hydrocarbon ring group, comprising one or more unsaturated carbon-carbon bonds, which may occur in any stable point of the ring, and having the specified number of carbon atoms.
- Monocyclic cycloalkenyl groups typically have from 3 to about 8 carbon ring atoms or from 3 to 7 (3, 4, 5, 6, or 7) carbon ring atoms.
- Cycloalkenyl substituents may be pendant from a substituted nitrogen or carbon atom, or a substituted carbon atom that may have two substituents may have a cycloalkenyl group, which is attached as a spiro group.
- cycloalkenyl groups include cyclopropenyl, cyclobutenyl, cyclopentenyl, or cyclohexenyl as well as bridged or caged saturated ring groups such as norbornene.
- heterocycloalkenyl refers to a 3- to 10- membered, including 4- to 8-membered, non-aromatic ring structure having one or more double bonds, and wherein one or more of the ring atoms is a heteroatom, e.g., N, O, or S.
- (cycloalkyl)C0-Cn alkyl means a substituent in which the cycloalkyl and alkyl are as defined herein, and the point of attachment of the (cycloalkyl)alkyl group to the molecule it substitutes is either a single covalent bond, (C 0 alkyl) or on the alkyl group.
- (Cycloalkyl)alkyl encompasses, but is not limited to, cyclopropylmethyl, cyclobutylmethyl, and cyclohexylmethyl.
- (heterocycloalkyl)C0-Cn alkyl means a substituent in which the heterocycloalkyl and alkyl are as defined herein, and the point of attachment of the (heterocycloalkyl)alkyl group to the molecule it substitutes is either a single covalent bond, (C0alkyl) or on the alkyl group.
- (Heterocycloalkyl)alkyl encompasses, but is not limited to, morpholinylmethyl, piperazinylmethyl, piperidinylmethyl, and pyrrolidinylmethyl groups.
- (heterocycloalkenyl)C0-C6 alkyl means a substituent in which the heterocycloalkenyl and alkyl are as defined herein, and the point of attachment of the (heterocycloalkenyl)alkyl group to the molecule it substitutes is either a single covalent bond, (C0alkyl) or on the alkyl group.
- aryl as used herein, means aromatic groups containing only carbon in the aromatic ring or rings. Typical aryl groups contain 1 to 3 separate, fused, or pendant rings and from 6 to about 18 ring atoms, without heteroatoms as ring members.
- aryl groups may be further substituted with carbon or non-carbon atoms or groups.
- Bicyclic aryl groups may be further substituted with carbon or non-carbon atoms or groups.
- Bicyclic aryl groups may contain two fused aromatic rings (naphthyl) or an aromatic ring fused to a 5- to 7-membered non-aromatic cyclic group that optionally contains 1 or 2 heteroatoms independently chosen from N, O, and S, for example, a 3,4- methylenedioxy-phenyl group.
- Aryl groups include, for example, phenyl, naphthyl, including 1-naphthyl and 2-naphthyl, and bi-phenyl.
- the term “mono- or bicyclic heteroaryl”, as used herein, indicates a stable 5- to 7-membered monocyclic or 7- to 10-membered bicyclic heterocyclic ring which contains at least 1 aromatic ring that contains from 1 to 4, or specifically from 1 to 3, heteroatoms chosen from N, O, and S, with remaining ring atoms being carbon.
- the total number of S and O atoms in the heteroaryl group exceeds 1, theses heteroatoms are not adjacent to one another.
- the total number of S and O atoms in the heteroaryl group is not more than 2, more specifically the total number of S and O atoms in the heteroaryl group is not more than 1.
- a nitrogen atom in a heteroaryl group may optionally be quaternized.
- such heteroaryl groups may be further substituted with carbon or non-carbon atoms or groups.
- Such substitution may include fusion to a 5 to 7-membered saturated cyclic group that optionally contains 1 or 2 heteroatoms independently chosen from N, O, and S, to form, for example, a [1,3]dioxolo[4,5-c]pyridyl group.
- 5- to 6-membered heteroaryl groups are used.
- heteroaryl groups include, but are not limited to, pyridyl, indolyl, pyrimidinyl, pyridizinyl, pyrazinyl, imidazolyl, oxazolyl, furanyl, thiophenyl, thiazolyl, triazolyl, tetrazolyl, isoxazolyl, quinolinyl, pyrrolyl, pyrazolyl, benz[b]thiophenyl, isoquinolinyl, quinazolinyl, quinoxalinyl, thienyl, isoindolyl, and 5,6,7,8- tetrahydroisoquinoline.
- Haloalkyl includes both branched and straight-chain alkyl groups having the specified number of carbon atoms, substituted with 1 or more halogen atoms, up to the maximum allowable number of halogen atoms. Examples of haloalkyl include, but are not limited to, trifluoromethyl, difluoromethyl, 2-fluoroethyl, and penta-fluoroethyl.
- Alkoxy is an alkyl group as defined herein attached through an oxygen bridge (oxygen of an alcohol radical).
- Haloalkoxy is a haloalkyl group as defined herein attached through an oxygen bridge (oxygen of an alcohol radical).
- Halo or “halogen” is any of fluoro, chloro, bromo, and iodo.
- “Mono- and/ or di-alkylamino” is a secondary or tertiary alkyl amino group, wherein the alkyl groups are independently chosen alkyl groups, as defined herein, having the indicated number of carbon atoms. The point of attachment of the alkylamino group is on the nitrogen. Examples of mono- and di-alkylamino groups include ethylamino, dimethylamino, and methyl-propyl-amino.
- substituted means that any one or more hydrogens on the designated atom or group is replaced with a selection from the indicated group, provided that the designated atom’s normal valence is not exceeded.
- an oxo group substitutes aromatic moieties, the corresponding partially unsaturated ring replaces the aromatic ring.
- a pyridyl group substituted by oxo is a pyridone.
- a stable compound or stable structure is meant to imply a compound that is sufficiently robust to survive isolation from a reaction mixture, and subsequent formulation into an effective therapeutic agent.
- substituents are named into the core structure. For example, it is to be understood that when (cycloalkyl)alkyl is listed as a possible substituent the point of attachment of this substituent to the core structure is in the alkyl portion, or when arylalkyl is listed as a possible substituent the point attachment to the core structure is the alkyl portion.
- Suitable groups that may be present on a “substituted” or “optionally substituted” position include, but are not limited to, halogen; cyano; hydroxyl; nitro; azido; alkanoyl (such as a C 2 -C 6 alkanoyl group such as acyl or the like); carboxamido; alkyl groups (including cycloalkyl groups) having 1 to about 8 carbon atoms, or 1 to about 6 carbon atoms; alkenyl and alkynyl groups including groups having one or more unsaturated linkages and from 2 to about 8, or 2 to about 6 carbon atoms; alkoxy groups having one or more oxygen linkages and from 1 to about 8, or from 1 to about 6 carbon atoms; aryloxy such as phenoxy; alkylsulfenyl groups including those having one or more sulfenyl linkages and from 1 to about 8 carbon atoms, or from 1 to about 6 carbon atoms; alkylsul
- salts of the present compounds can be synthesized from a parent compound that contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate, or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid.
- a stoichiometric amount of the appropriate base such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate, or the like
- Salts of the present compounds further include solvates of the compounds and of the compound salts.
- Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
- the pharmaceutically acceptable salts include the conventional non-toxic salts and the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
- conventional non-toxic acid salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, mesylic, esylic, besylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, HOOC-(CH 2
- compositions comprising a compound of Formulas (I)-(III), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- Such pharmaceutical compositions may contain the compound of Formulas(I)-(III) as the only active agent or may contain a combination with an additional pharmaceutically active agent including an additional extracellular thiol isomerase inhibitor or an active agent from a different pharmaceutical class, including an anti-thrombotic agent, and anti-coagulant agent, an anti-inflammatory agent, an anti-viral agent, a chemotherapeutic or an anti-cancer agent, etc., or a combination thereof.
- extracellular thiol isomerase inhibitor compound is an inhibitor of one or more of the extracellular thiol isomerases.
- Exemplary extracellular thiol isomerase inhibitor compounds include a compound of Formula (I), (II), (III), or a pharmaceutically acceptable salt thereof, zafirlukast, montelukast, quercetin, PACMA-31, curcumin, rutin, isoquercetin, CCF642, and a combination thereof.
- the compound may be administered orally, topically, parenterally, by inhalation or spray, sublingually, transdermally, via buccal administration, rectally, as an ophthalmic solution, or by other means, in dosage form containing conventional pharmaceutically acceptable carriers.
- the pharmaceutical composition may be formulated as any pharmaceutically useful form, e.g., as an aerosol, a cream, a gel, a pill, a capsule, a tablet, a syrup, a transdermal patch, or an ophthalmic solution.
- Some dosage forms, such as tablets and capsules, can be subdivided into suitably sized unit doses containing appropriate quantities of the active components, e.g., an effective amount to achieve the desired purpose.
- dosage form means a unit of administration of an active agent.
- dosage forms include tablets, capsules, injections, suspensions, liquids, emulsions, creams, ointments, suppositories, inhalable forms, transdermal forms, and the like.
- An exemplary dosage form is a solid oral dosage form.
- pharmaceutical compositions are compositions comprising at least one active agent, such as a compound or salt of Formula (I), (II), or (III) and at least one other substance, such as a carrier.
- Pharmaceutical compositions meet the U.S. FDA’s GMP (good manufacturing practice) standards for human or non-human drugs.
- the pharmaceutical compositions can be formulated into a dosage form.
- carrier refers to a diluent, excipient, or vehicle with which an active compound is provided.
- Carriers include excipients and diluents and must be of sufficiently high purity and sufficiently low toxicity to render them suitable for administration to the patient being treated.
- the carrier can be inert or it can possess pharmaceutical benefits of its own.
- the amount of carrier employed in conjunction with the compound is sufficient to provide a practical quantity of material for administration per unit dose of the active compound.
- Classes of carriers include, for example, buffering agents, coloring agents, diluents, disintegrants, emulsifiers, flavorants, glidants, lubricants, preservatives, stabilizers, surfactants, tableting agents, and wetting agents.
- Some carriers may be listed in more than one class, for example vegetable oil may be used as a lubricant in some formulations and a diluent in others.
- Exemplary pharmaceutically acceptable carriers include sugars, starches, celluloses, powdered tragacanth, malt, gelatin, talc, and vegetable oils.
- Optional additional active agents may be included in a pharmaceutical composition, which do not substantially interfere with the activity of the compound of Formula (I), (II), (III), etc.
- compositions can be formulated for oral administration. These compositions contain between 0.1 and 99 weight percent (“wt.%”) of the active compound of Formula (I), (II), (III) or pharmaceutically acceptable salt thereof, specifically at least about 5 wt.%. In some embodiments, the composition contains from about 25 wt.% to about 50 wt. % or from about 5 wt.% to about 75 wt.% of the active compound.
- terapéuticaally effective amount of a pharmaceutical composition means an amount effective, when administered to a patient, to provide a therapeutic benefit such as a prevention or an amelioration of symptoms, e.g., to treat a patient suffering from a disease or condition influenced by the activity of one or more of the extracellular thiol isomerases.
- a therapeutically effective amount may vary according to factors such as the disease state, age, and weight of the patient, and the ability of the compound to elicit a desired response in the patient. Dosage regimens may be adjusted to provide the optimum therapeutic response.
- a therapeutically effective amount is also one in which any toxic or detrimental effects (e.g., side effects) of the inhibitor compound are outweighed by the therapeutically beneficial effects.
- a therapeutically effective amount may range from about 0.001 ⁇ g/kg/day to about 500 mg/kg/day, preferably 0.01 ⁇ g/kg/day and 100 mg/kg/day of the compound of Formula (I), (II), (III) or pharmaceutically acceptable salt thereof.
- the skilled artisan will appreciate that certain factors may influence the dosage required to effectively treat a patient, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the patient, and other diseases present.
- treatment of a patient with a therapeutically effective amount of an inhibitor compound can include a single treatment or, can include a series of treatments. It will also be appreciated that the effective dosage of an inhibitor compound used for treatment may increase or decrease over the course of a particular treatment.
- the compound of Formula (I), (II), (III) or pharmaceutically acceptable salt thereof can be administered once, twice, or three times a day to the patient in need thereof. Within this embodiment, the administration can be made orally. [0080] When administered orally, the total daily dose of the compound of Formula (I), (II), (III) or pharmaceutically acceptable salt thereof, can be about 0.1 to about 200 mg, specifically about 1 to about 175 mg, more specifically about 20 to about 150 mg, and still more specifically about 60 to about 125 mg administered once, twice, or three times a day orally.
- the pharmaceutical composition can be formulated in a package comprising the pharmaceutical composition in a container and further comprising instructions for using the composition in the prevention and treatment of a disease or disorder mediated by the one or more thiol isomerases of the extracellular thiol isomerases.
- a method of treating or preventing cancer-induced thrombosis comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (I), (II), (III), or a pharmaceutically acceptable salt thereof, optionally as a pharmaceutical composition comprising the compound.
- a method of inhibiting one or more of the extracellular thiol isomerases in a patient in need thereof for the treatment or prevention of a disease or condition influenced by the activity of one or more of the extracellular thiol isomerases, or for inhibiting a process influenced by the activity of one or more of the extracellular thiol isomerases comprises administering to the patient a therapeutically effective amount of a compound of Formula (I), (II), (III) or pharmaceutically acceptable salt thereof or composition comprising the compound.
- the disease or condition is thrombosis, cancer-induced thrombosis, a thrombotic disease, an infectious disease including human immunodeficiency virus (HIV), a cancer, inflammation, or a combination thereof, as described herein.
- Extracellular thiol isomerases include at least protein disulfide isomerase (PDI), thioredoxin (TRX), and the following endoplasmic reticulum resident proteins: ERp5, ERp57, and ERp72.
- PDI is a 508 amino acid protein that has an important role in platelet activation.
- ERp5 is a 440 amino acid protein that contains two thioredoxin (CGHC containing motifs) domains and shares a 47% sequence identify with PDI. Blocking cell- surface ERp5 results in decreased platelet aggregation, fibrinogen binding, and alpha-granule secretion.
- ERp57 is a thiol isomerase consisting of 505 amino acids and it plays important roles in regulating initial platelet activation and also supporting arterial thrombus formation, affecting platelet aggregation, dense granule secretion, fibrinogen binding, calcium mobilization and thrombus formation under arterial blood flow conditions.
- ERp72 is a 645 amino acid soluble ER protein which shares 37% sequence homology with PDI. ERp72 has three catalytic CGHC domains compared to the two found in PDI, ERp5 and ERp57. The percent increase of ERp72 recruited to the surface of platelets after activation is higher than that of PDI, ERp5 and ERp57, suggesting it performs an important albeit currently unknown role in platelet activation.
- ERp72 inhibition on thrombus formation is similarly unknown.
- ERp72 has been implicated in the infectious process of polyomavirus and also in the redox signaling of NADPH oxidase (Nox) 1.
- Nox NADPH oxidase
- Zafirlukast and montelukast are inhibitors of the four thiol isomerases PDI, ERp5, ERp57, and ERp72 and are able to inhibit both venous and arterial thrombosis without enhancing bleeding risk, and cancer cell and tumor growth.
- Certain zafirlukast derivatives described herein demonstrate improved activity when compared to zafirlukast.
- the target for inhibition is one or more thiol isomerases of the extracellular thiol isomerases, including protein disulfide isomerase (PDI), thioredoxin (TRX), ERp5, ERp57, and ERp72.
- PDI protein disulfide isomerase
- TRX thioredoxin
- ERp5 protein disulfide isomerase
- TRX thioredoxin
- ERp5 protein disulfide isomerase
- TRX thioredoxin
- ERp5 protein disulfide isomerase
- TRX thioredoxin
- ERp5 protein disulfide isomerase
- TRX thioredoxin
- ERp5 protein disulfide isomerase
- TRX thioredoxin
- ERp5 protein disulfide isomerase
- TRX thioredoxin
- ERp5 protein disulfide isomerase
- TRX thi
- Medical treatment can include treatment of an existing condition, such as a disease or disorder, prophylactic or preventative treatment, or diagnostic treatment.
- the patient is a human patient.
- providing means giving, administering, selling, distributing, transferring (for profit or not), manufacturing, compounding, or dispensing.
- the term “providing a compound of Formula (I), (II), (III), or a pharmaceutically acceptable salt thereof, with an additional pharmaceutically active agent”, as used herein, means the compound of Formula (I), (II), (III), or a pharmaceutically acceptable salt thereof, and the additional pharmaceutically active agent are provided simultaneously in a single dosage form, provided concomitantly in separate dosage forms, or provided in separate dosage forms for administration separated by some amount of time that is within the time in which both the compound of Formula (I), (II), (III), or a pharmaceutically acceptable salt thereof, and the additional pharmaceutically active agent are within the blood stream of a patient.
- the additional pharmaceutically active agent need not require a prescription.
- Administration of the compound of Formula (I), (II), (III), or a pharmaceutically acceptable salt thereof, or the additional pharmaceutically active agent can occur via any appropriate route, for example, oral tablets, oral capsules, oral liquids, inhalation, injection, suppositories or topical contact.
- the term “providing an extracellular thiol isomerase inhibitor compound or pharmaceutically acceptable salt thereof with at least one additional therapeutic agent”, as used herein, means an extracellular thiol isomerase inhibitor compound or pharmaceutically acceptable salt thereof and the additional active agent(s) are provided simultaneously in a single dosage form, provided concomitantly in separate dosage forms, or provided in separate dosage forms for administration separated by some amount of time that is within the time in which both the extracellular thiol isomerase inhibitor compound or pharmaceutically acceptable salt thereof and the at least one additional active agent are within the blood stream of a patient.
- the extracellular thiol isomerase inhibitor compound or pharmaceutically acceptable salt thereof and the additional active agent need not be prescribed for a patient by the same medical care worker.
- the additional active agent or agents need not require a prescription.
- Administration of the extracellular thiol isomerase inhibitor compound or pharmaceutically acceptable salt thereof or the at least one additional active agent can occur via any appropriate route, for example, oral tablets, oral capsules, oral liquids, inhalation, injection, suppositories or topical contact.
- treatment includes providing an extracellular thiol isomerase inhibitor compound, a compound of Formula (I), (II), (III), or pharmaceutically acceptable salt thereof, either as the only active agent or together with at least one additional active agent sufficient to: (a) prevent a disease or condition or a symptom of a disease or condition from occurring in a patient who may be predisposed to the disease or condition but has not yet been diagnosed as having it; (b) inhibiting the disease or condition, i.e. arresting its development; and (c) relieving the disease or condition, i.e., causing regression of the disease or condition.
- Treating” and “treatment” also means providing a therapeutically effective amount of an extracellular thiol isomerase inhibitor compound or pharmaceutically acceptable salt thereof, as the only active agent or together with at least one additional active agent to a patient suffering from a disease or condition influenced by the activity of one or more extracellular thiol isomerases.
- a disease or condition influenced by the activity of one or more extracellular thiol isomerases means the one or more extracellular thiol isomerase is implicated in the disease or condition.
- the extracellular thiol isomerase inhibitor compound or pharmaceutical compositions/combinations disclosed herein are useful for treating patients.
- the extracellular thiol isomerase inhibitor compound or pharmaceutical compositions/combinations are useful for treating or preventing diseases and disorders where the activity of one or more extracellular thiol isomerases are involved.
- the patient is afflicted with thrombosis or is at a risk of developing a thrombosis.
- the patient is afflicted with cancer.
- the patient is at risk of, or afflicted with, cancer-induced thrombosis.
- the disease is hematological cancer, HPV associated cancer, ovarian cancer, prostate cancer, gastric cancer, breast cancer, or colorectal cancer.
- the patient to be treated is afflicted with an inflammatory disorder, an infectious disease, an immune disorder, or a neurologic disease.
- Anti-thrombotic Extracellular thiol isomerases are involved the regulation of hemostasis and thrombosis, as the inhibition of one or more extracellular thiol isomerases will block platelet aggregation, granule secretion, adhesion, thrombus formation and fibrin generation.
- Antithrombotics can be used therapeutically for prevention (primary prevention, secondary prevention) or treatment of a dangerous blood clot (acute thrombosis).
- the thrombotic disease or condition to be prevented or treated by the extracellular thiol isomerase inhibitor compound can be acute myocardial infarction, stable angina, unstable angina, acute occlusion following coronary angioplasty and/or stent placement, a transient ischemic attack, cerebrovascular disease, stroke, peripheral vascular disease, placental insufficiency, atrial fibrillation, deep vein thrombosis, pulmonary embolism, or a combination thereof.
- Platelet responses in the presence of zafirlukast, (0.1 ⁇ M –10 ⁇ M) were tested in a range of platelet functional assays including aggregation, granule secretion and spreading studies.
- Zafirlukast was found to inhibit platelet aggregation, dense and ⁇ -granule secretion, platelet spreading upon collagen and thrombus formation under flow. These data suggest that zafirlukast and other broad spectrum inhibitors of thiol isomerases of the protein disulfide isomerase subfamily can be used as an anti-thrombotic drug.
- the disease or condition influenced by the activity of one or more extracellular thiol isomerases is arterial thrombosis, venous thrombosis, a thrombotic disease such as acute myocardial infarction, stable angina, unstable angina, acute occlusion following coronary angioplasty and/or stent placement, a transient ischemic attack, cerebrovascular disease, stroke, peripheral vascular disease, placental insufficiency, atrial fibrillation, deep vein thrombosis, and pulmonary embolism, or a combination thereof; and wherein the extracellular thiol isomerase inhibitor compound is a compound of Formula (I), (II), (III), or a pharmaceutically acceptable salt thereof.
- a thrombotic disease such as acute myocardial infarction, stable angina, unstable angina, acute occlusion following coronary angioplasty and/or stent placement, a transient ischemic attack, cerebrovascular disease, stroke, peripheral vascular disease, placen
- PDI inhibition is a viable target for cancer therapy. See, Xu et al. “Protein disulfide isomerase: a promising target for cancer therapy” Drug Discovery Today, Vol. 19, No. 3, March 2014. [0105] There is further evidence for tumor metastasis role for ERp5. See Gumireddy et al. “In vivo selection for metastasis promoting genes in the mouse” PNAS (2007) 104, 6696-6701. [0106] ERp57 is expressed from the PDIA3 gene in humans. It consists of 505 amino acids and it is upregulated in breast, lung, uterine, stomach and hepatic cancer, as well as melanoma in comparison to normal tissues.
- ERp57 has the ability to interact with nuclear DNA and activate gene expression as ERp57 interacts with DNA molecules through its catalytically active a’ domain.
- ERp57 is also a component of the STAT3-transcriptional complex and the ERp57- STAT3 modulates the cell signaling and proliferation regulated by STAT3.
- ERp57 also regulates gene expression through the mTOR pathway, which is another important regulator of cell proliferation and survival.
- ERp57 has also been implicated in binding at least three proteins involved with DNA repair, including Ref-1/APE, which itself has the ability to activate additional transcription factors.
- increased ERp57 expression is correlated to a resistance to treatment with paclitaxel in ovarian cancer and radioresistance in laryngeal cancer, promotes the metastasis of breast cancer into bone, and is involved in the deregulation of EGFR signaling in a breast cancer cell line, preventing its downstream activation of target molecules such as STAT3, Akt and PLC ⁇ .
- target molecules such as STAT3, Akt and PLC ⁇ .
- the cancer to be treated can be ovarian, prostate, lung, melanoma, lymphoma, glioma, breast, colon, colorectal, hematological, laryngeal, melanoma, or neuroblastoma.
- the compound of Formula (I), (II), (III), or a pharmaceutically acceptable salt thereof can be used alone or optionally in combination with another anti-cancer or chemotherapeutic agent.
- the cancer is treated with a combination of the compound of Formula (I), (II), (III), or a pharmaceutically acceptable salt thereof and a chemotherapeutic agent such as carboplatin or cisplatin.
- ZAF Zafirlukast
- Scheme I is a general three-step linear synthesis that will be used to make the indole derivatives proposed (alternative synthetic routes or additional steps may be used for the preparation of some of the proposed derivatives).
- This representative synthetic route shows: (a) a condensation reaction between substituted indoles and methyl-5-formyl-2- methoxy benzoate using triethylsilane, which is a source of anhydride, trifluoroacetic acid, and dichloromethane, (b) hydrolysis of the ester to a carboxylic acid using sodium hydroxide, methanol, tetrahydrofuran, and water, followed by (c) amide coupling using an arylsulfonamide, N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride, which is the reducing agent, 4-dimethylaminopyridine, and dichloromethane.
- Scheme II. is a general synthesis that will be used to make additional heteroaryl and heterocycles derivatives (containing N, O, or S) beyond the indole ring.
- the step that will differ from that of Scheme I. is the first step with the condensation reaction (labeled as step (a) in Scheme II.), while steps (q) and (r) will remain the same as steps (b) and (c) for Scheme I. in terms of the hydrolysis of the ester to the carboxylic acid and amide coupling as the final two steps of the synthesis.
- VNMRS500 Varian 500
- 400 (MR400) MHz spectrometers were used to record 1 H NMR spectra at 500 or 400 MHz, respectively.
- a Varian 400 MHz spectrometer was used to record all 13 C NMR spectra at 100 MHz. All NMR spectra chemical shifts ( ⁇ ) are given in parts per million (ppm). All coupling constants (J) are given in Hertz (Hz), and the abbreviations used for signal shape are singlet (s), doublet (d), triplet (t), multiplet (m), doublet of doublets (dd), doublet of triplets (dt), and triplet of doublets (td).
- Example 2 Determination of the potency of ZAF derivatives for inhibition of PDI, ERp5, ERp57, and ERp72 [0146] Two methods are used to determine the potency of ZAF derivatives for inhibition of PDI, ERp5, ERp57, and ERp72.
- the first assay is the insulin turbidity assay used to measure the thiol isomerase inhibitory activity of the analogues.
- This insulin inhibition assay has a high-nM IC 50 sensitivity limit.
- the second assay is a highly sensitive continuous assay, where the fluorescence of di-(O-aminobenzoyl) glutathione disulfide (diabz-GSSG) is enhanced upon its reduction catalyzed by the above glutathione isomerase enzymes for very potent compounds.
- the substrate diabz-GSSG is straightforward to prepare, by a reaction of isatoic anhydride and oxidized glutathione in an aqueous buffer, followed by Sephadex G-10 purification. Fluorescence of the substrate is self-quenched in the oxidized S-S form and is greatly ( ⁇ 20-fold) enhanced upon enzymatic reduction.
- ZAF and MON inhibit thiol isomerases.
- the potency of ZAF and MON in the insulin turbidity assay for PDI, ERp5, ERp57, and ERp72 was determined.
- the reduction of insulin catalyzed by thiol isomerases in the presence of dithiothreitol (DTT) results in aggregation of insulin chains.
- the turbidity of insulin aggregation is monitored by measuring light absorbance at 650 nm.
- the insulin-based turbidometric assay was adapted to a 384-well format.
- the importance of the 2-F phenyl for the arylsulfonamide of compound 21 was investigated by the synthesis of compounds 27-31 that contained other halogens and di-fluoro groups, which led to compounds with a slight decrease in activity compared to the lead compound 21.
- ZAF and compound 21 inhibit cancer cell growth. ZAF and compound 21 were tested to assess the viability of HCT116 colon cancer cells and OVCAR-8 ovarian cancer cells. HEK-293 embryonic kidney cells were used as a non-cancer cell control.
- IC 50 values were in the 3-10 ⁇ M range.
- cellular growth inhibition by Compound 21 (inverted triangles) was measured using the standard 3-day growth inhibition assay and compared to ZAF (circles). Compound 21 was 3- to 8-fold more potent than ZAF.
- the FIG. 3 presents a summary of at least 3 independent experiments per cell line. Cell lines used include HEK-293 non-cancer cells (not shown); OVCAR-8 and HCT116.
- ZAF and MON inhibit platelet aggregation and fibrin formation.
- Compound 21 (FIG. 4A, FIG. 4B) inhibits platelet aggregation. Platelet aggregation was measured in washed platelet suspensions in the presence of either DMSO, ZAF (0.1-40 ⁇ M), or compound 21 (0.6-30 ⁇ M) and stimulated for 180 seconds with collagen, decreasing platelet aggregation in a dose dependent manner, with a potency of compound 21 > ZAF > MON.
- ZAF inhibits platelet aggregation and thrombus formation in mice
- Mouse platelet aggregation (in animal) and thrombus formation are inhibited by ZAF.
- Thiol isomerases inhibition prevents thrombus formation inside of a live mouse after laser injury, as measured by intravital microscopy (See Holbrook et al. “Zafirlukast is a broad-spectrum thiol isomerase inhibitor that inhibits thrombosis without altering bleeding times” Br. J. Pharmacol. 2021;178:550–563).
- thiol isomerase inhibition diminishes fibrin formation using the same model, and it has been shown that thiol isomerase inhibition diminishes tumor growth and progression without causing damage to normal tissues. Importantly, thiol isomerase inhibition does not increase bleeding times (Holbrook et al.), which is a major side effect associated with current antithrombotic therapies.
- Example 8. Compound 21 Assessment of platelet aggregation and thrombus formation in mice [0155] In order to assess the ability of compound 21 to inhibit arterial thrombus formation, intravital microscopy using laser injury will be performed.
- mice aged 4-5 weeks Male C57BL/6J mice aged 4-5 weeks will be anaesthetized with a weight range of 19-25 g by intraperitoneal injection of ketamine (125 mg/kg), xylazine (12.5 mg/kg), and atropine (0.25 mg/kg). Platelets will be labelled by intravenous infusion of DyLight 649-conjugated anti-GPIb platelet labelling antibody (0.2 ⁇ g/g of body weight).
- the vehicle of DMSO (0.1% v/v) or zafirlukast derivative will be infused intravenously and following a 5-min incubation period, the arteriole wall injury will be induced by laser ablation (Micropoint, Andor Technology, Harbor, UK). Then thrombus formation will be observed using an Olympus BX microscope (Olympus, Essex, UK) and a Hamamatsu (Hamamatsu Photonics, Hertfordshine, UK) CCD camera, with the data analyzed using Slidebook Software 5.0 (Intelligent Imaging Innovations, Denver, USA). Mice will be killed using Schedule 1 approved methods at the end of the experiment.
- Compound 32 is an analogue of zafirlukast where it has been modified to significantly decrease or abolish its affinity for the leukotriene receptor 1 (LTR1) receptor while retaining its potency as a thiol isomerase inhibitor.
- Compound 32 maintained a similar potency ( ⁇ 1.5 ⁇ fold less) to that of zafirlukast at inhibiting thiol isomerases in the insulin turbidity assay ( Figure 6).
- the thiol isomerase activity of OVCAR8 cells is also inhibited by zafirlukast treatment.
- cleavage of the fluorescent di ⁇ eosin thiol isomerase substrate was inhibited after treatment with zafirlukast in a concentration ⁇ dependent manner.
- thiol isomerases levels were measured following 1 hour of treatment with 10 ⁇ M and 30 ⁇ M zafirlukast in OVCAR8 cells.
- OVCAR8 cells were plated at 10,000 cells per well, allowed to grow overnight, then treated with 0 ⁇ 100 ⁇ M of zafirlukast, montelukast, or compound 32 for 10 minutes.
- compositions, methods, and articles can alternatively comprise, consist of, or consist essentially of, any ingredients, steps, or components herein disclosed.
- compositions, methods, and articles can additionally, or alternatively, be formulated, conducted, or manufactured so as to be devoid, or substantially free, of any ingredients, steps, or components not necessary to the achievement of the function or objectives of the present claims.
- “Optional” or “optionally” means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event occurs and instances where it does not.
- “About” or “approximately” as used herein is inclusive of the stated value and means within an acceptable range of deviation for the particular value as determined by one of ordinary skill in the art, considering the measurement in question and the error associated with measurement of the particular quantity (e.g., the limitations of the measurement system).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Disclosed are novel thiol isomerase inhibitors and their use in the prevention or treatment of the development or progression of a disease or condition involving one or more of the extracellular thiol isomerases. Further disclosed a method for preventing or treating thrombosis, a thrombotic disease, platelet aggregation, fibrin generation, an infectious disease, a viral disease, an immune disorder, inflammation, a neurologic disease, a neurodegenerative disorder, a cancer or a combination thereof in a patient, comprising: administering to the patient in need thereof a therapeutically effective amount of a compound.
Description
THIOL ISOMERASES INHIBITORS; PREPARATION THEREOF; AND METHODS OF USE THEREOF CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This Application claims the benefit of U.S. Provisional Application No. 63/399,516, filed August 19, 2022, and U.S. Provisional Application No. 63/454,974, filed March 28, 2023, each of which is incorporated by reference in its entirety for all purposes. STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT [0002] This invention was made with government support under R21 CA231000 and F31DE029661 awarded by the National Institutes of Health (NIH). The government has certain rights in the invention. BACKGROUND: [0003] Thiol isomerases are members of a large family of disulfide oxidoreductases, which catalyze the posttranslational disulfide exchange necessary for the proper folding of newly synthesized proteins. Approximately twenty members of a large family of thiol isomerase/disulfide oxidoreductases exist in humans with a domain composition of thiol isomerases is a-b-b’-a’. These thiol isomerases are generally capable of oxidation reduction and isomerization reactions and are often found in the endoplasmic reticulum where they catalyze the proper folding of newly translated proteins. [0004] Additionally, some thiol isomerases such as protein disulfide isomerase (PDI), ERp5, ERp57, ERp72 and thioredoxin (TRX) have recently been discovered to perform extracellular functions. These five thiol isomerases, henceforth referred to as extracellular thiol isomerases, are secreted by cells such as platelets and reattach to the plasma membrane, where they function as extracellular oxidoreductases. Extracellular thiol isomerases have also been identified on the surface of endothelial cells and to play a role in the activation of thrombus formation and fibrin formation, as well as in platelet aggregation, granule secretion, fibrinogen binding, and calcium mobilization. Of these enzymes, the role of PDI in thrombus formation is the most-well studied and understood, while ERp5, ERp57 and ERp72 are also known to be required. [0005] PDI family members are upregulated in many distinct cancer types, including ovarian, prostate, lung, melanoma, lymphoma and glioma, while inhibition of PDI is
cytotoxic in ovarian cancer cell lines. These enzymes are thought to have polyfunctional involvement in the oncogenesis of cancer, where they play roles in the oncogene activation, avoidance of apoptosis, secretion of major histocompatibility complex class I-related A protein (MICA), and the resistance to chemotherapeutic agents. [0006] Patients with cancer have a significantly greater risk of developing arterial thrombosis and venous thromboembolism, and the risk is substantially higher in patients receiving systemic chemotherapy. The mortality risk of a cancer patient who suffers a thromboembolism is doubled, with thrombosis being the second leading cause of death for cancer patients. The annual death rates due to arterial thrombosis or venous thrombosis in cancer patients are ~3-fold and 50-fold higher than the general population, respectively, and they can account for up to 14% of cancer mortality. [0007] Thromboembolic events frequently complicate the treatment of cancer and, while venous events are more common, arterial events are also more prevalent in patients with malignancy than in the rest of the population. However, there is a significant variation in risk among individuals, depending on the type of cancer, chemotherapy regimen, and other clinical risk factors such as stage of cancer, use of catheters, or other interventions, like surgery. When deciding whether a patient will be placed on prophylactic anticoagulation, the risk of the patient developing a thrombotic event needs to be weighed against the risks of taking the anticoagulant medication. A significant amount of time and resources is devoted to developing risk models and scores, such as the Khorana Score, to try and predict the patients who are at the highest risk for a thromboembolic event. Unfortunately, recent studies have found that these risk models are generally poor predictors of the risk of venous thromboembolism (VTE). Moreover, even if the risk scores could be properly predicted and applied to patients for a VTE, using low molecular weight heparin or similar anticoagulation treatments would not be indicated for arterial thrombosis and its sequelae such as myocardial infarctions and strokes. [0008] There remains a need in the art for novel compounds and methods for the treatment of cancer, thrombosis, thromobotic disease, and the treatment or prevention of cancer-induced thrombosis. SUMMARY: [0009] In an embodiment, a method of treating cancer or treating or preventing cancer-induced thrombosis, comprises administering to a patient in need thereof a
therapeutically effective amount of a compound of formula (I), (II), (III), or a pharmaceutically acceptable salt thereof:
R1 is hydrogen, NO2, cyano, halogen, NH2, COOH, hydroxyl, C1-C8 alkyl, C1-C6 haloalkyl, C1-C8 alkyl-OH, C1-C8 alkyl-NH2, C1-C8 alkoxy, mono-C1-C8 alkylamino, di-C1-C8 alkylamino, C2-C6 alkenyl, C3-C7 cycloalkyl, (C3-C7 cycloalkyl)C0-C6 alkyl, C2-C6 alkanoyl, or -Q1(C=O)Q2R9 wherein R9 is hydrogen, C1-C8 alkyl, C1-C6 haloalkyl, C1-C8 alkyl-OH, or aryl; Q1 each and Q2 independently is a bond, O, or NR10, and R10 is hydrogen, C1-C8 alkyl, C1-C6 haloalkyl, or C1-C8 alkyl-OH; R2 is hydrogen, C1-C8 alkyl, C1-C6 haloalkyl, C1-C8 alkyl-OH, C3-C7 cycloalkyl, (C3- C7 cycloalkyl)C0-C6 alkyl, C1-C4 alkanoyl, or unsubstituted or substituted aryl; X is O, S, or N; Y is N or CH; R6 is hydrogen, C1-C8 alkyl, C3-C7 cycloalkyl, (C3-C7 cycloalkyl)C0-C6 alkyl, or C1-C4 alkanoyl when X is N, and R6 is absent when X is S or O; R7 is hydrogen, NO2, cyano, halogen, NH2, COOH, hydroxyl, C1-C8 alkyl, C1-C6 haloalkyl, C1-C8 alkyl-OH, C1-C8 alkyl-NH2, C1-C8 alkoxy, mono-C1-C8 alkylamino, di-C1-C8 alkylamino, C2-C6 alkenyl, C3-C7 cycloalkyl, (C3-C7 cycloalkyl)C0-C6 alkyl, C2-C6 alkanoyl, or -Q1(C=O)Q2R9 wherein Q1, Q2, and R9 are as previously defined; Ar2 is unsubstituted or substituted aryl or unsubstituted or substituted heteroaryl substituted with R8 wherein R8 is NO2, cyano, halogen, NH2, COOH, hydroxyl, C1-C8 alkyl, C1-C6 haloalkyl, C1-C8 alkyl-OH, C1-C8 alkyl-NH2, C1-C8 alkoxy, mono-C1-C8 alkylamino, di- C1-C8 alkylamino, C2-C6 alkenyl, C3-C7 cycloalkyl, (C3-C7 cycloalkyl)C0-C6 alkyl, C2-C6 alkanoyl, or -Q1(C=O)Q2R9 wherein Q1, Q2, and R9 are as previously defined;
R4 is hydrogen, NO2, cyano, halogen, NH2, COOH, hydroxyl, C1-C8 alkyl, C1-C6 haloalkyl, C1-C8 alkyl-OH, C1-C8 alkyl-NH2, C1-C8 alkoxy, mono-C1-C8 alkylamino, di-C1-C8 alkylamino, C2-C6 alkenyl, C3-C7 cycloalkyl, (C3-C7 cycloalkyl)C0-C6 alkyl, C2-C6 alkanoyl, or -Q1(C=O)Q2R9 wherein Q1, Q2, and R9 are as previously defined; and R5 is hydrogen, C1-C6 alkyl, C3-C7 cycloalkyl, (C3-C7 cycloalkyl)C0-C6 alkyl, or C1-C4 alkanoyl, with the following provisos a) and b): a) when
hydrogen, and Ar2 is phenyl or phenyl substituted with R8, then R1, R2, and R8 do not meet the following six conditions for a compound of Formula (III):
NO2, NH2, mono-C1-C8 alkylamino, or di-C1-C8 alkylamino; R2 is hydrogen or C1-C8 alkyl; R4 is hydrogen or C1-C8 alkyl; and R5 is hydrogen; then Ar2 is not unsubstituted phenyl or phenyl substituted at the 2 position with C1- C8 alkyl. [0010] In another embodiment, a compound of Formula (I), (II), (III), or a pharmaceutically acceptable salt thereof:
wherein
R1 is hydrogen, NO2, cyano, halogen, NH2, COOH, hydroxyl, C1-C8 alkyl, C1-C6 haloalkyl, C1-C8 alkyl-OH, C1-C8 alkyl-NH2, C1-C8 alkoxy, mono-C1-C8 alkylamino, di-C1-C8 alkylamino, C2-C6 alkenyl, C3-C7 cycloalkyl, (C3-C7 cycloalkyl)C0-C6 alkyl, C2-C6 alkanoyl, or -Q1(C=O)Q2R9 wherein R9 is hydrogen, C1-C8 alkyl, C1-C6 haloalkyl, C1-C8 alkyl-OH, or aryl; Q1 each and Q2 independently is a bond, O, or NR10, and R10 is hydrogen, C1-C8 alkyl, C1-C6 haloalkyl, or C1-C8 alkyl-OH; R2 is hydrogen, C1-C8 alkyl, C1-C6 haloalkyl, C1-C8 alkyl-OH, C3-C7 cycloalkyl, (C3- C7 cycloalkyl)C0-C6 alkyl, C1-C4 alkanoyl, or unsubstituted or substituted aryl; X is O, S, or N; Y is N or CH; R6 is hydrogen, C1-C8 alkyl, C3-C7 cycloalkyl, (C3-C7 cycloalkyl)C0-C6 alkyl, or C1-C4 alkanoyl when X is N, and R6 is absent when X is S or O; R7 is hydrogen, NO2, cyano, halogen, NH2, COOH, hydroxyl, C1-C8 alkyl, C1-C6 haloalkyl, C1-C8 alkyl-OH, C1-C8 alkyl-NH2, C1-C8 alkoxy, mono-C1-C8 alkylamino, di-C1-C8 alkylamino, C2-C6 alkenyl, C3-C7 cycloalkyl, (C3-C7 cycloalkyl)C0-C6 alkyl, C2-C6 alkanoyl, or -Q1(C=O)Q2R9 wherein Q1, Q2, and R9 are as previously defined; Ar2 is unsubstituted or substituted aryl or unsubstituted or substituted heteroaryl; R4 is hydrogen, NO2, cyano, halogen, NH2, COOH, hydroxyl, C1-C8 alkyl, C1-C6 haloalkyl, C1-C8 alkyl-OH, C1-C8 alkyl-NH2, C1-C8 alkoxy, mono-C1-C8 alkylamino, di-C1-C8 alkylamino, C2-C6 alkenyl, C3-C7 cycloalkyl, (C3-C7 cycloalkyl)C0-C6 alkyl, C2-C6 alkanoyl, or -Q1(C=O)Q2R9 wherein Q1, Q2, and R9 are as previously defined; and R5 is hydrogen, C1-C6 alkyl, C3-C7 cycloalkyl, (C3-C7 cycloalkyl)C0-C6 alkyl, or C1-C4 alkanoyl with the following provisos a) and b): a) when
hydrogen, and Ar2 is phenyl or phenyl substituted with R8, then R1, R2, and R8 do not meet the following six conditions for a compound of Formula (III): R1 R2 R8
gen, NO2, NH2, mono-C1-C8 alkylamino, or di-C1-C8 alkylamino; R2 is hydrogen or C1-C8 alkyl; R4 is hydrogen or C1-C8 alkyl; and R5 is hydrogen; then Ar2 is not unsubstituted phenyl or phenyl substituted at the 2 position with C1- C8 alkyl. [0011] In yet another embodiment, a pharmaceutical composition comprises a compound of Formula (I), (II), (III), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. [0012] The above described and other features are exemplified by the following figures and detailed description. [0013] In general, the disclosure may alternately comprise, consist of, or consist essentially of, any appropriate components herein disclosed. The disclosure may additionally, or alternatively, be formulated so as to be devoid, or substantially free, of any components, materials, ingredients, adjuvants or species used in the prior art compositions or that are otherwise not necessary to the achievement of the function and/or objectives of the present disclosure. DRAWINGS: [0014] Referring now to the figures, which are exemplary embodiments and not to be considered limiting: FIG. 1A and FIG. 1B: The inhibition of thiol isomerase activity with ZAF (FIG. 1A) and MON (FIG. 1B) in an enzymatic thiol isomerase activity assay. [0015] FIG. 2A and FIG. 2B: Evaluation of cytotoxicity for analogues 21, 27, 28, ZAF, and MON against BEAS-2B cell line (FIG. 2A); and HEK-293 cell line (FIG. 2B, legend is the same as found in FIG. 2A). Controls included treatment with Triton-X® (TX, 1% v/v, positive control) and 1% DMSO (negative control). In instances where >100% cell survival was observed, the data as 100% cell survival (normalized data) was displayed. Experiments were performed in quadruplicate.
[0016] FIG. 3A and FIG. 3B: The inhibition of mammalian cell growth with ZAF and compound 21. Cells were seeded and treated with drug 24 h later. After an additional 24 h of incubation, cell viability was determined using Prestoblue. The figures presents a summary of at least 3 independent experiments per cell line. Cell lines used include HEK-293 non-cancer cells (not shown); OVCAR-8 and HCT116. Comparison of ZAF (circles) and compound 21 (inverted triangles) in a 3-day growth inhibition against OVCAR-8 (FIG. 3A) and HCT116 cancer cells (FIG. 3B). [0017] FIG. 4A and FIG. 4B: Washed human platelets were incubated with compound 21 five minutes prior to stimulation with collagen and measured by an optical aggregometer. [0018] FIG. 5: ZAF inhibits cancer cell-induced activation of the coagulation cascade. ZAF has inhibitory effects on Factor Xa generation even at low concentrations on HCT116 cells. [0019] FIG. 6: Insulin turbidity assay, compound 32 inhibits PDI, ERp5, ERp57, and ERp72 similarly to zafirlukast. [0020] FIG. 7A-7D: Cellular thiol isomerase activity is inhibited by zafirlukast. (FIG. 7A) Cellular thiol isomerase activity is inhibited by zafirlukast treatment in a concentration dependent manner as measured by di‐eosin‐GSSG fluorescence (n=4) Data is presented as mean ±SD. One‐way ANOVA and a post‐hoc Dunnett’s test where *p=0.0217 for 3 μM zafirlukast, **p=0.0020 for 10 μM zafirlukast and ****p<0.0001 for 30 μM 14 zafirlukast compared to the control. (FIG. 7B) Levels of PDI, ERp5, ERp57, and ERp72 remain similar with increasing concentrations of zafirlukast in OVCAR8 cells (n=3). Data is presented as mean ±SD. A student’s t‐test was used for comparison to control. No significant changes were present. Cellular thiol isomerase activity is also inhibited by (FIG. 7C) montelukast (n=3) and (FIG. 7D) compound 32 analogue (n=4). Data is presented as mean ±SD. One‐way ANOVA and a post‐hoc Dunnett’s test where *p=0.0219 for 10 μM montelukast, **p=0.0018 for 30 μM montelukast and ***p=0.0002 for 100 μM montelukast compared to the control, while *p=0.0383 for 1 μM compound 32, **p=0.0017 for 3 μM compound 32, ***p= 0.0004 for 10 μM compound 32and ****p<0.0001 for 30 μM compound 32 compared to the control. [0021] FIG. 8A and FIG. 8B: Zafirlukast, montelukast, and compound 32 selectively cause cancer cell cytotoxicity. (FIG. 8A) Zafirlukast is about 5x more cytotoxic than montelukast and 1.5x more cytotoxic than the compound 32 (n=3). (FIG. 8B) Comparison of the relative potency of each compound in the experiments from FIG. 6, FIG. 7, and FIG. 8A.
DETAILED DESCRIPTION: [0022] Disclosed herein are novel thiol isomerase inhibitors and their therapeutic use in the prevention or treatment of the development or progression of a disease or condition involving one or more of the extracellular thiol isomerases, including protein disulfide isomerase (PDI), thioredoxin, ERp5, ERp57, ERp72, or a combination thereof. These compounds find potential use in the prevention and/or treatment of a cancer, thrombosis (arterial, venous), a thrombotic disease, or a combination thereof. [0023] One promising mechanism to combat cancer-induced thrombosis is to utilize compounds that can inhibit thiol isomerases, which include protein disulfide isomerase (PDI) and the closely related enzymes, ERp5, ERp57, and ERp72. These enzymes have extracellular activity with important roles in both arterial and venous thrombosis as well as in a variety of cancers. PDI, ERp5, ERp57, and ERp72 are secreted by platelets; they attach to the plasma membrane, where they function as extracellular oxidoreductases. They are required for thrombus formation and fibrin formation as well as for platelet aggregation, dense granule secretion, fibrinogen binding, and calcium mobilization. The ability to inhibit both arterial and venous thrombosis is unprecedented amongst potential and current antithrombotic agents. Thiol isomerases are also upregulated in many distinct cancer types, including ovarian, prostate, lung, melanoma, lymphoma, and glioma, and increased levels of thiol isomerases have been positively correlated with increased oncogenic transformation, gene transcription, metastasis, and even promoting resistance to chemotherapy and radiation. Similar to their role in platelets, thiol isomerases can also be secreted from tumor cells and perform functions on the cell surface. Thiol isomerase inhibition is cytotoxic to multiple tumor types. For example, inhibiting thiol isomerases significantly suppresses ovarian tumor growth in xenograft mice without causing toxicity to normal tissues. [0024] Because of the potential dual utility of thiol isomerase inhibitors as anticancer and antithrombotic agents, thiol isomerases hold significant promise as targets in the prevention of cancer-associated thrombosis. Interestingly, despite their similarity, thiol isomerases are non-redundant in arterial and venous thrombosis formation in that the inhibition of one thiol isomerase will block thrombosis, and they have distinct roles in cancer growth and progression. An inhibitor of any one of thiol isomerases or a pan-thiol isomerase inhibitor would be valuable. FDA-approved medications zafirlukast (ZAF) and the related montelukast (MON) have been identified as promising broad-spectrum thiol isomerase inhibitors and their potential for the prevention and treatment of cancer-induced thrombosis
have been confirmed, verifying the antineoplastic, antiplatelet, and anticoagulation functions of both compounds. [0025] The use of the compounds described herein can overcome the two major weaknesses of current prophylactic anticoagulation treatment. Data shows that ZAF was able to inhibit both arterial and venous thrombosis, unlike any clinically used antithrombotic agent. Also, while both arterial and venous thrombosis were affected, hemostasis was not, so that there was no increase in bleeding risk. Additionally, thiol isomerase inhibition-induced cytotoxicity to select cancer cell lines and in a xenograft model of ovarian cancer. Together, these data suggest that thiol isomerase inhibitors could significantly improve therapeutic outcomes of cancer-associated thrombosis by targeting both major types of thrombosis without effecting bleeding times, diminishing the risks of current prophylactic treatment and at the same time they could constitute a part of the chemotherapeutic regimen as antineoplastic agents. [0026] Disclosed herein are zafirlukast derivative compounds of Formula (I), (II), (III), or a pharmaceutically acceptable salt thereof:
R1 is hydrogen, NO2, cyano, halogen, NH2, COOH, hydroxyl, C1-C8 alkyl, C1-C6 haloalkyl, C1-C8 alkyl-OH, C1-C8 alkyl-NH2, C1-C8 alkoxy, mono-C1-C8 alkylamino, di-C1-C8 alkylamino, C2-C6 alkenyl, C3-C7 cycloalkyl, (C3-C7 cycloalkyl)C0-C6 alkyl, C2-C6 alkanoyl, or -Q1(C=O)Q2R9 wherein R9 is hydrogen, C1-C8 alkyl, C1-C6 haloalkyl, C1-C8 alkyl-OH, or aryl; Q1 each and Q2 independently is a bond, O, or NR10, and R10 is hydrogen, C1-C8 alkyl, C1-C6 haloalkyl, or C1-C8 alkyl-OH; specifically R1 is an electron withdrawing group; more specifically R1 is NO2, cyano, C1-C6 haloalkyl, CF3, or C2-C6 alkanoyl;
R2 is hydrogen, C1-C8 alkyl, C1-C6 haloalkyl, C1-C8 alkyl-OH, C3-C7 cycloalkyl, (C3- C7 cycloalkyl)C0-C6 alkyl, C1-C4 alkanoyl, or unsubstituted or substituted aryl; specifically R2 is hydrogen, C1-C6 alkyl, C1-C8 alkyl-OH, or unsubstituted or substituted phenyl; X is O, S, or N; Y is N or CH; R6 is hydrogen, C1-C8 alkyl, C3-C7 cycloalkyl, (C3-C7 cycloalkyl)C0-C6 alkyl, or C1-C4 alkanoyl when X is N, and R6 is absent when X is S or O; R7 is hydrogen, NO2, cyano, halogen, NH2, COOH, hydroxyl, C1-C8 alkyl, C1-C6 haloalkyl, C1-C8 alkyl-OH, C1-C8 alkyl-NH2, C1-C8 alkoxy, mono-C1-C8 alkylamino, di-C1-C8 alkylamino, C2-C6 alkenyl, C3-C7 cycloalkyl, (C3-C7 cycloalkyl)C0-C6 alkyl, C2-C6 alkanoyl, or -Q1(C=O)Q2R9 wherein Q1, Q2, and R9 are as previously defined; Ar2 is unsubstituted or substituted aryl or unsubstituted or substituted heteroaryl; specifically Ar2 is phenyl or naphthalene unsubstituted or substituted with R8 wherein R8 is NO2, cyano, halogen, NH2, COOH, hydroxyl, C1-C8 alkyl, C1-C6 haloalkyl, C1-C8 alkyl-OH, C1-C8 alkyl-NH2, C1-C8 alkoxy, mono-C1-C8 alkylamino, di-C1-C8 alkylamino, C2-C6 alkenyl, C3-C7 cycloalkyl, (C3-C7 cycloalkyl)C0-C6 alkyl, C2-C6 alkanoyl, or -Q1(C=O)Q2R9 wherein Q1, Q2, and R9 are as previously defined; more specifically Ar2 is phenyl or 2-naphthalene; R4 is hydrogen, NO2, cyano, halogen, NH2, COOH, hydroxyl, C1-C8 alkyl, C1-C6 haloalkyl, C1-C8 alkyl-OH, C1-C8 alkyl-NH2, C1-C8 alkoxy, mono-C1-C8 alkylamino, di-C1-C8 alkylamino, C2-C6 alkenyl, C3-C7 cycloalkyl, (C3-C7 cycloalkyl)C0-C6 alkyl, C2-C6 alkanoyl, or -Q1(C=O)Q2R9 wherein Q1, Q2, and R9 are as previously defined; specifically R4 is C1-C6 alkyl or C1-C6 alkoxy; more specifically R4 is C1-C2 alkyl or C1-C2 alkoxy; and R5 is hydrogen, C1-C6 alkyl, C3-C7 cycloalkyl, (C3-C7 cycloalkyl)C0-C6 alkyl, or C1-C4 alkanoyl; specifically R5 is hydrogen. with the following provisos a) and b): [0027] In an embodiment, a compound of Formula (I), (II), (III), or a pharmaceutically acceptable salt thereof, as reported herein with the provisos that a) when
hydrogen, and Ar2 is phenyl or phenyl substituted with R8, then R1, R2, and R8 do not meet the following six conditions for a compound of Formula (III):
gen, NO2, NH2, mono-C1-C8 alkylamino, or di-C1-C8 alkylamino; R2 is hydrogen or C1-C8 alkyl; R4 is hydrogen or C1-C8 alkyl; and R5 is hydrogen; then Ar2 is not unsubstituted phenyl or phenyl substituted at the 2 position with C1- C8 alkyl. As understood herein, the compounds excluded from Formula (III) according to proviso b) are also excluded within the scope of Formula (I) and (II). [0028] A compound of Formula (I), or a pharmaceutically acceptable salt thereof,
wherein Ar1, Ar2, R4, and R5 and are as previously defined. [0030] A compound of Formula (III), or a pharmaceutically acceptable salt thereof,
wherein Ar1, Ar2, R4, and R5 and are as previously defined.
[0031] In an embodiment, the compound of Formula (I), (II), or (III), or a pharmaceutically acceptable salt thereof, wherein
wherein R1 and R2 are as previously defined. [0032] In an embodiment, the compound of Formula (I), (II), or (III), or a pharmaceutically acceptable salt thereof, wherein R4 is C1-C8 alkoxy, including branched alkoxy; more specifically wherein R4 is C1-C4 alkoxy. [0033] In an embodiment, the compound of Formula (I), (II), or (III), or a pharmaceutically acceptable salt thereof, wherein
wherein R1 and R2 are as previously defined and R4 is C1-C8 alkoxy, including branched alkoxy. [0034] In an embodiment, the compound of Formula (I), (II), or (III), or a pharmaceutically acceptable salt thereof, wherein Ar2 is phenyl substituted with R8 at the 2 position. Within this embodiment, R8 is halogen, specifically F. [0035] In an embodiment, the compound of Formula (I), (II), or (III), or a pharmaceutically acceptable salt thereof, wherein
wherein R1 and R2 are as previously defined and Ar2 is phenyl substituted with R8 at the 2 position; specifically, R8 is halogen, specifically F. In a further embodiment, R4 is C1-C8 alkoxy, including branched alkoxy. [0036] In an embodiment, the compound of Formula (I), (II), or (III), or a pharmaceutically acceptable salt thereof, wherein
wherein R1 is hydrogen, methyl, ethyl, methoxy, NH2, NO2, -CH2OH, or -Q1(C=O)Q2R9 wherein R9 is hydrogen, C1-C8 alkyl, C1-C6 haloalkyl, C1-C8 alkyl-OH, or aryl and Q1 and Q2 are NH; and R2 is methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, -CH2OH, - CH2NH2, or phenyl; R4 is C1-C4 alkoxy; R5 is hydrogen; and Ar2 is phenyl substituted with R8 at the 2 position; specifically, R8 is halogen, specifically F.
[0037] Also included in this disclosure are compounds of Formula (I) as set out in Table 1 in a non-salt form (e.g. free base form), or as a pharmaceutically acceptable salt thereof. [0038] The compounds are described using standard nomenclature. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this disclosure belongs. Unless clearly contraindicated by the context each compound name includes the free acid or free base form of the compound as well hydrates of the compound and all pharmaceutically acceptable salts of the compound. [0039] The term “Formula (I)”, “Formula (II)”, and “Formula (III)”, as used herein, encompasses all compounds that satisfy Formula (I), (II), and (III) including any enantiomers, racemates and stereoisomers as well as all pharmaceutically acceptable salts, solvates, and hydrates of such compounds. [0040] In certain situations, the compounds of Formula (I), (II), and (III) may contain one or more asymmetric elements such as stereogenic centers, stereogenic axes and the like, e.g. asymmetric carbon atoms, so that the compounds can exist in different stereoisomeric forms. These compounds can be, for example, racemates or optically active forms. For compounds with two or more asymmetric elements, these compounds can additionally be mixtures of diastereomers. For compounds having asymmetric centers, it should be understood that all of the optical isomers and mixtures thereof are encompassed. In these situations, single enantiomers, i.e., optically active forms, can be obtained by asymmetric synthesis, synthesis from optically pure precursors, or by resolution of the racemates or racemic intermediates. Resolution of the racemates can also be accomplished, for example, by conventional methods such as crystallization in the presence of a resolving agent, or chromatography, using, for example, a chiral HPLC column. [0041] Where a compound exists in various tautomeric forms, the compound is not limited to any one of the specific tautomers, but rather includes all tautomeric forms. [0042] All isotopes of atoms occurring in the present compounds are contemplated. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example, and without limitation, isotopes of hydrogen include tritium and deuterium and isotopes of carbon include 11C, 13C, and 14C. [0043] Certain compounds are described herein using a general formula that includes variables, e.g. R1-R9, Y, Z, etc. Unless otherwise specified, each variable within such a formula is defined independently of other variables. Thus, if a group is said to be substituted,
e.g., with 0-2 R1, then the group may be substituted with up to two R1 groups and R1 at each occurrence is selected independently from the definition of R1. Also, combinations of substituents and/or variables are permissible only if such combinations result in a stable compound. [0044] The term “active agent”, as used herein, means a compound (including a compound of Formula (I), (II), and (III)), element, or mixture that when administered to a patient, alone or in combination with another compound, element, or mixture, confers, directly or indirectly, a physiological effect on the patient. The indirect physiological effect may occur via a metabolite or other indirect mechanism. When the active agent is a compound, then salts, solvates (including hydrates) of the free compound, crystalline forms, non-crystalline forms, and any polymorphs of the compound are included. All forms are contemplated herein regardless of the methods used to obtain them. [0045] A dash ("-") that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, -(CH2)C3-C8 cycloalkyl is attached through carbon of the methylene (CH2) group. [0046] “Alkanoyl” is an alkyl group as defined herein, covalently bound to the group it substitutes by a keto (-(C=O)-) bridge. Alkanoyl groups have the indicated number of carbon atoms, with the carbon of the keto group being included in the numbered carbon atoms. For example a C2alkanoyl group is an acetyl group having the formula CH3(C=O)-. A C4alkanoyl group or greater can include a cycloalkyl group (e.g. cyclopropane group) as well as linear or branched groups. [0047] The term “alkyl”, as used herein, means a branched or straight chain saturated aliphatic hydrocarbon group having the specified number of carbon atoms, generally from 1 to about 12 carbon atoms. The term C1-C6 alkyl as used herein indicates an alkyl group having from 1, 2, 3, 4, 5, or 6 carbon atoms. Other embodiments include alkyl groups having from 1 to 8 carbon atoms, 1 to 4 carbon atoms or 1 or 2 carbon atoms, e.g. C1-C6 alkyl, C1-C4 alkyl, and C1-C2 alkyl. When C0-Cn alkyl is used herein in conjunction with another group, for example, (cycloalkyl)C0-C4 alkyl, the indicated group, in this case cycloalkyl, is either directly bound by a single covalent bond (C0), or attached by an alkyl chain having the specified number of carbon atoms, in this case 1, 2, 3, or 4 carbon atoms. Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, 3-methylbutyl, t- butyl, n-pentyl, and sec-pentyl. [0048] The term “cycloalkyl”, as used herein, indicates a saturated hydrocarbon ring group, having only carbon ring atoms and having the specified number of carbon atoms,
usually from 3 to about 8 ring carbon atoms, or from 3 to about 7 carbon atoms. Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl as well as bridged or caged saturated ring groups such as norborane or adamantane. [0049] The term “heterocycloalkyl”, as used herein, indicates a saturated cyclic group containing from 1 to about 3 heteroatoms chosen from N, O, and S, with remaining ring atoms being carbon. Heterocycloalkyl groups have from 3 to about 8 ring atoms, and more typically have from 5 to 7 ring atoms. Examples of heterocycloalkyl groups include morpholinyl, piperazinyl, piperidinyl, and pyrrolidinyl groups. A nitrogen in a heterocycloalkyl group may optionally be quaternized. [0050] The term “alkenyl”, as used herein, means straight and branched hydrocarbon chains comprising one or more unsaturated carbon-carbon bonds, which may occur in any stable point along the chain. Alkenyl groups described herein typically have from 2 to about 12 carbon atoms. Exemplary alkenyl groups are lower alkenyl groups, those alkenyl groups having from 2 to about 8 carbon atoms, e.g. C2-C8, C2-C6, and C2-C4 alkenyl groups. Examples of alkenyl groups include ethenyl, propenyl, and butenyl groups. [0051] The term “cycloalkenyl”, as used herein, means a saturated hydrocarbon ring group, comprising one or more unsaturated carbon-carbon bonds, which may occur in any stable point of the ring, and having the specified number of carbon atoms. Monocyclic cycloalkenyl groups typically have from 3 to about 8 carbon ring atoms or from 3 to 7 (3, 4, 5, 6, or 7) carbon ring atoms. Cycloalkenyl substituents may be pendant from a substituted nitrogen or carbon atom, or a substituted carbon atom that may have two substituents may have a cycloalkenyl group, which is attached as a spiro group. Examples of cycloalkenyl groups include cyclopropenyl, cyclobutenyl, cyclopentenyl, or cyclohexenyl as well as bridged or caged saturated ring groups such as norbornene. [0052] The term “heterocycloalkenyl”, as used herein, refers to a 3- to 10- membered, including 4- to 8-membered, non-aromatic ring structure having one or more double bonds, and wherein one or more of the ring atoms is a heteroatom, e.g., N, O, or S. [0053] The terms “(cycloalkyl)C0-Cn alkyl”, as used herein, means a substituent in which the cycloalkyl and alkyl are as defined herein, and the point of attachment of the (cycloalkyl)alkyl group to the molecule it substitutes is either a single covalent bond, (C0alkyl) or on the alkyl group. (Cycloalkyl)alkyl encompasses, but is not limited to, cyclopropylmethyl, cyclobutylmethyl, and cyclohexylmethyl. [0054] The term “(heterocycloalkyl)C0-Cn alkyl”, as used herein, means a substituent in which the heterocycloalkyl and alkyl are as defined herein, and the point of attachment of
the (heterocycloalkyl)alkyl group to the molecule it substitutes is either a single covalent bond, (C0alkyl) or on the alkyl group. (Heterocycloalkyl)alkyl encompasses, but is not limited to, morpholinylmethyl, piperazinylmethyl, piperidinylmethyl, and pyrrolidinylmethyl groups. [0055] The term “(heterocycloalkenyl)C0-C6 alkyl”, as used herein, means a substituent in which the heterocycloalkenyl and alkyl are as defined herein, and the point of attachment of the (heterocycloalkenyl)alkyl group to the molecule it substitutes is either a single covalent bond, (C0alkyl) or on the alkyl group. [0056] The term “aryl”, as used herein, means aromatic groups containing only carbon in the aromatic ring or rings. Typical aryl groups contain 1 to 3 separate, fused, or pendant rings and from 6 to about 18 ring atoms, without heteroatoms as ring members. When indicated, such aryl groups may be further substituted with carbon or non-carbon atoms or groups. Bicyclic aryl groups may be further substituted with carbon or non-carbon atoms or groups. Bicyclic aryl groups may contain two fused aromatic rings (naphthyl) or an aromatic ring fused to a 5- to 7-membered non-aromatic cyclic group that optionally contains 1 or 2 heteroatoms independently chosen from N, O, and S, for example, a 3,4- methylenedioxy-phenyl group. Aryl groups include, for example, phenyl, naphthyl, including 1-naphthyl and 2-naphthyl, and bi-phenyl. [0057] The term “mono- or bicyclic heteroaryl”, as used herein, indicates a stable 5- to 7-membered monocyclic or 7- to 10-membered bicyclic heterocyclic ring which contains at least 1 aromatic ring that contains from 1 to 4, or specifically from 1 to 3, heteroatoms chosen from N, O, and S, with remaining ring atoms being carbon. When the total number of S and O atoms in the heteroaryl group exceeds 1, theses heteroatoms are not adjacent to one another. Specifically, the total number of S and O atoms in the heteroaryl group is not more than 2, more specifically the total number of S and O atoms in the heteroaryl group is not more than 1. A nitrogen atom in a heteroaryl group may optionally be quaternized. When indicated, such heteroaryl groups may be further substituted with carbon or non-carbon atoms or groups. Such substitution may include fusion to a 5 to 7-membered saturated cyclic group that optionally contains 1 or 2 heteroatoms independently chosen from N, O, and S, to form, for example, a [1,3]dioxolo[4,5-c]pyridyl group. In certain embodiments 5- to 6-membered heteroaryl groups are used. Examples of heteroaryl groups include, but are not limited to, pyridyl, indolyl, pyrimidinyl, pyridizinyl, pyrazinyl, imidazolyl, oxazolyl, furanyl, thiophenyl, thiazolyl, triazolyl, tetrazolyl, isoxazolyl, quinolinyl, pyrrolyl, pyrazolyl,
benz[b]thiophenyl, isoquinolinyl, quinazolinyl, quinoxalinyl, thienyl, isoindolyl, and 5,6,7,8- tetrahydroisoquinoline. [0058] “Haloalkyl” includes both branched and straight-chain alkyl groups having the specified number of carbon atoms, substituted with 1 or more halogen atoms, up to the maximum allowable number of halogen atoms. Examples of haloalkyl include, but are not limited to, trifluoromethyl, difluoromethyl, 2-fluoroethyl, and penta-fluoroethyl. [0059] “Alkoxy” is an alkyl group as defined herein attached through an oxygen bridge (oxygen of an alcohol radical). [0060] “Haloalkoxy” is a haloalkyl group as defined herein attached through an oxygen bridge (oxygen of an alcohol radical). [0061] “Halo” or “halogen” is any of fluoro, chloro, bromo, and iodo. [0062] “Mono- and/ or di-alkylamino” is a secondary or tertiary alkyl amino group, wherein the alkyl groups are independently chosen alkyl groups, as defined herein, having the indicated number of carbon atoms. The point of attachment of the alkylamino group is on the nitrogen. Examples of mono- and di-alkylamino groups include ethylamino, dimethylamino, and methyl-propyl-amino. [0063] The term “substituted”, as used herein, means that any one or more hydrogens on the designated atom or group is replaced with a selection from the indicated group, provided that the designated atom’s normal valence is not exceeded. When the substituent is oxo (i.e., =O) then 2 hydrogens on the atom are replaced. When an oxo group substitutes aromatic moieties, the corresponding partially unsaturated ring replaces the aromatic ring. For example, a pyridyl group substituted by oxo is a pyridone. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds or useful synthetic intermediates. A stable compound or stable structure is meant to imply a compound that is sufficiently robust to survive isolation from a reaction mixture, and subsequent formulation into an effective therapeutic agent. [0064] Unless otherwise specified substituents are named into the core structure. For example, it is to be understood that when (cycloalkyl)alkyl is listed as a possible substituent the point of attachment of this substituent to the core structure is in the alkyl portion, or when arylalkyl is listed as a possible substituent the point attachment to the core structure is the alkyl portion. [0065] Suitable groups that may be present on a “substituted” or “optionally substituted” position include, but are not limited to, halogen; cyano; hydroxyl; nitro; azido; alkanoyl (such as a C2-C6 alkanoyl group such as acyl or the like); carboxamido; alkyl groups
(including cycloalkyl groups) having 1 to about 8 carbon atoms, or 1 to about 6 carbon atoms; alkenyl and alkynyl groups including groups having one or more unsaturated linkages and from 2 to about 8, or 2 to about 6 carbon atoms; alkoxy groups having one or more oxygen linkages and from 1 to about 8, or from 1 to about 6 carbon atoms; aryloxy such as phenoxy; alkylsulfenyl groups including those having one or more sulfenyl linkages and from 1 to about 8 carbon atoms, or from 1 to about 6 carbon atoms; alkylsulfinyl groups including those having one or more sulfinyl linkages and from 1 to about 8 carbon atoms, or from 1 to about 6 carbon atoms; alkylsulfonyl groups including those having one or more sulfonyl linkages and from 1 to about 8 carbon atoms, or from 1 to about 6 carbon atoms; aminoalkyl groups including groups having one or more N atoms and from 1 to about 8, or from 1 to about 6 carbon atoms; aryl having 6 or more carbons and one or more rings, (e.g., phenyl, biphenyl, naphthyl, or the like, each ring either substituted or unsubstituted aromatic); arylalkyl having 1 to 3 separate or fused rings and from 6 to about 18 ring carbon atoms, with benzyl being an exemplary arylalkyl group; arylalkoxy having 1 to 3 separate or fused rings and from 6 to about 18 ring carbon atoms, with benzyloxy being an exemplary arylalkoxy group; or a saturated, unsaturated, or aromatic heterocyclic group having 1 to 3 separate or fused rings with 3 to about 8 members per ring and one or more N, O or S atoms, e.g. coumarinyl, quinolinyl, isoquinolinyl, quinazolinyl, pyridyl, pyrazinyl, pyrimidinyl, furanyl, pyrrolyl, thienyl, thiazolyl, triazinyl, oxazolyl, isoxazolyl, imidazolyl, indolyl, benzofuranyl, benzothiazolyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, morpholinyl, piperazinyl, and pyrrolidinyl. Such heterocyclic groups may be further substituted, e.g. with hydroxy, alkyl, alkoxy, halogen and amino. [0066] The term “pharmaceutically acceptable salt”, as used herein, includes derivatives of the disclosed compounds in which the parent compound is modified by making inorganic and organic, acid or base addition salts thereof. The salts of the present compounds can be synthesized from a parent compound that contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate, or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid. Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two. Generally, non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are used, where practicable. Salts of the present compounds further include solvates of the compounds and of the compound salts.
[0067] Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts and the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, conventional non-toxic acid salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, mesylic, esylic, besylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, HOOC-(CH2)n-COOH where n is 0-4, and the like. Lists of additional suitable salts may be found, e.g., in Remington’s Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., p. 1418 (1985). [0068] Also provided are pharmaceutical compositions comprising a compound of Formulas (I)-(III), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Such pharmaceutical compositions may contain the compound of Formulas(I)-(III) as the only active agent or may contain a combination with an additional pharmaceutically active agent including an additional extracellular thiol isomerase inhibitor or an active agent from a different pharmaceutical class, including an anti-thrombotic agent, and anti-coagulant agent, an anti-inflammatory agent, an anti-viral agent, a chemotherapeutic or an anti-cancer agent, etc., or a combination thereof. [0069] As used herein, “extracellular thiol isomerase inhibitor compound” is an inhibitor of one or more of the extracellular thiol isomerases. Exemplary extracellular thiol isomerase inhibitor compounds include a compound of Formula (I), (II), (III), or a pharmaceutically acceptable salt thereof, zafirlukast, montelukast, quercetin, PACMA-31, curcumin, rutin, isoquercetin, CCF642, and a combination thereof. [0070] The compound may be administered orally, topically, parenterally, by inhalation or spray, sublingually, transdermally, via buccal administration, rectally, as an ophthalmic solution, or by other means, in dosage form containing conventional pharmaceutically acceptable carriers. The pharmaceutical composition may be formulated as any pharmaceutically useful form, e.g., as an aerosol, a cream, a gel, a pill, a capsule, a tablet, a syrup, a transdermal patch, or an ophthalmic solution. Some dosage forms, such as tablets and capsules, can be subdivided into suitably sized unit doses containing appropriate quantities of the active components, e.g., an effective amount to achieve the desired purpose.
[0071] The term “dosage form”, as used herein, means a unit of administration of an active agent. Examples of dosage forms include tablets, capsules, injections, suspensions, liquids, emulsions, creams, ointments, suppositories, inhalable forms, transdermal forms, and the like. An exemplary dosage form is a solid oral dosage form. [0072] The term “pharmaceutical compositions”, as used herein, are compositions comprising at least one active agent, such as a compound or salt of Formula (I), (II), or (III) and at least one other substance, such as a carrier. Pharmaceutical compositions meet the U.S. FDA’s GMP (good manufacturing practice) standards for human or non-human drugs. The pharmaceutical compositions can be formulated into a dosage form. [0073] The term “carrier”, as used herein, applied to pharmaceutical compositions refers to a diluent, excipient, or vehicle with which an active compound is provided. [0074] Carriers include excipients and diluents and must be of sufficiently high purity and sufficiently low toxicity to render them suitable for administration to the patient being treated. The carrier can be inert or it can possess pharmaceutical benefits of its own. The amount of carrier employed in conjunction with the compound is sufficient to provide a practical quantity of material for administration per unit dose of the active compound. [0075] Classes of carriers include, for example, buffering agents, coloring agents, diluents, disintegrants, emulsifiers, flavorants, glidants, lubricants, preservatives, stabilizers, surfactants, tableting agents, and wetting agents. Some carriers may be listed in more than one class, for example vegetable oil may be used as a lubricant in some formulations and a diluent in others. Exemplary pharmaceutically acceptable carriers include sugars, starches, celluloses, powdered tragacanth, malt, gelatin, talc, and vegetable oils. Optional additional active agents may be included in a pharmaceutical composition, which do not substantially interfere with the activity of the compound of Formula (I), (II), (III), etc. [0076] The pharmaceutical compositions can be formulated for oral administration. These compositions contain between 0.1 and 99 weight percent (“wt.%”) of the active compound of Formula (I), (II), (III) or pharmaceutically acceptable salt thereof, specifically at least about 5 wt.%. In some embodiments, the composition contains from about 25 wt.% to about 50 wt. % or from about 5 wt.% to about 75 wt.% of the active compound. [0077] The term “therapeutically effective amount” of a pharmaceutical composition, as used herein, means an amount effective, when administered to a patient, to provide a therapeutic benefit such as a prevention or an amelioration of symptoms, e.g., to treat a patient suffering from a disease or condition influenced by the activity of one or more of the extracellular thiol isomerases. A therapeutically effective amount may vary according to
factors such as the disease state, age, and weight of the patient, and the ability of the compound to elicit a desired response in the patient. Dosage regimens may be adjusted to provide the optimum therapeutic response. A therapeutically effective amount is also one in which any toxic or detrimental effects (e.g., side effects) of the inhibitor compound are outweighed by the therapeutically beneficial effects. [0078] A therapeutically effective amount may range from about 0.001 µg/kg/day to about 500 mg/kg/day, preferably 0.01 µg/kg/day and 100 mg/kg/day of the compound of Formula (I), (II), (III) or pharmaceutically acceptable salt thereof. The skilled artisan will appreciate that certain factors may influence the dosage required to effectively treat a patient, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the patient, and other diseases present. Moreover, treatment of a patient with a therapeutically effective amount of an inhibitor compound can include a single treatment or, can include a series of treatments. It will also be appreciated that the effective dosage of an inhibitor compound used for treatment may increase or decrease over the course of a particular treatment. [0079] The compound of Formula (I), (II), (III) or pharmaceutically acceptable salt thereof can be administered once, twice, or three times a day to the patient in need thereof. Within this embodiment, the administration can be made orally. [0080] When administered orally, the total daily dose of the compound of Formula (I), (II), (III) or pharmaceutically acceptable salt thereof, can be about 0.1 to about 200 mg, specifically about 1 to about 175 mg, more specifically about 20 to about 150 mg, and still more specifically about 60 to about 125 mg administered once, twice, or three times a day orally. [0081] The pharmaceutical composition can be formulated in a package comprising the pharmaceutical composition in a container and further comprising instructions for using the composition in the prevention and treatment of a disease or disorder mediated by the one or more thiol isomerases of the extracellular thiol isomerases. [0082] Also provided are methods for therapeutic treatment using the compound of Formula (I), (II), (III), or a pharmaceutically acceptable salt thereof. In an embodiment, a method of treating or preventing cancer-induced thrombosis comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (I), (II), (III), or a pharmaceutically acceptable salt thereof, optionally as a pharmaceutical composition comprising the compound.
[0083] In an embodiment, a method of inhibiting one or more of the extracellular thiol isomerases in a patient in need thereof for the treatment or prevention of a disease or condition influenced by the activity of one or more of the extracellular thiol isomerases, or for inhibiting a process influenced by the activity of one or more of the extracellular thiol isomerases, the method comprises administering to the patient a therapeutically effective amount of a compound of Formula (I), (II), (III) or pharmaceutically acceptable salt thereof or composition comprising the compound. In certain embodiments, the disease or condition is thrombosis, cancer-induced thrombosis, a thrombotic disease, an infectious disease including human immunodeficiency virus (HIV), a cancer, inflammation, or a combination thereof, as described herein. Extracellular thiol isomerases [0084] As used herein, “extracellular thiol isomerase” includes at least protein disulfide isomerase (PDI), thioredoxin (TRX), and the following endoplasmic reticulum resident proteins: ERp5, ERp57, and ERp72. [0085] PDI is a 508 amino acid protein that has an important role in platelet activation. The release of PDI from activated platelets was demonstrated nearly two decades ago and confirmed in many subsequent studies and it is also released by endothelial cells. Antibodies directed at PDI and micromolar concentrations of the antibiotic bacitracin inhibit platelet aggregation, adhesion, and secretion. Inhibition of PDI has been shown to inhibit cancer cell growth and induce tumor necrosis in an ovarian cancer model. [0086] ERp5 is a 440 amino acid protein that contains two thioredoxin (CGHC containing motifs) domains and shares a 47% sequence identify with PDI. Blocking cell- surface ERp5 results in decreased platelet aggregation, fibrinogen binding, and alpha-granule secretion. In addition to its role in hemostasis, high levels of ERp5 expression have been shown to correlate with preventing an efficient antitumor response in Hodgkin lymphomas and have been proposed as a biomarker for prostate and breast cancer progression. [0087] ERp57 is a thiol isomerase consisting of 505 amino acids and it plays important roles in regulating initial platelet activation and also supporting arterial thrombus formation, affecting platelet aggregation, dense granule secretion, fibrinogen binding, calcium mobilization and thrombus formation under arterial blood flow conditions. In addition to its role in thrombus formation, ERp57 has also been shown to be required for proper folding of influenza hemaagglutinin and implicated in disease progression of Alzheimer’s disease and cancer metastasis.
[0088] ERp72 is a 645 amino acid soluble ER protein which shares 37% sequence homology with PDI. ERp72 has three catalytic CGHC domains compared to the two found in PDI, ERp5 and ERp57. The percent increase of ERp72 recruited to the surface of platelets after activation is higher than that of PDI, ERp5 and ERp57, suggesting it performs an important albeit currently unknown role in platelet activation. The effect of ERp72 inhibition on thrombus formation is similarly unknown. In addition to its relocation to the activated platelet surface, ERp72 has been implicated in the infectious process of polyomavirus and also in the redox signaling of NADPH oxidase (Nox) 1. [0089] Four thiol isomerases, PDI, ERp5, ERp57, and ERp72, have been demonstrated to be important for thrombosis associated with cancer. These four enzymes are non-redundant, i.e., inhibition of only one of them blocks thrombosis. Therefore, one or a combination of two or more of these enzymes are attractive targets for antithrombosis drug development. Furthermore, some cancers are dependent on these enzymes, which would make inhibitors of these enzymes have anticancer activities in these settings. [0090] Zafirlukast and montelukast are inhibitors of the four thiol isomerases PDI, ERp5, ERp57, and ERp72 and are able to inhibit both venous and arterial thrombosis without enhancing bleeding risk, and cancer cell and tumor growth. Certain zafirlukast derivatives described herein demonstrate improved activity when compared to zafirlukast. [0091] In an embodiment, the target for inhibition is one or more thiol isomerases of the extracellular thiol isomerases, including protein disulfide isomerase (PDI), thioredoxin (TRX), ERp5, ERp57, and ERp72. In an embodiment, the target for inhibition is PDI. In an embodiment, the target for inhibition is thioredoxin (TRX). In an embodiment, the target for inhibition is ERp5. In an embodiment, the target for inhibition is ERp57. In an embodiment, the target for inhibition is ERp72. [0092] The term “patient”, as used herein, is a human or non-human animal in need of medical treatment. Medical treatment can include treatment of an existing condition, such as a disease or disorder, prophylactic or preventative treatment, or diagnostic treatment. In some embodiments the patient is a human patient. [0093] The term “providing”, as used herein, means giving, administering, selling, distributing, transferring (for profit or not), manufacturing, compounding, or dispensing. [0094] The term “providing a compound of Formula (I), (II), (III), or a pharmaceutically acceptable salt thereof, with an additional pharmaceutically active agent”, as used herein, means the compound of Formula (I), (II), (III), or a pharmaceutically acceptable salt thereof, and the additional pharmaceutically active agent are provided
simultaneously in a single dosage form, provided concomitantly in separate dosage forms, or provided in separate dosage forms for administration separated by some amount of time that is within the time in which both the compound of Formula (I), (II), (III), or a pharmaceutically acceptable salt thereof, and the additional pharmaceutically active agent are within the blood stream of a patient. The compound of Formula (I), (II), (III), or a pharmaceutically acceptable salt thereof, and the additional pharmaceutically active agent not be prescribed for a patient by the same medical care worker. The additional pharmaceutically active agent need not require a prescription. Administration of the compound of Formula (I), (II), (III), or a pharmaceutically acceptable salt thereof, or the additional pharmaceutically active agent can occur via any appropriate route, for example, oral tablets, oral capsules, oral liquids, inhalation, injection, suppositories or topical contact. [0095] The term “providing an extracellular thiol isomerase inhibitor compound or pharmaceutically acceptable salt thereof with at least one additional therapeutic agent”, as used herein, means an extracellular thiol isomerase inhibitor compound or pharmaceutically acceptable salt thereof and the additional active agent(s) are provided simultaneously in a single dosage form, provided concomitantly in separate dosage forms, or provided in separate dosage forms for administration separated by some amount of time that is within the time in which both the extracellular thiol isomerase inhibitor compound or pharmaceutically acceptable salt thereof and the at least one additional active agent are within the blood stream of a patient. The extracellular thiol isomerase inhibitor compound or pharmaceutically acceptable salt thereof and the additional active agent need not be prescribed for a patient by the same medical care worker. The additional active agent or agents need not require a prescription. Administration of the extracellular thiol isomerase inhibitor compound or pharmaceutically acceptable salt thereof or the at least one additional active agent can occur via any appropriate route, for example, oral tablets, oral capsules, oral liquids, inhalation, injection, suppositories or topical contact. [0096] The term “treatment”, as used herein, includes providing an extracellular thiol isomerase inhibitor compound, a compound of Formula (I), (II), (III), or pharmaceutically acceptable salt thereof, either as the only active agent or together with at least one additional active agent sufficient to: (a) prevent a disease or condition or a symptom of a disease or condition from occurring in a patient who may be predisposed to the disease or condition but has not yet been diagnosed as having it; (b) inhibiting the disease or condition, i.e. arresting its development; and (c) relieving the disease or condition, i.e., causing regression of the disease or condition. “Treating” and “treatment” also means providing a therapeutically
effective amount of an extracellular thiol isomerase inhibitor compound or pharmaceutically acceptable salt thereof, as the only active agent or together with at least one additional active agent to a patient suffering from a disease or condition influenced by the activity of one or more extracellular thiol isomerases. “A disease or condition influenced by the activity of one or more extracellular thiol isomerases” means the one or more extracellular thiol isomerase is implicated in the disease or condition. [0097] The extracellular thiol isomerase inhibitor compound or pharmaceutical compositions/combinations disclosed herein are useful for treating patients. The extracellular thiol isomerase inhibitor compound or pharmaceutical compositions/combinations are useful for treating or preventing diseases and disorders where the activity of one or more extracellular thiol isomerases are involved. In certain embodiments the patient is afflicted with thrombosis or is at a risk of developing a thrombosis. In certain embodiments the patient is afflicted with cancer. In certain embodiments the patient is at risk of, or afflicted with, cancer-induced thrombosis. In certain embodiments the disease is hematological cancer, HPV associated cancer, ovarian cancer, prostate cancer, gastric cancer, breast cancer, or colorectal cancer. In other embodiments the patient to be treated is afflicted with an inflammatory disorder, an infectious disease, an immune disorder, or a neurologic disease. Anti-thrombotic [0098] Extracellular thiol isomerases are involved the regulation of hemostasis and thrombosis, as the inhibition of one or more extracellular thiol isomerases will block platelet aggregation, granule secretion, adhesion, thrombus formation and fibrin generation. Antithrombotics can be used therapeutically for prevention (primary prevention, secondary prevention) or treatment of a dangerous blood clot (acute thrombosis). [0099] Inhibiting the activity of PDI, ERp5 or ERp57 blocks thrombus formation following laser-induced injury of blood vessels in a murine model of thrombosis. [0100] Furthermore, since inhibiting the activity of thiol isomerases effects both platelet accumulation and fibrin formation, these therapeutics would be an improvement over currently available therapies that only target either arterial clots (heart attacks and strokes largely triggered by inappropriate activation of platelets) or venous clots (deep-vein thrombosis and pulmonary embolism largely caused by inappropriate activation of the coagulation system). Data suggests that each thiol isomerase has unique substrate specificities and mechanisms of action suggesting each could be an independent target.
[0101] The thrombotic disease or condition to be prevented or treated by the extracellular thiol isomerase inhibitor compound can be acute myocardial infarction, stable angina, unstable angina, acute occlusion following coronary angioplasty and/or stent placement, a transient ischemic attack, cerebrovascular disease, stroke, peripheral vascular disease, placental insufficiency, atrial fibrillation, deep vein thrombosis, pulmonary embolism, or a combination thereof. [0102] Platelet responses in the presence of zafirlukast, (0.1µM –10µM) were tested in a range of platelet functional assays including aggregation, granule secretion and spreading studies. Zafirlukast was found to inhibit platelet aggregation, dense and α-granule secretion, platelet spreading upon collagen and thrombus formation under flow. These data suggest that zafirlukast and other broad spectrum inhibitors of thiol isomerases of the protein disulfide isomerase subfamily can be used as an anti-thrombotic drug. [0103] In an embodiment, the disease or condition influenced by the activity of one or more extracellular thiol isomerases is arterial thrombosis, venous thrombosis, a thrombotic disease such as acute myocardial infarction, stable angina, unstable angina, acute occlusion following coronary angioplasty and/or stent placement, a transient ischemic attack, cerebrovascular disease, stroke, peripheral vascular disease, placental insufficiency, atrial fibrillation, deep vein thrombosis, and pulmonary embolism, or a combination thereof; and wherein the extracellular thiol isomerase inhibitor compound is a compound of Formula (I), (II), (III), or a pharmaceutically acceptable salt thereof. Anti-Cancer [0104] PDI inhibition is a viable target for cancer therapy. See, Xu et al. “Protein disulfide isomerase: a promising target for cancer therapy” Drug Discovery Today, Vol. 19, No. 3, March 2014. [0105] There is further evidence for tumor metastasis role for ERp5. See Gumireddy et al. “In vivo selection for metastasis promoting genes in the mouse” PNAS (2007) 104, 6696-6701. [0106] ERp57 is expressed from the PDIA3 gene in humans. It consists of 505 amino acids and it is upregulated in breast, lung, uterine, stomach and hepatic cancer, as well as melanoma in comparison to normal tissues. The expression levels of ERp57 have been positively correlated with the transforming abilities of the oncogenic sarcoma virus in NIH3T3 cells, suggesting that ERp57 is involved in oncogenic transformation. Unlike the other PDI family members, ERp57 has the ability to interact with nuclear DNA and activate
gene expression as ERp57 interacts with DNA molecules through its catalytically active a’ domain. ERp57 is also a component of the STAT3-transcriptional complex and the ERp57- STAT3 modulates the cell signaling and proliferation regulated by STAT3. ERp57 also regulates gene expression through the mTOR pathway, which is another important regulator of cell proliferation and survival. ERp57 has also been implicated in binding at least three proteins involved with DNA repair, including Ref-1/APE, which itself has the ability to activate additional transcription factors. In addition to gene regulation functions, increased ERp57 expression is correlated to a resistance to treatment with paclitaxel in ovarian cancer and radioresistance in laryngeal cancer, promotes the metastasis of breast cancer into bone, and is involved in the deregulation of EGFR signaling in a breast cancer cell line, preventing its downstream activation of target molecules such as STAT3, Akt and PLCγ. As ERp57 plays a role in thrombus formation it is a potential target in the prevention of cancer- associated thrombosis, a major cause of morbidity and mortality in cancer patients. [0107] The cancer to be treated can be ovarian, prostate, lung, melanoma, lymphoma, glioma, breast, colon, colorectal, hematological, laryngeal, melanoma, or neuroblastoma. [0108] The compound of Formula (I), (II), (III), or a pharmaceutically acceptable salt thereof can be used alone or optionally in combination with another anti-cancer or chemotherapeutic agent. [0109] In an embodiment, the cancer is treated with a combination of the compound of Formula (I), (II), (III), or a pharmaceutically acceptable salt thereof and a chemotherapeutic agent such as carboplatin or cisplatin. [0110] This invention is further illustrated by the following examples that should not be construed as limiting. EXAMPLES: Example 1. Representative schemes for the synthesis of compounds [0111] Zafirlukast (ZAF) derivatives were prepared having Scaffolds I (indole), IIa, and IIb (Table 1). Scaffold I where the organization of the substituents on the benzoyl group (ring B) was kept the same as that found in the parent ZAF, and scaffolds IIa and IIb where the organization of the substituents on ring B was different than that found in ZAF. The use of three different ZAF scaffolds offered an ideal opportunity for initial SAR studies.
Scheme I.
X = R6, O, S; Y = CH, N; R11 = I, Br, Li; R12 = MgI, MgBr a. NIS, TFA, THF; b. NIH, CH2Cl2; c. NBS, Al2O3, Et3N, THF, hexanes; d. NBS, DMF; e. n- BuLi, THF, hexanes; f. I2, hexanes, Et2O, H2O; g. Mg, I2, THF.
X = R6, O, S; Y = CH, N; R13 = I, Br, Li, MgI, MgBr h. NaBH4, THF, i. PBr3, Et2O; j. n-BuLi, THF; k. n-BuLi, ZnBr2, Pd(PPh3)4, THF; l. n-BuLi, Et2O; m. Zn, I2, S-Phos, Pd2dba3, DMF; n. Zn, P(Ph)3, Pd(OAc)2, TMSCl, 1,2- dibromoethane, THF, o. Zn, Cl2Pd(PPh3)2, DMA, benzene; p. THF; q. KOH, MeOH/THF/H2O; r. arylsulfonamide, EDC•HCl, DMAP, CH2Cl2. [0112] Scheme I is a general three-step linear synthesis that will be used to make the indole derivatives proposed (alternative synthetic routes or additional steps may be used for the preparation of some of the proposed derivatives). This representative synthetic route shows: (a) a condensation reaction between substituted indoles and methyl-5-formyl-2- methoxy benzoate using triethylsilane, which is a source of anhydride, trifluoroacetic acid, and dichloromethane, (b) hydrolysis of the ester to a carboxylic acid using sodium hydroxide, methanol, tetrahydrofuran, and water, followed by (c) amide coupling using an arylsulfonamide, N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride, which is the reducing agent, 4-dimethylaminopyridine, and dichloromethane. [0113] Scheme II. is a general synthesis that will be used to make additional heteroaryl and heterocycles derivatives (containing N, O, or S) beyond the indole ring. For Scheme II. the step that will differ from that of Scheme I. is the first step with the condensation reaction (labeled as step (a) in Scheme II.), while steps (q) and (r) will remain the same as steps (b) and (c) for Scheme I. in terms of the hydrolysis of the ester to the carboxylic acid and amide coupling as the final two steps of the synthesis. For Scheme II., 5-
and 6-membered heterocyclic rings will first undergo iodination, bromination, or undergo the addition of lithium at the C-2 position for 5-membered rings and the C-3 position for 6- membered. rings (using one of the steps a-f). These compounds will either be taken directly to the next step (with R1 = iodine, bromine, or lithium) or they will undergo step (g) to synthesize a Grignard reagent to further push the reaction forward (with R1 = magnesium iodide or magnesium bromide). This synthesis is a convergent synthesis where methyl-5- formyl-2-methoxybenzoate undergoes a reduction (h) of the aldehyde to a primary alcohol, followed by (i) bromination, the addition of the heterocycle with R1 = iodine, bromine, lithium, magnesium iodide, or magnesium bromide (using one of the steps j-p) to yield the ester which undergoes the same hydrolysis of the ester to the carboxylic acid (step b from Scheme I.), and the final step as the amide coupling (step c from Scheme I.). These steps may allow for the 5- and 6-membered heterocycles to be more reactive in order to push the reactions to go to completion to move forward in making the final compounds. [0114] Representative compounds of Formula (I), (II), or (III) are described in Table 1.
Table 1.
Compounds 1-5 Compounds 6-35, 38-42 Compounds 36-37
* insulin-based turbidometric assay; “ND” = >100 µM. [0115] Materials and instrumentation. All chemicals were purchased from Oakwood Chemical (San Diego, CA), Combi-Blocks (San Diego, CA), TCI America (Portland, OR), Sigma Aldrich (St. Louis, MO), Synthonix (Wake Forest, NC), Matrix Scientific (Columbia, SC), Ricca Chemical Company (Arlington, TX), Acros Organics (Geel, Belgium), Beantown Chemical (Hudson, NH), Chem-Impex (Wood Dale, IL), Alfa Aesar (Ward Hill, MA), and used without further purification. All chemical reactions were monitored by thin layer chromatography (TLC) using glass plates coated with Merk silica gel 60 F254. UV light was used to visualize the chromatographic bands on the TLC plates. Silica gel column chromatography with SiliaFlash® F60 (40-63 ^M, SiliCycle, Québec, Canada) was used to purify compounds. Varian 500 (VNMRS500) or 400 (MR400) MHz spectrometers were used to record 1H NMR spectra at 500 or 400 MHz, respectively. A Varian 400 MHz spectrometer was used to record all 13C NMR spectra at 100 MHz. All NMR spectra chemical shifts (δ) are given in parts per million (ppm). All coupling constants (J) are given in Hertz (Hz), and the abbreviations used for signal shape are singlet (s), doublet (d), triplet (t), multiplet (m), doublet of doublets (dd), doublet of triplets (dt), and triplet of doublets (td). High-resolution mass spectrometry (HRMS) was performed on an AB SCIEX TripleTOFTM5600 mass spectrometer. [0116] Synthesis of compound SM2. A solution of 5- nitroindole (3.0 g, 18.5 mmol) in anhydrous DMF (15 mL) was cooled to 0 °C and treated with NaH (60% in mineral oil, 1.48 g, 37.0 mmol).
The reaction mixture was allowed to stir at room temperature for 1 h. The mixture was cooled to 0 °C, iodoethane (2.98 mL, 37.0 mmol) was then slowly added, and the resulting mixture was stirred at room temperature for 1 h. The reaction was quenched
by pouring onto ice and extracted with CH2Cl2 (3×). The combined organic layers were washed with NaHCO3, H2O, and brine, dried over MgSO4, filtered, and concentrated. The crude product obtained was purified by column chromatography (SiO2 gel, Hexanes:EtOAc/3:1, Rf 0.46) to yield compound SM2 (1.70 g, 48%) as a yellow solid: 1H NMR (500 MHz, CDCl3) δ 8.58 (dd, J1 = 2.2 Hz, J2 = 0.5 Hz, 1H, aromatic), 8.10 (dd, J1 = 9.1 Hz, J2 = 2.3 Hz, 1H, aromatic), 7.34 (dt, J1 = 9.1 Hz, J2 = 0.7 Hz, 1H, aromatic), 7.25 (d, J = 3.3 Hz, 1H, aromatic), 6.66 (dd, J1 = 3.3 Hz, J2 = 0.9 Hz, 1H, aromatic), 4.21 (q, J = 7.4 Hz, 2H, NCH2CH3), 1.49 (t, J = 7.4 Hz, 3H, NCH2CH3); 13C NMR (100 MHz, CDCl3) δ 138.7, 131.9, 130.4, 128.0, 118.5, 117.3, 109.3, 104.2, 41.7, 15.6. [0117] Synthesis of compound SM3 . A solution of 5- nitroindole (3.0 g, 18.5 mmol) in anhydrous DMF (15 mL) was cooled to 0 °C and treated with NaH (60% in mineral oil, 1.48 g, 37.0 mmol). The
reaction mixture was allowed to stir at room temperature for 1 h. The mixture was cooled to 0 °C, 1-iodopropane (3.59 mL, 37.0 mmol) was then slowly added, and the resulting mixture was stirred at room temperature for 1 h. The reaction was quenched by pouring onto ice and extracted with CH2Cl2 (3×). The combined organic layers were washed with NaHCO3, H2O, and brine, dried over MgSO4, filtered, and concentrated. The crude product obtained was purified by column chromatography (SiO2 gel, Hexanes:EtOAc/1:1, Rf 0.81) to yield compound SM3 (2.71 g, 72%) as a brown liquid: 1H NMR (500 MHz, CDCl3) δ 8.57 (d, J = 2.3Hz, 1H, aromatic), 8.09 (dd, J1 = 9.1 Hz, J2 = 2.3 Hz, 1H, aromatic), 7.33 (dd, J1 = 9.1 Hz, J2 = 0.7 Hz, 1H, aromatic), 7.23 (d, J = 3.2 Hz, 1H, aromatic), 6.66 (dt, J1 = 3.3 Hz, J2 = 0.8 Hz, 1H, aromatic), 4.12 (t, J = 7.1 Hz, 2H, NCH2CH2CH3), 1.88 (sextet, J = 7.4 Hz, 2H, NCH2CH2CH3), 0.93 (t, J = 7.4 Hz, 3H, NCH2CH2CH3); 13C NMR (100 MHz, CDCl3) δ 141.6, 139.0, 131.2, 127.8, 118.4, 117.2, 109.4, 104.0, 48.7, 23.7, 11.6. [0118] Synthesis of compound SM4 KCH-3-26 (SGT1631). A solution of 5-nitroindole (3.0 g, 18.5 mmol) in anhydrous DMF (15 mL) was cooled to 0 °C and treated with NaH (60% in mineral oil, 1.48 g, 37.0 mmol). The reaction mixture was allowed to stir at room temperature for 1
h. The mixture was cooled to 0 °C, 1-iodobutane (4.20 mL, 37.0 mmol) was then slowly added, and the resulting mixture was stirred at room temperature for 1 h. The reaction was quenched by pouring onto ice and extracted with CH2Cl2 (3×). The combined
organic layers were washed with NaHCO3, H2O, and brine, dried over MgSO4, filtered, and concentrated. The crude product obtained was purified by column chromatography (SiO2 gel, Hexanes:EtOAc/3:1, Rf 0.53) to yield compound SM4 (1.54 g, 38%) as a brown liquid: 1H NMR (500 MHz, CDCl3) δ 8.57 (d, J = 2.2 Hz, 1H, aromatic), 8.09 (dd, J1 = 9.1 Hz, J2 = 2.3 Hz, 1H, aromatic), 7.33 (d, J = 9.1 Hz, 1H, aromatic), 7.23 (d, J = 3.3 Hz, 1H, aromatic), 6.65 (dd, J1 = 3.3 Hz, J2 = 0.8 Hz, 1H, aromatic), 4.15 (t, J = 7.2 Hz, 2H, NCH2CH2CH2CH3), 1.82 (p, J = 7.7 Hz, 2H, NCH2CH2CH2CH3), 1.33 (sextet, J = 7.7 Hz, 2H, NCH2CH2CH2CH3), 0.93 (t, J = 7.4 Hz, 3H, NCH2CH2CH2CH3); 13C NMR (100 MHz, CDCl3) δ 141.7, 139.0, 131.2, 127.9, 118.5, 117.3, 109.4, 104.0, 46.8, 32.5, 20.3, 13.8. [0119] Synthesis of compound SM5 . A solution of 5-nitroindole (3.0 g, 18.5 mmol) in anhydrous DMF (15 mL) was cooled to 0 °C and treated with NaH (60% in mineral oil, 1.48 g, 37.0 mmol). The reaction
mixture was allowed to stir at room temperature for 1 h. The mixture was cooled to 0 °C, 1-iodo-2-methylpropane (4.25 mL, 37.0 mmol) was then slowly added, and the resulting mixture was stirred at room temperature for 1 h. The reaction was quenched by pouring onto ice and extracted with CH2Cl2 (3×). The combined organic layers were washed with NaHCO3, H2O, and brine, dried over MgSO4, filtered, and concentrated. The crude product obtained was purified by column chromatography (SiO2 gel, Hexanes:EtOAc/1:1, Rf 0.89) to yield compound SM5 (1.12 g, 28%) as a yellow solid: 1H NMR (500 MHz, CDCl3,) δ 8.57 (d, J = 2.3 Hz, 1H, aromatic), 8.09 (dd, J1 = 9.1 Hz, J2 = 2.3 Hz, 1H, aromatic), 7.32 (dt, J1 = 9.1 Hz, J2 = 0.7 Hz, 1H, aromatic), 7.20 (d, J = 3.3 Hz, 1H, aromatic), 6.66 (dd, J1 = 3.2 Hz, J2 = 0.8 Hz, 1H, aromatic), 3.94 (d, J = 7.4 Hz, 2H, NCH2), 2.18 (septet, J = 7.3 Hz, 1H, CH(CH3)2), 0.92 (d, J = 6.7 Hz, 6H, CH(CH3)2); 13C NMR (100 MHz, CDCl3) δ 141.6, 139.3, 131.7, 127.8, 118.4, 117.3, 109.6, 103.9, 54.7, 29.9, 20.4 (2CH3). [0120] Synthesis of compound SM6 . A solution of 5-nitroindole (3.0 g, 18.5 mmol) in anhydrous DMF (15 mL) was cooled to 0 °C and treated with NaH (60% in mineral oil, 1.11 g, 27.8 mmol). The reaction mixture was allowed to stir at room temperature for 1 h. The mixture was
cooled to 0 °C, benzyl bromide (3.30 mL, 27.8 mmol) was then slowly added, and the resulting mixture was stirred at room temperature for 1 h. The reaction was quenched by pouring onto ice and extracted with CH2Cl2 (3×). The combined organic layers were washed with NaHCO3, H2O, and brine, dried over MgSO4, filtered, and concentrated.
The crude product obtained was purified by column chromatography (SiO2 gel, Hexanes:EtOAc/3:1, Rf 0.58) to yield compound SM6 (3.10 g, 66%) as a tan solid: 1H NMR (500 MHz, CDCl3) δ 8.59 (dd, J1 = 2.3 Hz, J2 = 0.6 Hz, 1H, aromatic ), 8.06 (dd, J1 = 9.1 Hz, J2 = 2.3 Hz, 1H, aromatic), 7.33-7.27 (m, 4H, aromatic), 7.26 (d, J = 3.3 Hz, 1H, aromatic), 7.09-7.18 (m, 2H, aromatic), 6.72 (dd, J1 = 3.3 Hz, J2 = 0.9 Hz, 1H, aromatic), 5.35 (s, 2H, NCH2); 13C NMR (100 MHz, CDCl3) δ 142.0, 139.2, 136.4, 131.7, 129.2 (2CH), 128.3, 128.1, 127.0 (2CH), 118.4, 117.6, 109.8, 104.6, 50.8.
. was was allowed to warm to room temperature overnight. The reaction was quenched with H2O and extracted with CH2Cl2 (3×). The combined organic layers were washed with NaHCO3, H2O, and brine, dried over MgSO4, filtered, and concentrated. The crude product obtained was purified by column chromatography (SiO2 gel, Hexanes:EtOAc/1:1, Rf 0.60) to yield compound SM9 (0.24 g, 63%) as a yellow solid: 1H NMR (500 MHz, CDCl3) δ 8.46 (dd, J1 = 2.2 Hz, J2 = 0.6 Hz, 1H, aromatic), 8.09 (dd, J1 = 9.1 Hz, J2 = 2.3 Hz, 1H, aromatic), 7.69 (d, J = 2.5 Hz, 1H, aromatic), 7.35 (dd, J1 = 8.6 Hz, J2 = 2.4 Hz, 1H, aromatic), 7.30 (dd, J1 = 9.2 Hz, J2 = 0.7 Hz, 1H, aromatic), 6.91 (d, J = 8.7 Hz, 1H, aromatic), 6.90 (s, 1H, aromatic), 4.14 (q, J = 7.4 Hz, 2H, NCH2CH3), 4.06 (s, 2H, CH2Ar), 3.87 (s, 3H, ArOCH3), 3.85 (s, 3H, ArCO2CH3), 1.44 (t, J = 7.4 Hz, 3H, NCH2CH3); 13C NMR (100 MHz, CDCl3) δ 167.0, 157.9, 141.4, 139.2, 133.8, 132.1, 131.9, 128.6, 127.3, 120.3, 117.7, 117.6, 116.8, 112.5, 109.3, 56.4, 52.3, 41.6, 30.4, 15.6.
was allowed to warm to room temperature overnight. The reaction was quenched with H2O and extracted with CH2Cl2 (3×). The combined organic
layers were washed with NaHCO3, H2O, and brine, dried over MgSO4, filtered, and concentrated. The crude product obtained was purified by column chromatography (SiO2 gel, Hexanes:EtOAc/1:1, Rf 0.73) to yield compound SM10 (0.24 g, 63%) as a dark yellow solid: 1H NMR (500 MHz, CDCl3) δ 8.46 (dd, J1 = 2.3 Hz, J2 = 0.5 Hz, 1H, aromatic), 8.08 (dd, J1 = 9.1 Hz, J2 = 2.2 Hz, 1H, aromatic), 7.68 (d, J = 2.5 Hz, 1H, aromatic), 7.34 (dd, J1 = 8.6 Hz, J2 = 2.5 Hz, 1H, aromatic), 7.29 (d, J = 9.1 Hz, 1H, aromatic), 6.91 (d, J = 8.6 Hz, 1H, aromatic), 6.88 (app. t, J = 1.1 Hz, 1H, aromatic), 4.06 (s, 2H, CH2Ar), 4.04 (t, J = 7.2 Hz, 2H, NCH2CH2CH3), 3.87 (s, 3H, ArOCH3), 3.85 (s, 3H, ArCO2CH3), 1.83 (sextet, J = 7.4 Hz, 3H, NCH2CH2CH3), 0.90 (t, J = 7.4 Hz, 3H, NCH2CH2CH3); 13C NMR (100 MHz, CDCl3) δ 166.9, 157.9, 141.3, 139.6, 133.7, 132.1, 131.9, 129.4, 127.2, 120.2, 117.54, 117.46, 116.8, 112.5, 109.5, 56.3, 52.2, 48.5, 30.3, 23.8, 11.6.
temperature overnight. The reaction was quenched with H2O and extracted with CH2Cl2 (3×). The combined organic layers were washed with NaHCO3, H2O, and brine, dried over MgSO4, filtered, and concentrated. The crude product obtained was purified by column chromatography (SiO2 gel, Hexanes:EtOAc/1:1, Rf 0.60) to yield compound SM11 (0.10 g, 8%) as a yellow liquid (which contained some methyl-5-formyl-2-methoxybenzoate that was removed in the next synthetic step): 1H NMR (500 MHz, CDCl3) δ 8.45 (dd, J1 = 2.3 Hz, J2 = 0.5 Hz, 1H, aromatic), 8.08 (dd, J1 = 9.1 Hz, J2 = 2.3 Hz, 1H, aromatic), 7.68 (d, J = 2.4 Hz, 1H, aromatic), 7.34 (dd, J1 = 8.6 Hz, J2 = 2.5 Hz, 1H, aromatic), 7.29 (d, J = 9.1 Hz, 1H, aromatic), 6.90 (d, J = 8.6 Hz, 1H, aromatic), 6.88 (app. t, J = 1.1 Hz, 1H, aromatic), 4.07 (t, J = 7.3 Hz, 2H, NCH2CH2CH2CH3), 4.05 (s, 2H, CH2Ar), 3.87 (s, 3H, ArOCH3), 3.85 (s, 3H, ArCO2CH3), 1.81-1.75 (m, 2H, NCH2CH2CH2CH3), 1.34-1.27 (m, 2H, NCH2CH2CH2CH3), 0.92 (t, J = 7.4 Hz, 3H, NCH2CH2CH2CH3); 13C NMR (100 MHz, (CD3)2SO) δ 166.2, 156.5, 140.2, 134.8, 133.3, 132.5, 130.4, 126.4, 119.8, 116.54, 116.47, 116.0, 113.2, 112.7, 110.4, 55.8, 51.8, 31.9, 29.0, 19.4, 13.5.
stirred at 0 C for 10 min and was allowed to warm to room temperature overnight. The reaction was quenched with H2O and extracted with CH2Cl2 (3×). The combined organic layers were washed with NaHCO3, H2O, and brine, dried over MgSO4, filtered, and concentrated. The crude product obtained was purified by column chromatography (SiO2 gel, Hexanes:EtOAc/1:1, Rf 0.72) to yield compound SM12 (0.11 g, 36%) as a yellow solid: 1H NMR (500 MHz, CDCl3) δ 8.45 (d, J = 2.2 Hz, 1H, aromatic), 8.08 (dd, J1 = 9.1 Hz, J2 = 2.2 Hz, 1H, aromatic), 7.68 (d, J = 2.5 Hz, 1H, aromatic), 7.34 (dd, J1 = 8.6 Hz, J2 = 2.5 Hz, 1H, aromatic), 7.28 (d, J = 9.1 Hz, 1H, aromatic), 6.90 (d, J = 8.6 Hz, 1H, aromatic), 6.87 (app. t, J = 1.1 Hz, 1H, aromatic), 4.06 (s, 2H, CH2Ar), 3.87 (d, J = 7.4 Hz, 2H, NCH2), 3.87 (s, 3H, ArOCH3),3.84 (s, 3H, ArCO2CH3), 2.14 (septet, J = 7.0 Hz, 1H, CH(CH3)2), 0.90 (t, J = 6.7 Hz, 6H, CH(CH3)2); 13C NMR (100 MHz, CDCl3) δ 166.9, 157.9, 141.3, 139.9, 133.7, 132.1, 131.9, 129.9, 127.1, 120.2, 117.6, 117.4, 116.8, 112.5, 109.7, 56.3, 54.5, 52.2, 30.3, 29.9, 20.4.
overnight. The reaction was quenched with H2O and extracted with CH2Cl2 (3×). The combined organic layers were washed with NaHCO3, H2O, and brine, dried over MgSO4, filtered, and concentrated. The crude product obtained was purified by column chromatography (SiO2 gel, Hexanes:EtOAc/1:1, Rf 0.59) to yield compound SM13 (0.23 g, 20%) as a yellow solid: 1H NMR (500 MHz, CDCl3) δ 8.47 (dd, J1 = 2.3 Hz, J2 = 0.5 Hz, 1H, aromatic), 8.05 (dd, J1 = 9.1 Hz, J2 = 2.2 Hz, 1H, aromatic), 7.68 (d, J = 2.4 Hz, 1H,
aromatic), 7.35 (dd, J1 = 8.6 Hz, J2 = 2.5 Hz, 1H, aromatic), 7.32-7.27 (m, 3H, aromatic), 7.08-7.05 (m, 2H, aromatic), 6.95 (app. t, J = 1.1 Hz, 1H, aromatic), 6.90 (d, J = 8.6 Hz, 1H, aromatic), 5.28 (s, 2H, NCH2Ar), 4.07 (s, 2H, CH2Ar), 3.87 (s, 3H, ArOCH3), 3.85 (s, 3H, ArCO2CH3); 13C NMR (100 MHz, CDCl3) δ 166.9, 157.9, 141.6, 139.8, 136.5, 133.7, 131.93, 131.87, 129.8, 129.2, 128.3, 127.5, 126.9, 120.3, 118.0, 117.9, 116.8, 112.5, 109.9, 56.3, 52.2, 50.7, 30.4.
[0126] Synthesis of compoundM14 A solution of methyl 2-methoxy-5-((1-methyl-5- nitro-1H-indol-3-yl)methyl)benzoate (112 mg, 0.32 mmol) in MeOH/THF/H2O (3 mL/1 mL/0.6 mL) was treated with KOH pellets (124 mg, 2.21 mmol), and the mixture was refluxed at 65° C. for 2 h. After completion of the reaction, the organic solvents were removed in vacuo. The resulting mixture was acidified to pH 1 with 1 N aqueous HCl. The precipitate was filtered and eluted with H2O to afford compound 20 (94 mg, 87%) as a yellow solid: 1H NMR (400 MHz, CDCl3) δ 10.7 (very br s, 1H, CO2H), 8.38 (d, J=2.0 Hz, 1H, aromatic), 8.10 (dd, J1=8.8 Hz, J2=2.0 Hz, 1H, aromatic), 8.04 (d, J=2.4 Hz, 1H, aromatic), 7.49 (dd, J1=8.4 Hz, J2=2.0 Hz, 1H, aromatic), 7.28 (d, J=9.2 Hz, 1H, aromatic), 7.00 (d, J=8.0 Hz, 1H, aromatic), 6.94 (s, 1H, aromatic), 4.09 (s, 2H, CH2Ar), 4.05 (s, 3H, ArOCH3), 3.79 (s, 3H, NCH3); 13C NMR (100 MHz, CDCl3) δ 165.2, 156.5, 141.2, 140.0, 135.0, 134.4, 133.6, 130.3, 126.8, 117.6, 117.5, 116.5, 116.4, 111.9, 109.2, 56.8, 33.2, 30.1; m/z calcd for C18H16N2O5340.1; found 323.1 [M−OH]+.
were removed in vacuo after the reaction was complete. The resulting mixture was acidified to pH 1 with 1 N aqueous HCl and extracted with CH2Cl2 (3×). The combined organic layers
were washed with brine, dried over MgSO4, filtered, and concentrated to yield compound SM15 (0.17 g, 75%) as a yellow solid: 1H NMR (500 MHz, CDCl3) δ 8.38 (d, J = 2.2 Hz, 1H, aromatic), 8.09 (dd, J1 = 9.1 Hz, J2 = 2.3 Hz, 1H, aromatic), 8.06 (d, J = 2.5 Hz, 1H, aromatic), 7.49 (dd, J1 = 8.5 Hz, J2 = 2.5 Hz, 1H, aromatic), 7.30 (d, J = 9.2 Hz, 1H, aromatic), 7.00 (d, J = 8.2 Hz, 1H, aromatic), 6.99 (s, 1H, aromatic), 4.15 (q, J = 7.4 Hz, 2H, NCH2CH3), 4.10 (s, 2H, CH2Ar), 4.05 (s, 3H, ArOCH3), 1.46 (t, J = 7.3 Hz, 3H, NCH2CH3); 13C NMR (100 MHz, CDCl3) δ 165.5, 156.8, 135.3, 134.7, 133.9, 128.7, 127.1, 117.8, 117.6, 116.9, 116.7, 112.1, 109.4, 57.0, 41.6, 30.5, 15.6.
resulting mixture was acidified to pH 1 with 1 N aqueous HCl and extracted with CH2Cl2 (3×). The combined organic layers were washed with brine, dried over MgSO4, filtered, and concentrated to yield compound SM16 (0.17 g, 88%) as a yellow solid: 1H NMR (500 MHz, CDCl3) δ 8.38 (d, J = 2.2 Hz, 1H, aromatic), 8.08 (dd, J1 = 9.1 Hz, J2 = 2.3 Hz, 1H, aromatic), 8.06 (d, J = 2.5 Hz, 1H, aromatic), 7.48 (dd, J1 = 8.5 Hz, J2 = 2.5 Hz, 1H, aromatic), 7.30 (d, J = 9.2 Hz, 1H, aromatic), 6.99 (d, J = 8.6 Hz, 1H, aromatic), 6.97 (app. t, J = 1.0 Hz, 1H, aromatic), 4.10 (s, 2H, CH2Ar), 4.06 (t, J = 7.2 Hz, 2H, NCH2CH2CH3), 4.05 (s, 3H, ArOCH3), 1.85 (sextet, J = 7.4 Hz, 2H, NCH2CH2CH3), 0.92 (t, J = 7.4 Hz, 3H, NCH2CH2CH3); 13C NMR (100 MHz, CDCl3) δ 165.5, 156.8, 141.3, 139.7, 135.2, 134.6, 133.8, 129.5, 127.0, 117.8, 117.6, 116.68, 116.66, 112.1, 109.6, 57.0, 48.6, 30.4, 23.8, 11.7.
was aqueous
and extracted with CH2Cl2 (3×). The combined organic layers were washed with brine, dried over MgSO4, filtered, and concentrated to yield compound SM17 (71 mg, 82%) as a yellow solid: 1H NMR (500 MHz, CD3OD) δ 8.30 (dd, J1 = 2.3 Hz, J2 = 0.6 Hz, 1H, aromatic), 7.97 (dd, J1 = 9.1 Hz, J2 = 2.3 Hz, 1H, aromatic), 7.66 (d, J = 2.4 Hz, 1H, aromatic), 7.42 (d, J = 9.1 Hz, 1H, aromatic), 7.39 (dd, J1 = 8.6 Hz, J2 = 2.5 Hz, 1H, aromatic), 7.17 (app. t, J = 1.0 Hz, 1H, aromatic), 6.99 (d, J = 8.6 Hz, 1H, aromatic), 4.13 (t, J = 7.1 Hz, 2H, NCH2CH2CH2CH3), 4.04 (s, 2H, CH2Ar), 3.91 (s, 1H, OH), 3.81 (s, 3H, ArOCH3), 1.76-1.70 (m, 2H, NCH2CH2CH2CH3), 1.27-1.20 (m, 2H, NCH2CH2CH2CH3), 0.86 (t, J = 7.5 Hz, 3H, NCH2CH2CH2CH3); 13C NMR (100 MHz, (CD3)2SO) δ 156.4, 140.2, 139.1, 132.8, 132.6, 132.5, 130.4, 126.4, 121.0, 116.6, 116.5, 116.0, 113.0, 112.5, 110.4, 55.8, 45.5, 31.9, 29.1, 19.4, 13.5.
resulting mixture was acidified to pH 1 with 1 N aqueous HCl and extracted with CH2Cl2 (3×). The combined organic layers were washed with brine, dried over MgSO4, filtered, and concentrated to yield compound SM18 (81 mg, 84%) as a yellow solid (which contained some methyl-5-formyl-2-methoxybenzoate that was removed in the next synthetic step): 1H NMR (500 MHz, (CD3)2SO) δ 8.41 (d, J = 2.3 Hz, 1H, aromatic), 8.00 (dd, J1 = 9.1 Hz, J2 = 2.3 Hz, 1H, aromatic), 7.68 (d, J = 9.2 Hz, 1H, aromatic), 7.54 (d, J = 2.5 Hz, 1H, aromatic), 7.47 (s, 1H, aromatic), 7.42 (dd, J1 = 8.6 Hz, J2 = 2.4 Hz, 1H, aromatic), 7.05 (d, J = 8.6 Hz, 1H, aromatic), 4.10 (s, 2H, CH2Ar), 4.04 (d, J = 7.4 Hz, 2H, NCH2), 3.77 (s, 3H, ArOCH3), 2.10 (septet, J = 7.2 Hz, 1H, CH(CH3)2), 0.84 (d, J = 6.7 Hz, 6H, CH(CH3)2); 13C NMR (100 MHz, (CD3)2SO) δ 166.4, 162.6, 140.2, 134.3, 132.8, 132.54, 132.45, 130.9, 128.7, 121.8, 121.0, 116.5, 116.0, 113.0, 112.5, 110.7, 56.4, 55.8, 29.3, 19.7 (2CH3).
[0131] Synthesis of compound SM19. A solution of compound SM13 (0.20 g, 0.46 mmol) in MeOH:THF:H2O/10:2:2 (14 mL total) was stirred and treated with KOH pellets (0.18 g, 3.25 mmol). The resulting mixture was refluxed at 65 °C for 2 h. The organic solvents were removed in vacuo after the reaction was complete. The resulting mixture was acidified to pH 1 with 1 N aqueous HCl and extracted with CH2Cl2 (3×). The combined organic layers were washed with brine, dried over MgSO4, filtered, and concentrated to yield compound SM19 (60 mg, 31%) as a yellow solid: 1H NMR (500 MHz, CD3OD) δ 8.33 (d, J = 2.1 Hz, 1H, aromatic), 7.94 (dd, J1 = 9.2 Hz, J2 = 2.3 Hz, 1H, aromatic), 7.64 (d, J = 2.5 Hz, 1H, aromatic), 7.39 (dd, J1 = 8.5 Hz, J2 = 2.6 Hz, 1H, aromatic), 7.37 (d, J = 9.1 Hz, 1H, aromatic), 7.24-7.20 (m, 3H, aromatic), 7.20-7.15 (m, 1H, aromatic), 7.09-7.07 (m, 2H, aromatic), 6.99 (d, J = 8.6 Hz, 1H, aromatic), 5.35 (s, 2H, NCH2Ar), 4.06 (s, 2H, CH2Ar), 3.90 (s, 1H, OH), 3.80 (s, 3H, ArOCH3); 13C NMR (100 MHz, CDCl3) δ 165.5, 156.8, 141.6, 139.9, 136.4, 135.2, 134.5, 133.8, 130.0, 129.3, 128.3, 127.3, 126.9, 118.0, 117.8, 117.2, 116.7, 112.1, 110.0, 57.0, 50.7, 30.4.
quenched with H2O and extracted with CH2Cl2 (3×). The combined organic layers were washed with brine, dried over MgSO4, filtered, and concentrated. The crude product obtained was purified by column chromatography (SiO2 gel, Hexanes:EtOAc/1:1, Rf 0.17) to yield compound 27 (18 mg, 40%) as an orange solid: 1H NMR (500 MHz, CDCl3) δ 10.66 (s, 1H, NH), 8.29 (dd, J1 = 7.9 Hz, J2 = 1.7 Hz, 1H, aromatic), 8.20 (d, J = 2.2 Hz, 1H, aromatic), 8.09 (dd, J1 = 9.1 Hz, J2 = 2.2 Hz, 1H, aromatic), 7.89 (d, J = 2.5 Hz, 1H, aromatic), 7.56 (dd, J1 = 8.6 Hz, J2 = 2.5 Hz, 1H, aromatic), 7.53-7.42 (m, 3H, aromatic), 7.29 (d, J = 9.1 Hz, 1H, aromatic), 7.03 (d, J = 8.6 Hz, 1H, aromatic), 6.55 (s, 1H, aromatic), 4.08 (s, 3H, NCH3), 3.71 (s, 5H, CH2Ar, ArOCH3); 13C NMR (100 MHz, (CD3)2SO) δ 155.5, 140.3, 139.8, 135.9,
135.2, 133.1, 132.3, 131.8 (2CH), 131.7, 130.8, 128.9, 127.61, 127.59, 125.8 (2CH), 119.8, 116.7, 116.3, 112.3, 110.5, 56.0, 36.6, 32.9; m/z calcd for C24H20ClN3O6S 513.95.
quenched with H2O and extracted with CH2Cl2 (3×). The combined organic layers were washed with brine, dried over MgSO4, filtered, and concentrated. The crude product obtained was purified by column chromatography (SiO2 gel, Hexanes:EtOAc/1:1, Rf 0.25) to yield compound 28 (26 mg, 53%) as an orange solid: 1H NMR (500 MHz, CDCl3) δ 10.72 (s, 1H, NH), 8.33 (dd, J1 = 7.9 Hz, J2 = 1.7 Hz, 1H, aromatic), 8.20 (d, J = 2.2 Hz, 1H, aromatic), 8.10 (dd, J1 = 9.1 Hz, J2 = 2.3 Hz, 1H, aromatic), 7.89 (d, J = 2.5 Hz, 1H, aromatic), 7.69 (dd, J1 = 7.9 Hz, J2 = 1.3 Hz, 1H, aromatic), 7.56 (dd, J1 = 8.6 Hz, J2 = 2.6 Hz, 1H, aromatic), 7.49 (td, J1 = 7.7 Hz, J2 = 1.3 Hz, 1H, aromatic), 7.42 (qd, J1 = 8.5 Hz, J2 = 1.8 Hz, 1H, aromatic), 7.29 (d, J = 9.1 Hz, 1H, aromatic), 7.03 (d, J = 8.6 Hz, 1H, aromatic), 6.55 (s, 1H, aromatic), 4.08 (s, 3H, NCH3), 3.71 (s, 5H, CH2Ar, ArOCH3); 13C NMR (100 MHz, (CD3)2SO) δ 155.6, 140.3, 139.8, 136.0, 135.2, 132.6, 131.9 (2CH), 129.1, 128.1, 125.8 (2CH), 119.8, 119.2 (2C), 116.7, 116.3, 112.4, 110.5 (2CH), 109.6, 56.1, 36.6, 32.9; m/z calcd for C24H20BrN3O6S 558.40.
. The combined organic layers were washed with brine, dried over MgSO4, filtered, and concentrated. The crude product obtained was purified by column chromatography (SiO2 gel, Hexanes:EtOAc/1:1, Rf 0.29) to yield compound 29 (11 mg, 25%) as an yellow solid: 1H
NMR (500 MHz, CDCl3) δ 10.64 (s, 1H, NH), 8.33 (d, J = 2.8 Hz, 1H, aromatic), 8.08 (dd, J1 = 9.3 Hz, J2 = 2.4 Hz, 1H, aromatic), 7.90 (d, J = 2.4 Hz, 1H, aromatic), 7.56-7.51 (m, 1H, aromatic), 7.48 (dd, J1 = 8.6 Hz, J2 = 2.6 Hz, 1H, aromatic), 7.26 (d, J = 9.2 Hz, 1H, aromatic), 7.01 (t, J = 8.7 Hz, 2H, aromatic), 6.84 (d, J = 8.6 Hz, 1H, aromatic), 6.88 (s, 1H, aromatic), 4.05 (s, 3H, NCH3), 4.03 (s, 2H, CH2Ar), 3.76 (s, 3H, ArOCH3); 13C NMR (100 MHz, (CD3)2SO) δ 164.1, 157.9, 148.8 (2C), 140.2, 139.6, 131.4, 129.2, 129.13 (2CH), 129.10, 129.06, 126.3, 126.0, 117.5, 116.6, 116.5, 115.9 (2CH), 112.2, 110.4, 55.9, 43.5, 32.8; m/z calcd for C24H19F2N3O6S 515.49.
CH2Cl2 (3×). The combined organic layers were washed with brine, dried over MgSO4, filtered, and concentrated. The crude product obtained was purified by column chromatography (SiO2 gel, Hexanes:EtOAc/1:1, Rf 0.41) to yield compound 30 (16 mg, 35%) as an yellow solid: 1H NMR (500 MHz, CDCl3) δ 10.57 (s, 1H, NH), 8.33 (d, J = 2.2 Hz, 1H, aromatic), 8.18-8.14 (m, 1H, aromatic), 8.08 (dd, J1 = 9.1 Hz, J2 = 2.4 Hz, 1H, aromatic), 7.87 (d, J = 2.5 Hz, 1H, aromatic), 7.47 (dd, J1 = 8.5 Hz, J2 = 2.1 Hz, 1H, aromatic), 7.26 (d, J = 9.1 Hz, 1H, aromatic), 7.05-7.01 (m, 1H, aromatic), 6.97 (d, J = 8.6 Hz, 1H, aromatic), 6.92-6.88 (m, 1H, aromatic), 6.87 (s, 1H, aromatic), 4.05 (s, 3H, NCH3), 4.03 (s, 2H, CH2Ar), 3.76 (s, 3H, ArOCH3); 13C NMR (100 MHz, (CD3)2SO) δ 155.3, 140.2, 139.6 (2C), 133.6, 133.5, 132.9, 131.4, 129.1, 126.3, 116.5, 116.4, 115.9, 112.3, 112.2, 110.4 (2CH), 106.2, 105.94, 105.91, 105.7, 55.9, 32.8, 28.9; m/z calcd for C24H19F2N3O6S 515.49.
and extracted with CH2Cl2 (3×). The combined organic layers were washed with brine, dried over MgSO4, filtered, and concentrated. The crude product obtained was purified by column chromatography (SiO2 gel, Hexanes:EtOAc/1:1, Rf 0.18) to yield compound 31 (12 mg, 26%) as an amber solid: 1H NMR (500 MHz, CDCl3) δ 10.43 (s, 1H, NH), 8.19 (d, J = 2.0 Hz, 1H, aromatic), 8.10 (dd, J1 = 9.1 Hz, J2 = 2.2 Hz, 1H, aromatic), 7.99-7.94 (m, 2H, aromatic), 7.92-7.89 (m, 1H, aromatic), 7.54 (dd, J1 = 8.6 Hz, J2 = 2.5 Hz, 1H, aromatic), 7.31 (d, J = 9.1 Hz, 2H, aromatic), 7.00 (d, J = 8.7 Hz, 1H, aromatic), 6.58 (s, 1H, aromatic), 4.06 (s, 3H, NCH3), 3.73 (s, 5H, CH2Ar, ArOCH3); 13C NMR (100 MHz, (CD3)2SO) δ 172.0, 164.1, 154.9 (2C), 140.2, 139.8, 134.6, 131.8, 131.7, 131.5, 128.3, 128.2, 125.9, 120.4 (2CH), 117.5, 116.8, 116.62, 116.58, 116.4, 110.5, 55.5, 37.1, 32.9; m/z calcd for C24H19F2N3O6S 515.49.
organic layers were washed with brine, dried over MgSO4, filtered, and concentrated. The crude product obtained was purified by column chromatography (SiO2 gel, Hexanes:EtOAc/1:1, Rf 0.46) to yield compound 32 (50 mg, quant.) as a yellow solid: 1H NMR (500 MHz, (CD3)2SO) δ 12.25 (s, 1H, NH), 8.43 (dd, J1 = 2.4 Hz, J2 = 0.5 Hz, 1H, aromatic), 8.00 (dd, J1 = 9.1 Hz, J2 = 2.3 Hz, 1H, aromatic), 7.95 (t, J = 7.7 Hz, 1H, aromatic), 7.81-7.75 (m, 1H, aromatic), 7.65 (dd, J1 = 9.2 Hz, J2 = 0.5 Hz, 1H, aromatic),
7.49 (s, 1H, aromatic), 7.47-7.43 (m, 1H, aromatic), 7.30 (d, J = 2.3 Hz, 1H, aromatic), 7.06 (d, J = 8.6 Hz, 1H, aromatic), 4.24 (q, J = 7.3 Hz, 2H, NCH2CH3), 4.07 (s, 2H, CH2Ar), 3.78 (s, 3H, ArOCH3), 1.35 (t, J = 7.3 Hz, 3H, NCH2CH3); 13C NMR (100 MHz, (CD3)2SO) δ 164.0, 157.0, 155.3, 140.2, 138.7, 132.9, 131.2, 129.8, 129.1, 126.4, 124.7, 117.5, 117.2, 117.0, 116.6, 116.4, 116.0, 112.2, 110.3, 109.6, 55.9, 40.7, 29.0, 15.4; m/z calcd for C25H22FN3O6S 511.52.
extracted with CH2Cl2 (3×). The combined organic layers were washed with brine, dried over MgSO4, filtered, and concentrated. The crude product obtained was purified by column chromatography (SiO2 gel, Hexanes:EtOAc/1:1, Rf 0.27) to yield compound 38 (37 mg, 82%) as an orange solid: 1H NMR (500 MHz, (CD3)2SO) δ 12.19 (s, 1H, NH), 8.45 (d, J = 8.9 Hz, 2H, aromatic), 8.40 (d, J = 2.3 Hz, 1H, aromatic), 8.20 (d, J = 9.0 Hz, 2H, aromatic), 7.99 (dd, J1 = 9.1 Hz, J2 = 2.3 Hz, 1H, aromatic), 7.64 (d, J = 9.1 Hz, 1H, aromatic), 7.48 (s, 1H, aromatic), 7.46 (dd, J1 = 8.6 Hz, J2 = 2.4 Hz, 1H, aromatic), 7.33 (d, J = 2.3 Hz, 1H, aromatic), 7.06 (d, J = 8.6 Hz, 1H, aromatic), 4.23 (q, J = 7.3 Hz, 2H, NCH2CH3), 4.06 (s, 2H, CH2Ar), 3.80 (s, 3H, ArOCH3), 1.33 (t, J = 7.3 Hz, 3H, NCH2CH3); 13C NMR (100 MHz, (CD3)2SO) δ 165.1, 155.5, 150.3, 144.6, 140.2, 138.6, 133.5, 133.0, 129.8, 129.4, 129.3, 126.4, 124.4, 121.6, 116.5, 116.4, 115.9, 112.3, 110.3, 56.0, 40.7, 28.9, 15.3; m/z calcd for C25H22N4O8S 538.53.
organic layers were washed with brine, dried over MgSO4, filtered, and concentrated. The crude product obtained was purified by column chromatography (SiO2 gel, Hexanes:EtOAc/1:1, Rf 0.46) to yield compound 33 (39 mg, 91%) as a yellow solid: 1H NMR (500 MHz, (CD3)2SO) δ 12.25 (s, 1H, NH), 8.42 (d, J = 2.3 Hz, 1H, aromatic), 7.99 (dd, J1 = 9.2 Hz, J2 = 2.4 Hz, 1H, aromatic), 7.95 (t, J = 7.3 Hz, 1H, aromatic), 7.81-7.74 (m, 1H, aromatic), 7.66 (d, J = 9.2 Hz, 1H, aromatic), 7.47 (s, 1H, aromatic), 7.44 (m, 3H, aromatic), 7.29 (d, J = 2.3 Hz, 1H, aromatic), 7.05 (d, J = 8.6 Hz, 1H, aromatic), 4.17 (t, J = 7.0 Hz, 2H, NCH2CH2CH3), 4.07 (s, 2H, CH2Ar), 3.78 (s, 3H, ArOCH3), 1.79 (sextet, J = 7.3 Hz, 2H, NCH2CH2CH3), 0.80 (t, J = 7.4 Hz, 3H, NCH2CH2CH3); 13C NMR (100 MHz, (CD3)2SO) δ 159.5, 157.0, 155.3, 140.2, 139.1, 136.5, 133.1, 132.9, 131.2, 130.4, 129.1, 126.3, 124.8, 124.7, 117.2, 117.0, 116.44, 116.37, 115.9, 112.2, 110.4, 59.7, 55.9, 47.3, 28.9, 23.1, 11.0; m/z calcd for C26H24FN3O6S 525.55.
. The combined organic layers were washed with brine, dried over MgSO4, filtered, and concentrated. The crude product obtained was purified by column chromatography (SiO2 gel, Hexanes:EtOAc/1:1, Rf 0.26) to yield compound 39 (22 mg, 49%) as an orange solid: 1H NMR (500 MHz, CDCl3) δ 10.49 (s, 1H, NH), 8.35 (d, J = 9.1 Hz, 2H, aromatic), 8.32 (d, J = 8.8 Hz, 2H, aromatic), 8.30 (d, J = 2.3 Hz, 1H, aromatic), 8.06 (dd, J1 = 9.1 Hz, J2 = 2.2 Hz,
1H, aromatic), 7.90 (d, J = 2.4 Hz, 1H, aromatic), 7.45 (dd, J1 = 8.6 Hz, J2 = 2.5 Hz, 1H, aromatic), 7.28 (d, J = 9.1 Hz, 1H, aromatic), 6.95 (d, J = 8.6 Hz, 1H, aromatic), 6.93 (s, 1H, aromatic), 4.03 (t, J = 7.2 Hz, 2H, NCH2CH2CH3), 4.04 (s, 2H, CH2Ar), 4.02 (s, 3H, ArOCH3), 1.83 (sextet, J = 7.3 Hz, 2H, NCH2CH2CH3), 0.90 (t, J = 7.4 Hz, 3H, NCH2CH2CH3); 13C NMR (100 MHz, CDCl3) δ 162.6, 156.7, 150.9, 144.6, 141.3, 139.6, 135.8, 134.4, 132.7, 130.3, 129.5, 127.0, 124.2, 118.3, 117.6, 116.6, 116.5, 112.3, 109.6, 56.9, 48.6, 30.3, 23.8, 11.7; m/z calcd for C26H24N4O8S 552.56.
MgSO4, filtered, and concentrated. The crude product obtained was purified by column chromatography (SiO2 gel, Hexanes:EtOAc/1:1, Rf 0.63) to yield compound 34 (24 mg, 56%) as a yellow solid: 1H NMR (500 MHz, CDCl3) δ 10.57 (s, 1H, NH), 8.33 (d, J = 2.3 Hz, 1H, aromatic), 8.14 (td, J1 = 7.6 Hz, J2 = 1.8 Hz, 1H, aromatic), 8.06 (dd, J1 = 9.1 Hz, J2 = 2.2 Hz, 1H, aromatic), 7.88 (d, J = 2.5 Hz, 1H, aromatic), 7.61-7.57 (m, 1H, aromatic), 7.44 (dd, J1 = 8.6 Hz, J2 = 2.6 Hz, 1H, aromatic), 7.33-7.30 (m, 1H, aromatic), 7.27 (d, J = 9.1 Hz, 1H, aromatic), 7.17-7.13 (m, 1H, aromatic), 6.96 (d, J = 8.6 Hz, 1H, aromatic), 6.89 (s, 1H, aromatic), 4.05 (t, J = 7.3 Hz, 2H, NCH2CH2CH2CH3), 4.05 (s, 3H, ArOCH3), 4.02 (s, 2H, CH2Ar), 1.76 (p, J = 7.6 Hz, 2H, NCH2CH2CH2CH3), 1.30 (sextet, J = 7.7 Hz, 2H, NCH2CH2CH2CH3), 0.91 (t, J = 7.4 Hz, 3H, NCH2CH2CH2CH3); 13C NMR (100 MHz, CDCl3) δ 162.7, 156.7, 141.3, 139.6, 136.4, 136.3, 135.5, 134.2, 132.6, 132.3, 129.4, 127.0, 124.7, 124.6, 118.8, 117.6, 117.3, 117.1, 116.6, 112.3, 109.5, 56.9, 46.7, 32.5, 30.3, 20.3, 13.8; m/z calcd for C27H26FN3O6S 539.58.
q . The combined organic layers were washed with brine, dried over MgSO4, filtered, and concentrated. The crude product obtained was purified by column chromatography (SiO2 gel, Hexanes:EtOAc/1:1, Rf 0.45) to yield compound 40 (28 mg, 62%) as a yellow solid: 1H NMR (500 MHz, CDCl3) δ 10.49 (s, 1H, NH), 8.35 (d, J = 9.0 Hz, 2H, aromatic), 8.32 (d, J = 9.1 Hz, 2H, aromatic), 8.29 (d, J = 2.3 Hz, 1H, aromatic), 8.05 (dd, J1 = 9.1 Hz, J2 = 2.2 Hz, 1H, aromatic), 7.90 (d, J = 2.5 Hz, 1H, aromatic), 7.45 (dd, J1 = 8.6 Hz, J2 = 2.5 Hz, 1H, aromatic), 7.28 (d, J = 9.1 Hz, 1H, aromatic), 6.95 (d, J = 8.6 Hz, 1H, aromatic), 6.92 (s, 1H, aromatic), 4.06 (t, J = 7.2 Hz, 1H, aromatic), 4.04 (s, 2H, CH2Ar), 4.03 (s, 3H, ArOCH3), 1.77 (p, J = 7.5 Hz, 2H, NCH2CH2CH2CH3), 1.30 (sextet, J = 7.6 Hz, 2H, NCH2CH2CH2CH3), 0.92 (t, J = 7.4 Hz, 3H, NCH2CH2CH2CH3); 13C NMR (100 MHz, CDCl3) δ 162.6, 156.7, 150.9, 144.6, 141.3, 139.6, 135.8, 134.4, 132.6, 130.3, 129.4, 126.9, 124.2, 118.3, 117.6, 116.6, 116.5, 112.3, 109.6, 56.9, 46.7, 32.5, 30.3, 20.3, 13.8; m/z calcd for C27H26N4O8S 566.59.
organic layers were washed with brine, dried over MgSO4, filtered, and concentrated. The crude product obtained was purified by column chromatography (SiO2 gel, Hexanes:EtOAc/1:1, Rf 0.29) to yield compound 35 (22 mg, 52%) as a yellow solid: 1H NMR (500 MHz, (CD3)2SO) δ 12.24 (s, 1H, NH), 8.41 (d, J = 7.7 Hz, 1H, aromatic), 7.98 (dd, J1 = 9.1 Hz, J2 = 2.3 Hz, 1H, aromatic), 7.95 (t, J = 7.7 Hz, 1H,
aromatic), 7.82-7.75 (m, 1H, aromatic), 7.67 (d, J = 9.1 Hz, 1H, aromatic), 7.45 (s, 1H, aromatic), 7.44 (m, 3H, aromatic), 7.28 (d, J = 2.3 Hz, 1H, aromatic), 7.06 (d, J = 8.6 Hz, 1H, aromatic), 4.07 (s, 2H, CH2Ar), 4.03 (d, J = 7.3 Hz, 2H, NCH2), 3.78 (s, 3H, ArOCH3), 2.09 (septet, J = 7.2 Hz, 1H, CH(CH3)2), 0.82 (d, J = 6.7 Hz, 6H, CH(CH3)2); 13C NMR (100 MHz, (CD3)2SO) δ 164.2, 159.6, 155.3, 140.2, 139.4, 136.6, 133.0, 131.2, 130.9, 129.1, 126.3, 124.8, 117.4, 117.3, 117.1, 116.5, 116.3, 115.9, 115.3, 112.2, 110.7, 55.9, 52.9, 29.2, 28.9, 19.7; m/z calcd for C27H26FN3O6S 539.58.
room temperature overnight. The reaction was quenched with H2O and extracted with CH2Cl2 (3×). The combined organic layers were washed with brine, dried over MgSO4, filtered, and concentrated. The crude product obtained was purified by column chromatography (SiO2 gel, Hexanes:EtOAc/1:1, Rf 0.41) to yield compound 41 (5 mg, 12%) as a yellow solid: 1H NMR (500 MHz, CD3OD) δ 8.40 (d, J = 8.9 Hz, 2H, aromatic), 8.31 (d, J = 2.2 Hz, 1H, aromatic), 8.27 (d, J = 9.0 Hz, 2H, aromatic), 8.02 (dd, J1 = 9.1 Hz, J2 = 2.3 Hz, 1H, aromatic), 7.49 (d, J = 9.2 Hz, 1H, aromatic), 7.48 (d, J = 2.2 Hz, 1H, aromatic), 7.45 (dd, J1 = 8.7 Hz, J2 = 1.8 Hz, 1H, aromatic), 7.23 (s, 1H, aromatic), 7.06 (d, J = 8.5 Hz, 1H, aromatic), 4.09 (s, 2H, CH2Ar), 3.99 (d, J = 7.4 Hz, 2H, NCH2), 3.91 (s, 3H, ArOCH3), 2.15 (septet, J = 7.3 Hz, 1H, CH(CH3)2), 0.89 (d, J = 6.7 Hz, 6H, CH(CH3)2); 13C NMR (100 MHz, (CD3)2SO) δ 165.1, 155.5, 150.2, 144.6, 140.1, 139.4, 133.4, 133.0, 130.9, 129.32, 129.26, 126.2, 124.4, 121.6, 116.4, 116.2, 115.9, 112.2, 110.6, 56.0, 52.9, 29.2, 28.8, 19.7; m/z calcd for C27H26N4O8S 566.59.
quenched with H2O and extracted with CH2Cl2 (3×). The combined organic layers were washed with brine, dried over MgSO4, filtered, and concentrated. The crude product obtained was purified by column chromatography (SiO2 gel, Hexanes:EtOAc/1:1, Rf 0.42) to yield compound 42 (29 mg, 66%) as a yellow solid: 1H NMR (500 MHz, CDCl3) δ 10.49 (s, 1H, NH), 8.35 (d, J = 9.1 Hz, 2H, aromatic), 8.32 (d, J = 9.1 Hz, 2H, aromatic), 8.31 (d, J = 2.3 Hz, 1H, aromatic), 8.02 (dd, J1 = 9.1 Hz, J2 = 2.3 Hz, 1H, aromatic), 7.90 (d, J = 2.4 Hz, 1H, aromatic), 7.46 (dd, J1 = 8.6 Hz, J2 = 2.5 Hz, 1H, aromatic), 7.32-7.27 (m, 3H, aromatic), 7.23 (d, J = 9.5 Hz, 1H, aromatic), 7.05 (dd, J1 = 7.9 Hz, J2 = 2.2 Hz, 2H, aromatic), 6.97 (s, 1H, aromatic), 6.96 (d, J = 8.7 Hz, 1H, aromatic), 5.27 (s, 2H, NCH2Ar), 4.05 (s, 2H, CH2Ar), 4.04 (s, 3H, ArOCH3); 13C NMR (100 MHz, CDCl3) δ 162.6, 156.7, 150.8, 144.6, 141.6, 139.8, 136.3, 135.8, 134.2, 132.6, 130.3, 129.9, 129.2, 128.3, 127.2, 126.9, 124.2, 118.3, 117.9, 117.0, 116.6, 112.3, 110.0, 56.9, 50.7, 30.3; m/z calcd for C30H24N4O8S 600.6. Example 2. Determination of the potency of ZAF derivatives for inhibition of PDI, ERp5, ERp57, and ERp72 [0146] Two methods are used to determine the potency of ZAF derivatives for inhibition of PDI, ERp5, ERp57, and ERp72. The first assay is the insulin turbidity assay used to measure the thiol isomerase inhibitory activity of the analogues. 30 µL of a cocktail consisting of 1.75 mg/mL insulin and an optimized concentration (0.5 µg/well of PDI, ERp57, and ERp72; 1 µg of ERp5) in 100 mM K2PO4, 0.2 mM EDTA, pH 7.2 will be added to a 384-well clear bottom plate. The reaction will be initiated by the addition of 0.3 mM DTT. Absorbance at 650 nm will be measured every minute. Wells containing no thiol isomerase, wells containing no inhibitors, and wells containing ZAF or MON will serve as controls. The IC50 of each compound will be determined by running 6-point dose curves with a minimum of three independent replicates. This insulin inhibition assay has a high-nM IC50 sensitivity limit. The second assay is a highly sensitive continuous assay, where the fluorescence of di-(O-aminobenzoyl) glutathione disulfide (diabz-GSSG) is enhanced upon its reduction catalyzed by the above glutathione isomerase enzymes for very potent compounds. The substrate diabz-GSSG is straightforward to prepare, by a reaction of isatoic anhydride and oxidized glutathione in an aqueous buffer, followed by Sephadex G-10 purification. Fluorescence of the substrate is self-quenched in the oxidized S-S form and is greatly (~20-fold) enhanced upon enzymatic reduction. The substrate (15 mM) will be preincubated with 50 mM DTT (where diabz-GSSH is resistant to reduction), followed by the
addition of one of the four enzymes (5 nM-500 nM, where low-nM concentrations will be used for inhibitors with respective potencies) in 0.1 potassium phosphate buffer pH 7.0, and the fluorescence (ex/em = 312 nm/415 nm) time course will be monitored. Time courses will be collected in triplicate for each inhibitor concentration. Initial velocities will then be used for the steady-state analysis of inhibitor potency. The mode of inhibition will be determined by performing above measurements at different substrate concentrations. The calibration will be performed by measuring the signal change by fully reducing the substrate with 10 mM DTT. [0147] ZAF and MON inhibit thiol isomerases. The potency of ZAF and MON in the insulin turbidity assay for PDI, ERp5, ERp57, and ERp72 was determined. The reduction of insulin catalyzed by thiol isomerases in the presence of dithiothreitol (DTT) results in aggregation of insulin chains. The turbidity of insulin aggregation is monitored by measuring light absorbance at 650 nm. The insulin-based turbidometric assay was adapted to a 384-well format. ZAF inhibited PDI, ERp5, ERp57, and ERp72 with IC50 values of 10-30 µM (FIG. 1A); data for MON is shown in FIG. 1B. [0148] The derivative compounds were tested for activity as inhibitors of PDI and ERp57. Derivatives 1-5, compounds belonging to Scaffold I, which all lacked the cyclopentyl carbamate group at the C-5 position of the indole (ring A) of ZAF, in general, displayed poor activity when tested for activity as inhibitors of PDI and ERp57. Compounds belonging to Scaffold IIa displayed similar or increased activity as inhibitors when compared to the parent ZAF. These data suggest that the cyclopentyl carbamate of ZAF is not required for activity as thiol isomerase inhibitors and the substituents on ring B were kept constant with the 2-methoxy-5-indoyl organization, as Scaffold IIa yielded the most active compound 21. When tested for inhibitory activity against thiol isomerases, derivative compounds 6-11 displayed no activity. Additionally, derivative compounds 12-14 were found to be inactive. Slight increase in activity was seen with derivative compounds 15-20 that contain N-methyl on indole (ring A) with derivative compound 16 displaying moderate activity (IC50 = 30 mM) as a thiol isomerase inhibitor. An electron withdrawing group (R1 = NO2) on the indole (ring A) resulted in increased thiol isomerase inhibition activity and yielded derivative compounds 22, 23, and 27 with moderate activity (IC50 = 30 mM) and compound 28 (IC50 = 40 mM), and the most active compound 21 (IC50 ~10 mM). By performing a pairwise comparison to observe the trend of the substituents on the arylsulfonamide (Ar2) was found to be similar for the nitro and naphthalene substituents and varying for the fluoro substituents for compounds 15-20 (R1 = H) vs compounds 21-26 (R1 = NO2) where compounds 15-20 (3-F phenyl
displayed better activity (>) than 2-F phenyl > 3-NO2 phenyl ≈ 4-NO2 phenyl ≈ 2-naphthyl > 4-F) and compounds 21-26 (2-F phenyl > 3-F phenyl ≈ 4-F phenyl > 3-NO2 phenyl > 4-NO2 phenyl ≈ 2-naphthyl). The most active compound from derivative compounds 1-26 was compound 21 Ar2 = 2-F phenyl. To investigate the importance of the N-methyl indole (ring A) on the most active compound 21, compounds 32-35 were synthesized with varying chain lengths that led to compounds with a slight decrease in activity (IC50 = 50 to >100 mM). Additionally, the importance of the 2-F phenyl for the arylsulfonamide of compound 21 was investigated by the synthesis of compounds 27-31 that contained other halogens and di-fluoro groups, which led to compounds with a slight decrease in activity compared to the lead compound 21. Example 3. Toxicity Studies [0149] The cytotoxic effect of ZAF, montelukast (MON), and compounds 21, 27, and 28 against two mammalian cell lines: BEAS-2B and HEK-293 were conducted. The two cell lines were plated in 96-well plates at 10,000 cells/well. After 24 h of incubation, the cells were treated with 1% Triton-X® (positive control), 1% DMSO (negative control), and treatments of ZAF, MON, compounds 21, 27, and 28 at concentrations of 0 to 62.6 mg/mL. After 12 h of incubation, 10 µL of resazurin was added to each well and the plate was read on a SpectraMax M5 plate reader at a fluorescence excitation at 560 nm and emission at 590 nm. None of the compounds were found to display toxicity against any of the mammalian cell lines tested (FIG. 2). Example 4. Zafirlukast and Compound 21 Inhibit Cancer Cell Growth [0150] ZAF and compound 21 inhibit cancer cell growth. ZAF and compound 21 were tested to assess the viability of HCT116 colon cancer cells and OVCAR-8 ovarian cancer cells. HEK-293 embryonic kidney cells were used as a non-cancer cell control. For ZAF, the IC50 values were in the 3-10 µM range. In FIG. 3, cellular growth inhibition by Compound 21 (inverted triangles) was measured using the standard 3-day growth inhibition assay and compared to ZAF (circles). Compound 21 was 3- to 8-fold more potent than ZAF. The inhibition of mammalian cell growth with ZAF and compound 21. Cells were seeded and treated with drug 24 h later. After an additional 24 h of incubation, cell viability was determined using Prestoblue. The FIG. 3 presents a summary of at least 3 independent experiments per cell line. Cell lines used include HEK-293 non-cancer cells (not shown);
OVCAR-8 and HCT116. Comparison of ZAF (circles) and compound 21 (inverted triangles) in a 3-day growth inhibition against OVCAR-8 (FIG. 3A) and HCT116 cancer cells (FIG. 3B). Example 5. Platelet Aggregation and Fibrin Inhibition [0151] ZAF and MON inhibit platelet aggregation and fibrin formation. Compound 21 (FIG. 4A, FIG. 4B) inhibits platelet aggregation. Platelet aggregation was measured in washed platelet suspensions in the presence of either DMSO, ZAF (0.1-40 µM), or compound 21 (0.6-30 µM) and stimulated for 180 seconds with collagen, decreasing platelet aggregation in a dose dependent manner, with a potency of compound 21 > ZAF > MON. [0152] Thiol isomerase inhibition also impaired integrin αIIbβ3 activation and conformational change leading to fibrinogen ligation. The effects of ZAF on platelet surface fibrinogen binding were measured using flow cytometry where ZAF pre-treatment (10 µM) significantly reduced fibrinogen binding to platelets and therefore integrin activation by 50% (2043 ± 165 AU. A higher concentration of 20 µM ZAF inhibited fibrinogen binding further causing 61% inhibition (1633 ± 162 AU). Example 6. ZAF inhibits cancer cell generated Factor Xa [0153] The ability of ZAF to prevent activation of the clotting cascade was made by measuring its ability to inhibit the generation of Factor Xa by HCT116 cells. Cells were plated in 12-well dishes at 50,000 cells/well. After 24 h of growth, they were treated with ZAF, washed twice with Tris-buffered saline (TBS) and read kinetically in a SpectraMax for 60 min with TBS containing 5 nmol/L of FVIIa, 150 nmol/L of FX, and 5 mmol/L of CaCl2. Fluorescence was measured with excitation and emission wavelengths of 352 nm and 450 nm, respectively. We found that in the presence of ZAF, Factor Xa generation was inhibited in a dose-dependent manner (FIG. 5). Example 7. ZAF inhibits platelet aggregation and thrombus formation in mice [0154] Mouse platelet aggregation (in animal) and thrombus formation are inhibited by ZAF. Thiol isomerases inhibition prevents thrombus formation inside of a live mouse after laser injury, as measured by intravital microscopy (See Holbrook et al. “Zafirlukast is a broad-spectrum thiol isomerase inhibitor that inhibits thrombosis without altering bleeding times” Br. J. Pharmacol. 2021;178:550–563). It has been previously demonstrated that thiol isomerase inhibition diminishes fibrin formation using the same model, and it has been
shown that thiol isomerase inhibition diminishes tumor growth and progression without causing damage to normal tissues. Importantly, thiol isomerase inhibition does not increase bleeding times (Holbrook et al.), which is a major side effect associated with current antithrombotic therapies. Example 8. Compound 21 Assessment of platelet aggregation and thrombus formation in mice [0155] In order to assess the ability of compound 21 to inhibit arterial thrombus formation, intravital microscopy using laser injury will be performed. Male C57BL/6J mice aged 4-5 weeks will be anaesthetized with a weight range of 19-25 g by intraperitoneal injection of ketamine (125 mg/kg), xylazine (12.5 mg/kg), and atropine (0.25 mg/kg). Platelets will be labelled by intravenous infusion of DyLight 649-conjugated anti-GPIb platelet labelling antibody (0.2 µg/g of body weight). After the exposure of the testicular cremaster muscle, the vehicle of DMSO (0.1% v/v) or zafirlukast derivative will be infused intravenously and following a 5-min incubation period, the arteriole wall injury will be induced by laser ablation (Micropoint, Andor Technology, Belfast, UK). Then thrombus formation will be observed using an Olympus BX microscope (Olympus, Essex, UK) and a Hamamatsu (Hamamatsu Photonics, Hertfordshine, UK) CCD camera, with the data analyzed using Slidebook Software 5.0 (Intelligent Imaging Innovations, Denver, USA). Mice will be killed using Schedule 1 approved methods at the end of the experiment. All animal experiments will be blinded for both the experimental treatment and the analysis. Animal experiments have previously been approved by the University of Reading Local Ethical Review Panel and authorized by the UK Home Office. Animal studies are reported in compliance with the ARRIVE guidelines and with the recommendations made by the British Journal of Pharmacology. Example 9. Ex-vivo Thrombus Formation [0156] Zafirlukast was found to inhibit thrombus formation under arterial flow conditions in an in vitro thrombus formation model using whole human blood (US20210008032A1). The active thiol isomerase inhibitor analogues described herein, e.g. compound 21, would be expected to also inhibit thrombus formation in vitro.
Example 10. Compound 32 [0157] Compound 32 is an analogue of zafirlukast where it has been modified to significantly decrease or abolish its affinity for the leukotriene receptor 1 (LTR1) receptor while retaining its potency as a thiol isomerase inhibitor. Compound 32 maintained a similar potency (~1.5‐fold less) to that of zafirlukast at inhibiting thiol isomerases in the insulin turbidity assay (Figure 6). [0158] The thiol isomerase activity of OVCAR8 cells is also inhibited by zafirlukast treatment. The cleavage of the fluorescent di‐eosin thiol isomerase substrate was inhibited after treatment with zafirlukast in a concentration‐dependent manner. Treatment of OVCAR8 cells with 3, 10, or 30 μM of zafirlukast for 10 minutes significantly inhibited PDI activity, by 18%, 24%, and 45%, respectively (Figure 7A). To confirm that the addition of zafirlukast did not alter thiol isomerase expression, thiol isomerases levels were measured following 1 hour of treatment with 10 µM and 30 µM zafirlukast in OVCAR8 cells. No significant change in expression was observed (Figure 7B), confirming that the observed change in activity was due to enzymatic inhibition and not a decrease in enzyme levels. The cellular thiol isomerase activity of OVCAR8 cells also significantly decreased upon treatment with montelukast and Compound 32, with montelukast being somewhat less effective (reduction by 20%, 30%, and 40%, at 10, 30, and 100 μM, respectively) than zafirlukast (Figure 7C). In contrast, the compound 32 was more potent than zafirlukast, significantly inhibiting activity by 25%, 39%, 29%, and 44% at 1, 3, 10, and 30 μM, respectively (Figure 7D). [0159] As inhibitors of thiol isomerase activity have been shown to have antineoplastic activity, the effect of these drugs on cancer cell viability was evaluated. Zafirlukast inhibited OVCAR8 cancer cell viability with an IC50 of 12 μM, while montelukast and compound 32 inhibited cell viability about 5‐ and ~1.5‐fold less potently (with IC50‘s of 60 and 20 μM, respectively) (Figure 8A). It is notable that relative potencies of zafirlukast, compound 32, and montelukast remained consistent across the assays (cell‐free and a cellular activity assay as well as between a cellular activity assay and a viability assay), with compound 32 having a similar potency to that of zafirlukast and montelukast being ~5‐fold less potent in each assay (Figure 8B). Insulin‐based Turbidimetric Assay [0160] An insulin‐based turbidimetric assay was utilized to determine the selectivity of zafirlukast and montelukast for thiol isomerases PDI, ERp57, ERp72, and ERp5. These drugs were diluted in a 6‐12 point dose curve in a 384‐well plate, and a final concentration of 10 µg/mL thiol isomerase (30 µg/mL for ERp5 only), 125 µM insulin, 2 mM EDTA, and 100
mM potassium phosphate buffer were added for a total volume of 30 µL per well. The turbidity of insulin aggregation was measured every minute for 75 minutes after initiating the reaction with 0.3 mM DTT using a SpectraMax M3 plate reader (Molecular Devices, Sunnyvale, CA). PrestoBlue Assay [0161] The indicated cell lines were plated at 5,000 cells per well in a 96‐well plate and allowed to grow for 24 hours. The cells were then treated with either a drug or a vehicle control for an additional 2‐24 hours prior to the addition of PrestoBlue reagent (Invitrogen, Waltham, MA) for 10‐20 minutes at 37°C. Cell viability was determined by measuring the fluorescent signal at an excitation wavelength of 560 nm and emission wavelength of 590 nm. The signal was normalized to a percentage of the control. Di‐eosin‐GSSG Disulfide Reductase Assay [0162] OVCAR8 cells were plated at 10,000 cells per well, allowed to grow overnight, then treated with 0‐100 μM of zafirlukast, montelukast, or compound 32 for 10 minutes. Samples were then subjected to 150 nM of the di‐eosin‐GSSG probe in the presence of 5 μM of DTT and potassium phosphate buffer 1 (containing 100 mM potassium phosphate (pH 7.4) and 2 mM EDTA). Increase in fluorescence was monitored every 30 seconds for 30 minutes by excitation at 520 nm and emission at 550 nm. Generated data were then normalized to the control for each sample, with raw data representing relative fluorescent units (RFU)/minute. [0163] With blood samples, the assay was performed as previously described (Raturi, A., and Mutus, B. (2007) Characterization of redox state and reductase activity of 24 protein disulfide isomerase under different redox environments using a sensitive 25 fluorescent assay. Free Radic Biol Med 43, 62-70) with a modification to use plasma at a 1:1 dilution with potassium phosphate buffer (containing 100 mM potassium phosphate (pH 7.4) and 2 mM EDTA). Samples were then subjected to 150 nM of the di‐eosin‐GSSG probe in the presence of 5 μM DTT. Increase in fluorescence was monitored for 30 minutes by excitation at 520 nm and emission at 550 nm. Generated data from day 28 were then normalized to day 0 control for each sample, with raw data representing relative fluorescent units (RFU)/minute (n=3 for each patient sample). [0164] The statistical analysis was performed using GraphPad Prism (Version 9.4.0, San Diego, CA). Data were presented as the mean ± SD. For di‐eosin‐GSSG assays a one way ANOVA with a post‐hoc Dunnett’s test was used for statistical analysis between test
groups and the control. *P < 0.05, **P < 0.01, ***P < 0.001, or ****P < 0.0001 was considered to be statistically significant. [0165] Unless defined otherwise, technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this disclosure belongs. [0166] The singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. The endpoints of all ranges directed to the same characteristic or component are independently combinable and inclusive of the recited endpoint. The suffix “(s)” as used herein is intended to include both the singular and the plural of the term that it modifies, thereby including one or more of that term (e.g., the carrier(s) includes one or more carriers). The term “or” means “and/or” unless clearly indicated otherwise by context. The term “combination” is inclusive of blends, mixtures, and the like. [0167] Reference throughout the specification to “an embodiment”, “another embodiment”, “some embodiments”, and so forth, means that a particular element (e.g., feature, structure, step, or characteristic) described in connection with the embodiment is included in at least one embodiment described herein, and may or may not be present in other embodiments. In addition, it is to be understood that the described elements may be combined in any suitable manner in the various embodiments. [0168] In general, the compositions, methods, and articles can alternatively comprise, consist of, or consist essentially of, any ingredients, steps, or components herein disclosed. The compositions, methods, and articles can additionally, or alternatively, be formulated, conducted, or manufactured so as to be devoid, or substantially free, of any ingredients, steps, or components not necessary to the achievement of the function or objectives of the present claims. [0169] “Optional” or “optionally” means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event occurs and instances where it does not. [0170] “About” or “approximately” as used herein is inclusive of the stated value and means within an acceptable range of deviation for the particular value as determined by one of ordinary skill in the art, considering the measurement in question and the error associated with measurement of the particular quantity (e.g., the limitations of the measurement system). For example, “about” can mean within one or more standard deviations.
[0171] While the invention has been described in detail in connection with only a limited number of embodiments, it should be readily understood that the invention is not limited to such disclosed embodiments. Rather, the invention can be modified to incorporate any number of variations, alterations, substitutions, or equivalent arrangements not heretofore described, but which are commensurate with the spirit and scope of the invention. Additionally, while various embodiments of the invention have been described, it is to be understood that aspects of the invention can include only some of the described embodiments. Accordingly, the invention is not to be seen as limited by the foregoing description, but is only limited by the scope of the appended claims. [0172] All cited patents, patent applications, and other references are incorporated herein by reference in their entirety. However, if a term in the present application contradicts or conflicts with a term in the incorporated reference, the term from the present application takes precedence over the conflicting term from the incorporated reference.
Claims
CLAIMS: 1. A method of treating cancer or treating or preventing cancer-induced thrombosis, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I), (II), (III), or a pharmaceutically acceptable salt thereof:
R1 is hydrogen, NO2, cyano, halogen, NH2, COOH, hydroxyl, C1-C8 alkyl, C1-C6 haloalkyl, C1-C8 alkyl-OH, C1-C8 alkyl-NH2, C1-C8 alkoxy, mono-C1-C8 alkylamino, di-C1-C8 alkylamino, C2-C6 alkenyl, C3-C7 cycloalkyl, (C3-C7 cycloalkyl)C0-C6 alkyl, C2-C6 alkanoyl, or -Q1(C=O)Q2R9 wherein R9 is hydrogen, C1-C8 alkyl, C1-C6 haloalkyl, C1-C8 alkyl-OH, or aryl; Q1 each and Q2 independently is a bond, O, or NR10, and R10 is hydrogen, C1-C8 alkyl, C1-C6 haloalkyl, or C1-C8 alkyl-OH; R2 is hydrogen, C1-C8 alkyl, C1-C6 haloalkyl, C1-C8 alkyl-OH, C3-C7 cycloalkyl, (C3- C7 cycloalkyl)C0-C6 alkyl, C1-C4 alkanoyl, or unsubstituted or substituted aryl; X is O, S, or N; Y is N or CH; R6 is hydrogen, C1-C8 alkyl, C3-C7 cycloalkyl, (C3-C7 cycloalkyl)C0-C6 alkyl, or C1-C4 alkanoyl when X is N, and R6 is absent when X is S or O; R7 is hydrogen, NO2, cyano, halogen, NH2, COOH, hydroxyl, C1-C8 alkyl, C1-C6 haloalkyl, C1-C8 alkyl-OH, C1-C8 alkyl-NH2, C1-C8 alkoxy, mono-C1-C8 alkylamino, di-C1-C8 alkylamino, C2-C6 alkenyl, C3-C7 cycloalkyl, (C3-C7 cycloalkyl)C0-C6 alkyl, C2-C6 alkanoyl, or -Q1(C=O)Q2R9 wherein Q1, Q2, and R9 are as previously defined; Ar2 is unsubstituted or substituted aryl or unsubstituted or substituted heteroaryl substituted with R8 wherein R8 is NO2, cyano, halogen, NH2, COOH, hydroxyl, C1-C8 alkyl, C1-C6 haloalkyl, C1-C8 alkyl-OH, C1-C8 alkyl-NH2, C1-C8 alkoxy, mono-C1-C8 alkylamino, di-
C1-C8 alkylamino, C2-C6 alkenyl, C3-C7 cycloalkyl, (C3-C7 cycloalkyl)C0-C6 alkyl, C2-C6 alkanoyl, or -Q1(C=O)Q2R9 wherein Q1, Q2, and R9 are as previously defined; R4 is hydrogen, NO2, cyano, halogen, NH2, COOH, hydroxyl, C1-C8 alkyl, C1-C6 haloalkyl, C1-C8 alkyl-OH, C1-C8 alkyl-NH2, C1-C8 alkoxy, mono-C1-C8 alkylamino, di-C1-C8 alkylamino, C2-C6 alkenyl, C3-C7 cycloalkyl, (C3-C7 cycloalkyl)C0-C6 alkyl, C2-C6 alkanoyl, or -Q1(C=O)Q2R9 wherein Q1, Q2, and R9 are as previously defined; and R5 is hydrogen, C1-C6 alkyl, C3-C7 cycloalkyl, (C3-C7 cycloalkyl)C0-C6 alkyl, or C1-C4 alkanoyl, with the following provisos a) and b): a) when
hydrogen, and Ar2 is phenyl or phenyl substituted with R8, then R1, R2, and R8 do not meet the following six conditions for a compound of Formula (III):
NO2, NH2, mono-C1-C8 alkylamino, or di-C1-C8 alkylamino; R2 is hydrogen or C1-C8 alkyl; R4 is hydrogen or C1-C8 alkyl; and R5 is hydrogen; then Ar2 is not unsubstituted phenyl or phenyl substituted at the 2 position with C1- C8 alkyl. 2. The method of claim 1, wherein
3. The method of any one of claims 1-2, wherein R1 is an electron withdrawing group; or R1 is NO2, cyano, C1-C6 haloalkyl, CF3, or C2-C6 alkanoyl.
4. The method of any one of claims 1-3, wherein R2 is hydrogen, C1-C6 alkyl, C1-C8 alkyl-OH, or unsubstituted or substituted phenyl. 5. The method of claim 1, wherein Ar1 is
, X is O, S, or N; Y is N or CH; and R6 is hydrogen, C1-C8 alkyl, C3-C7 cycloalkyl, (C3-C7 cycloalkyl)C0-C6 alkyl, or C1-C4 alkanoyl when X is N, and R6 is absent when X is S or O. The method of claim 1, wherein Ar is
and R7 is hydrogen, NO2, cyano, halogen, NH2, COOH, hydroxyl, C1-C8 alkyl, C1-C6 haloalkyl, C1-C8 alkyl-OH, C1-C8 alkyl-NH2, C1-C8 alkoxy, mono-C1-C8 alkylamino, di-C1-C8 alkylamino, C2-C6 alkenyl, C3-C7 cycloalkyl, (C3-C7 cycloalkyl)C0-C6 alkyl, C2-C6 alkanoyl, or -Q1(C=O)Q2R9 wherein Q1, Q2, and R9 are as previously defined. 7. The method of any one of claims 1-6, wherein Ar2 is unsubstituted phenyl or naphthalene or R8 substituted phenyl or naphthalene. 8. The method of any one of claims 1-6, wherein Ar2 is phenyl substituted with halogen or 2-naphthalene. 9. The method of any one of claims 1-8, wherein R4 is C1-C6 alkyl or C1-C6 alkoxy. 10. The method of any one of claims 1-8, wherein R4 is C1-C2 alkyl or C1-C2 alkoxy. 11. The method of any one of claims 1-10, wherein R5 is hydrogen. 12. The method of any one of claims 1-11, wherein the cancer is breast, colon, colorectal, glioma, hematological, laryngeal, lung, lymphoma, melanoma, neuroblastoma, ovarian, prostate, or a combination thereof.
13. The method of any one of claims 1-11, wherein the cancer-induced thrombosis is arterial, venous, or a combination thereof. 14. The method of any one of claims 1-13, further comprising providing the patient with an additional pharmaceutically active agent. 15. The method of claim 14, wherein the additional pharmaceutically active agent is an anti-thrombotic, an anti-coagulant, a chemotherapeutic, an anti-viral, or an anti- inflammatory. 16. A method for preventing or treating thrombosis, a thrombotic disease, platelet aggregation, fibrin generation, an infectious disease, a viral disease, an immune disorder, inflammation, a neurologic disease, a neurodegenerative disorder, or a combination thereof in a patient, comprising: administering to the patient in need thereof a therapeutically effective amount of a compound of Formula (I), (II), (III), or a pharmaceutically acceptable salt thereof. 17. The method of claim 16, wherein the thrombosis is arterial thrombosis or venous thrombosis and wherein the thrombotic disease is acute myocardial infarction, stable angina, unstable angina, acute occlusion following coronary angioplasty and/or stent placement, a transient ischemic attack, cerebrovascular disease, stroke, peripheral vascular disease, placental insufficiency, atrial fibrillation, deep vein thrombosis, pulmonary embolism, or a combination thereof. 18. A compound of Formula (I), (II), (III), or a pharmaceutically acceptable salt thereof:
wherein
R1 is hydrogen, NO2, cyano, halogen, NH2, COOH, hydroxyl, C1-C8 alkyl, C1-C6 haloalkyl, C1-C8 alkyl-OH, C1-C8 alkyl-NH2, C1-C8 alkoxy, mono-C1-C8 alkylamino, di-C1-C8 alkylamino, C2-C6 alkenyl, C3-C7 cycloalkyl, (C3-C7 cycloalkyl)C0-C6 alkyl, C2-C6 alkanoyl, or -Q1(C=O)Q2R9 wherein R9 is hydrogen, C1-C8 alkyl, C1-C6 haloalkyl, C1-C8 alkyl-OH, or aryl; Q1 each and Q2 independently is a bond, O, or NR10, and R10 is hydrogen, C1-C8 alkyl, C1-C6 haloalkyl, or C1-C8 alkyl-OH; R2 is hydrogen, C1-C8 alkyl, C1-C6 haloalkyl, C1-C8 alkyl-OH, C3-C7 cycloalkyl, (C3- C7 cycloalkyl)C0-C6 alkyl, C1-C4 alkanoyl, or unsubstituted or substituted aryl; X is O, S, or N; Y is N or CH; R6 is hydrogen, C1-C8 alkyl, C3-C7 cycloalkyl, (C3-C7 cycloalkyl)C0-C6 alkyl, or C1-C4 alkanoyl when X is N, and R6 is absent when X is S or O; R7 is hydrogen, NO2, cyano, halogen, NH2, COOH, hydroxyl, C1-C8 alkyl, C1-C6 haloalkyl, C1-C8 alkyl-OH, C1-C8 alkyl-NH2, C1-C8 alkoxy, mono-C1-C8 alkylamino, di-C1-C8 alkylamino, C2-C6 alkenyl, C3-C7 cycloalkyl, (C3-C7 cycloalkyl)C0-C6 alkyl, C2-C6 alkanoyl, or -Q1(C=O)Q2R9 wherein Q1, Q2, and R9 are as previously defined; Ar2 is unsubstituted or substituted aryl or unsubstituted or substituted heteroaryl; R4 is hydrogen, NO2, cyano, halogen, NH2, COOH, hydroxyl, C1-C8 alkyl, C1-C6 haloalkyl, C1-C8 alkyl-OH, C1-C8 alkyl-NH2, C1-C8 alkoxy, mono-C1-C8 alkylamino, di-C1-C8 alkylamino, C2-C6 alkenyl, C3-C7 cycloalkyl, (C3-C7 cycloalkyl)C0-C6 alkyl, C2-C6 alkanoyl, or -Q1(C=O)Q2R9 wherein Q1, Q2, and R9 are as previously defined; and R5 is hydrogen, C1-C6 alkyl, C3-C7 cycloalkyl, (C3-C7 cycloalkyl)C0-C6 alkyl, or C1-C4 alkanoyl with the following provisos a) and b): a) when
hydrogen, and Ar2 is phenyl or phenyl substituted with R8, then R1, R2, and R8 do not meet the following six conditions for a compound of Formula (III): R1 R2 R8
gen, NO2, NH2, mono-C1-C8 alkylamino, or di-C1-C8 alkylamino; R2 is hydrogen or C1-C8 alkyl; R4 is hydrogen or C1-C8 alkyl; and R5 is hydrogen; then Ar2 is not unsubstituted phenyl or phenyl substituted at the 2 position with C1- C8 alkyl. 19. The compound of claim 18, wherein
20. The compound of claim 18 or 19, wherein R1 is an electron withdrawing group; or R1 is NO2, cyano, C1-C6 haloalkyl, CF3, or C2-C6 alkanoyl. 21. The compound of any one of claims 18-20, wherein R2 is hydrogen, C1-C6 alkyl, C1-C8 alkyl-OH, or unsubstituted or substituted phenyl. 22. The compound of claim 18, wherein Ar1 is
, X is O, S, or N; Y is N or CH; and R6 is hydrogen, C1-C8 alkyl, C3-C7 cycloalkyl, (C3-C7 cycloalkyl)C0-C6 alkyl, or C1-C4 alkanoyl when X is N, and R6 is absent when X is S or O. 23. The compound of claim 18, wherein Ar1 is
and R7 is hydrogen, NO2, cyano, halogen, NH2, COOH, hydroxyl, C1-C8 alkyl, C1-C6 haloalkyl, C1-C8 alkyl-OH, C1-C8 alkyl-NH2, C1-C8 alkoxy, mono-C1-C8 alkylamino, di-C1-C8
alkylamino, C2-C6 alkenyl, C3-C7 cycloalkyl, (C3-C7 cycloalkyl)C0-C6 alkyl, C2-C6 alkanoyl, or -Q1(C=O)Q2R9 wherein Q1, Q2, and R9 are as previously defined. 24. The compound of any one of claims 18-23, wherein Ar2 is phenyl or naphthalene unsubstituted or substituted with R8 wherein R8 is NO2, cyano, halogen, NH2, COOH, hydroxyl, C1-C8 alkyl, C1-C6 haloalkyl, C1-C8 alkyl-OH, C1-C8 alkyl-NH2, C1-C8 alkoxy, mono-C1-C8 alkylamino, di-C1-C8 alkylamino, C2-C6 alkenyl, C3-C7 cycloalkyl, (C3-C7 cycloalkyl)C0-C6 alkyl, C2-C6 alkanoyl, or -Q1(C=O)Q2R9 wherein Q1, Q2, and R9 are as previously defined 25. The compound of any one of claims 18-23, wherein Ar2 is phenyl substituted with halogen or 2-naphthalene. 26. The compound of any one of claims 18-25, wherein R4 is C1-C6 alkyl or C1-C6 alkoxy. 27. The compound of any one of claims 18-25, wherein R4 is C1-C2 alkyl or C1-C2 alkoxy. 28. The compound of any one of claims 18-27, wherein R5 is hydrogen. 29. A pharmaceutical composition, comprising the compound of any one of claims 18-28 and a pharmaceutically acceptable excipient. 30. The pharmaceutical composition of claim 29, formulated for administration orally, topically, parenterally, by inhalation or spray, sublingually, transdermally, via buccal administration, or rectally. 31. The pharmaceutical composition of claim 29, formulated as a tablet or capsule.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263399516P | 2022-08-19 | 2022-08-19 | |
US63/399,516 | 2022-08-19 | ||
US202363454974P | 2023-03-28 | 2023-03-28 | |
US63/454,974 | 2023-03-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024039822A1 true WO2024039822A1 (en) | 2024-02-22 |
Family
ID=89942168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/030535 WO2024039822A1 (en) | 2022-08-19 | 2023-08-18 | Thiol isomerases inhibitors; preparation thereof; and methods of use thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024039822A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5334765A (en) * | 1989-12-11 | 1994-08-02 | Imperial Chemical Industries Plc | Carbamoyl derivatives |
US20200385348A1 (en) * | 2019-06-07 | 2020-12-10 | University Of Kentucky Research Foundation | Antimicrobial compounds, compositions, and methods |
US20210008032A1 (en) * | 2017-01-30 | 2021-01-14 | Western New England University | Thiol isomerases inhibitors and use thereof |
-
2023
- 2023-08-18 WO PCT/US2023/030535 patent/WO2024039822A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5334765A (en) * | 1989-12-11 | 1994-08-02 | Imperial Chemical Industries Plc | Carbamoyl derivatives |
US20210008032A1 (en) * | 2017-01-30 | 2021-01-14 | Western New England University | Thiol isomerases inhibitors and use thereof |
US20200385348A1 (en) * | 2019-06-07 | 2020-12-10 | University Of Kentucky Research Foundation | Antimicrobial compounds, compositions, and methods |
Non-Patent Citations (3)
Title |
---|
GOVERDHAN, G. ; REDDY, A.R. ; SRINIVAS, K. ; HIMABINDU, V. ; REDDY, G.M.: "Identification, characterization and synthesis of impurities of zafirlukast", JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, ELSEVIER B.V., AMSTERDAM, NL, vol. 49, no. 4, 1 May 2009 (2009-05-01), AMSTERDAM, NL , pages 895 - 900, XP026071217, ISSN: 0731-7085, DOI: 10.1016/j.jpba.2009.01.023 * |
SCHIERLE SIMONE, FLAUAUS CATHRIN, HEITEL PASCAL, WILLEMS SABINE, SCHMIDT JUREMA, KAISER ASTRID, WEIZEL LILIA, GOEBEL TAMARA, KAHNT: "Boosting Anti-Inflammatory Potency of Zafirlukast by Designed Polypharmacology", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 61, no. 13, 12 July 2018 (2018-07-12), US , pages 5758 - 5764, XP093143065, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.8b00458 * |
SUKNUNTHA KRAN, YUBOLPHAN RUEDEEMARS, KRUEAPRASERTKUL KANOKPAN, SRIHIRUN SIRADA, SIBMOOH NATHAWUT, VIVITHANAPORN PORNPUN: "Leukotriene Receptor Antagonists Inhibit Mitogenic Activity in Triple Negative Breast Cancer Cells", ASIAN PACIFIC JOURNAL OF CANCER PREVENTION : APJCP, WEST ASIA ORGANIZATION FOR CANCER PREVENTION, THAILAND, 28 March 2018 (2018-03-28), Thailand, pages 833 - 837, XP093143071, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980863/pdf/APJCP-19-833.pdf> [retrieved on 20240319], DOI: 10.22034/APJCP.2018.19.3.833 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI795362B (en) | Antagonist and immune checkpoint inhibitor | |
TWI316937B (en) | Spirocyclic thrombin receptor antagonists | |
AU2014340110B2 (en) | Inhibitors of human immunodeficiency virus replication | |
JP4982482B2 (en) | HIV integrase inhibitor | |
JP2020515583A (en) | Aryl cyclopropyl-amino-isoquinolinyl amide compound | |
US10023591B2 (en) | Heterocyclic derivatives and use thereof | |
TWI290046B (en) | Phenanthroindolizidine alkaloids | |
AU2005303904A1 (en) | Azaindole carboxamides | |
AU2008275735A2 (en) | Tetrahydropyranochromene gamma secretase inhibitors | |
WO2010075869A1 (en) | Toluidine sulfonamides and their use | |
CA2675357A1 (en) | 6-benzyl-2,3,4,7-tetrahydro-indolo [2, 3-c] quinoline compounds useful as pde5 inhibitors | |
TW201702226A (en) | Urea derivative or pharmacologically acceptable salt thereof | |
JP6859358B2 (en) | Tetrahydroindazole and its medical use | |
WO2010085968A1 (en) | Toluidine sulfonamides and their use as hif-inhibitors | |
JP2015526396A (en) | Substituted tropolone derivatives and methods of use thereof | |
WO2024039822A1 (en) | Thiol isomerases inhibitors; preparation thereof; and methods of use thereof | |
AP1208A (en) | 2-Aminopyridines containing fused ring substituents | |
WO2022173795A1 (en) | OXADIAZOLYL DIHYDROPYRANO[2,3-b]PYRIDINE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS | |
CN104530029B (en) | Heterocyclic compounds as factor Xa inhibitors as well as using methods and application of heterocyclic compounds | |
DE60209029T2 (en) | POLYCYCLIC COMPOUNDS WITH ANTITUMOR EFFECT | |
Wu et al. | Synthesis and Anticancer Activity of 7, 8-dihydroxy-4-arylcoumarins | |
CN115141204A (en) | Naphthalene [1,2-b ] furan-4,5-diketone derivative and preparation and application thereof | |
KR20230142000A (en) | Isoxazolidine derivative compounds, and uses thereof | |
TW201402569A (en) | Substituted tricyclic compounds with activity towards EP1 receptors | |
JP2016210687A (en) | Benzofuropyrazole derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23855484 Country of ref document: EP Kind code of ref document: A1 |